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Summary	
 
With the introduction of highly active antiretrovirals, HIV moved from being a 
terminal disease with a bleak prognosis to being a manageable chronic disease, with 
comparable impact on quality of life to hypertension and diabetes. This new status of 
HIV called for a deeper understanding of HIV on the population, individual, and 
molecular levels, to appropriately address the issues of an aging population that is 
infectious for a longer time (if treatment is absent or interrupted). 
 
On the population level, HIV public health surveillance has been one of the most 
effective tools in combating HIV spread, and its failure or the complacency of the 
supervising bodies has been met many times with undesired outbreaks. For that, in 
this thesis two cases of HIV surveillance were studied. The first tackles the issue of 
representativeness of the sampled population and cohort coverage in one of the most 
comprehensive HIV cohort studies in the world, the Swiss HIV Cohort Study (SHCS). 
Using genotypic resistance tests from the cohort and from non-cohort individuals and 
phylogenetic analysis, we found that non-B subtype, female gender, and heterosexual 
transmission group were all associated with underrepresentation in the SHCS. The 
study also showed that purely non-SHCS outbreaks were not infrequent yet they were 
small and strongly overlapping with the SHCS’. This suggests that marginalized 
populations are underrepresented in the SHCS. However, the limited size of outbreaks 
among non-SHCS patients in-care implies that no major HIV outbreak in Switzerland 
was missed by the SHCS surveillance.  
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In the second case, we delved deeper into the underlying similarities and differences 
of the HIV epidemic in two western countries (Switzerland and the UK). Using a 
standardized phylogenetics pipeline, the two cohorts separately assessed HIV 
outbreaks patterns. The study concluded that the UK and Swiss HIV epidemics have 
similar underlying dynamics and the observed differences in outbreaks are mainly due 
to different population sizes. Both studies demonstrate the potential of sequence data 
to assess and extend the scope of infectious-disease surveillance. 
 
On the individual level, with the increased life expectancy of the HIV infected 
population, and the ever-increasing number of patients on ART, the understanding of 
the collateral effects of antiretrovirals has become crucial. Three directions were 
followed in this thesis within the frame of this topic. Firstly, the case of Hepatitis B 
virus, which given the similar routes of transmission it shares with HIV, is highly (co)-
transmissible. Knowing that HBV is susceptible to 3 of HIV specific drugs, we 
evaluated their protective association and the incidence of HBV in individuals on 
dually active antiretrovirals. Dually active antiretrovirals were found to be associated 
with up to 90% less incidence of HBV in susceptible HIV infected individuals.  
 
Another recurrent co-infection in the HIV population is syphilis. While readily 
treatable with Penicillin, syphilis co-infection enhances HIV and other co-infections 
transmission (such as Hepatitis B and C), thus posing a public health hazard, both in 
itself, and its ability to enhance transmission of HIV and other co-infections. We 
studied the trends of syphilis incidence in the SHCS and assessed the factors associated 
with its incidence and the effect of ART on it. We found that in recent years syphilis 
incidence has almost tripled with the main drivers being risk-taking behavior in young 
HIV infected individuals. We also found an interesting association between 
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administration of NVP and lower syphilis incidence which has not been reported before 
and for the same reason has no mechanistic explanation.  
 
Given this finding that nevirapine could be effective against a bacterium, and earlier 
reports of azidothymidine being effective against bacteria as well. We evaluated 25 HIV 
antiretrovirals against gram-positive and gram-negative bacteria, in order to assess 
their antibacterial effect. We found that three of the 25 tested antiretrovirals 
(Efavirenz, azidothymidine, 2',3' Dideoxyinosine) have antibacterial effects against 
gram positive and gram-negative bacteria. The long chronic nature of HIV treatment 
emphasizes the importance of comprehending the antibacterial effects of 
antiretrovirals and their potential consequence on altering the gut microbiota.  
 
The final frontier in HIV is its eradication, which is exceptionally challenging as HIV 
establishes a persistent reservoir by integrating its genome within the cellular DNA. 
The features of these integration sites are examined both ex-vivo and in-vivo using a 
bioinformatics pipeline that addresses several known issues of integration sites 
analysis. This analysis sheds light on the differences of the integration patterns 
between different cell types ex-vivo. In addition, the integration patterns were 
examined in HIV infected individuals directly after the infection and longitudinally 
along the years, revealing several levels of selection the latent reservoir undergoes. The 
first of these occurs when the infected cell transitions from the activated to the resting 
state, and the second when the resting infected cells are under pressure by treatment. 
Our findings here have implications in terms of explaining HIV pathogenesis as well 
as designing future strategies for eradication of the latent reservoir. 
 
 6 
In summary, in this thesis HIV was studied on the population, individual, cellular, and 
genomic level, to add another stepping stone for HIV prevention and eradication and, 
with the hope that these efforts help one day ending the HIV pandemic. 
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Zusammenfassung	
 
Mit der Einführung von hochaktiven Antiretroviralen, zog HIV von einer terminalen 
Krankheit mit einer düsteren Prognose zu einer überschaubaren chronischen 
Krankheit, mit vergleichbaren Auswirkungen auf die Lebensqualität auf 
Bluthochdruck und Diabetes. Dieser neue Status von HIV forderte ein tieferes 
Verständnis von HIV auf der Bevölkerung, auf individuellen und molekularen Ebenen, 
um die Probleme einer alternden Bevölkerung, die für eine längere Zeit ansteckend ist 
(wenn die Behandlung nicht vorhanden oder unterbrochen ist) angemessen zu 
behandeln. 
 
Auf der Ebene der Bevölkerung ist die HIV-Bekämpfung der öffentlichen Gesundheit 
zu den wirksamsten Mitteln bei der Bekämpfung der HIV-Ausbreitung gekommen, 
und ihr Versagen oder die Selbstzufriedenheit der Überwachungsorgane wurde oft mit 
unerwünschten Ausbrüchen getroffen. Dafür wurden in dieser Arbeit zwei Fälle von 
HIV-Überwachung untersucht. Die erste thematisiert die Repräsentativität der 
Stichproben- und Kohortenabdeckung in einer der umfassendsten HIV-
Kohortenstudien der Welt, der Swiss HIV-Kohortenstudie (SHCS). Unter Verwendung 
genotypischer Resistenztests der Kohorte und der Nicht-Kohorten-Individuen sowie 
der phylogenetischen Analyse fanden wir, dass der nicht B-Subtyp, das weibliche 
Geschlecht und die heterosexuelle Übertragungsgruppe alle mit einer 
Unterrepräsentation in der SHCS assoziiert waren. Die Studie zeigte auch, dass rein 
Nicht-SHCS-Ausbrüche nicht selten waren, aber sie waren klein und stark 
überlappend mit dem SHCS. Dies deutet darauf hin, dass marginalisierte Populationen 
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in der SHCS unterrepräsentiert sind. Die begrenzte Größe der Ausbrüche bei Nicht-
SHCS-Patienten in Pflege bedeutet jedoch, dass kein großer HIV-Ausbruch in der 
Schweiz von der SHCS-Überwachung verpasst wurde. 
 
Im zweiten Fall beschäftigten wir uns tiefer in die zugrundeliegenden 
Gemeinsamkeiten und Unterschiede der HIV-Epidemie in zwei westlichen Ländern 
(Schweiz und Großbritannien). Unter Verwendung einer standardisierten 
phylogenetischen Pipeline, die beiden Kohorten getrennt beurteilt HIV-Ausbrüche 
Muster. Die Studie kam zu dem Schluss, dass die britischen und schweizerischen HIV-
Epidemien eine ähnliche Dynamik haben und die beobachteten Unterschiede in den 
Ausbrüchen sind hauptsächlich auf unterschiedliche Bevölkerungsgrößen 
zurückzuführen. Beide Studien zeigen das Potenzial von Sequenzdaten, den Umfang 
der Infektionskrankheit-Überwachung zu bewerten und zu erweitern. 
 
Auf der individuellen Ebene, mit der erhöhten Lebenserwartung der HIV-infizierten 
Bevölkerung und der ständig wachsenden Anzahl von Patienten auf ART, ist das 
Verständnis der Sicherheitseffekte von Antiretroviralen entscheidend geworden. Drei 
Richtungen wurden in dieser Arbeit im Rahmen dieses Themas verfolgt. Erstens ist der 
Fall des Hepatitis-B-Virus, das die ähnlichen Übertragungswege gibt, die es mit HIV 
teilt, hoch (co)-übertragbar. Wissend, dass HBV anfällig für 3 von HIV-spezifischen 
Medikamenten ist, untersuchten wir ihre schützende Assoziation und die Häufigkeit 
von HBV in Einzelpersonen auf dual aktiven Antiretroviralen. Dual-aktive 
Antiretrovirale wurden mit bis zu 90% weniger Inzidenz von HBV bei anfälligen HIV-
infizierten Individuen assoziiert. 
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Eine weitere rezidivierende Co-Infektion in der HIV-Population ist Syphilis. Während 
sie leicht mit Penicillin behandelbar ist, erhöht die Syphilis-Co-Infektion die HIV- und 
andere Co-Infektionsübertragung (wie Hepatitis B und C) und stellt somit eine Gefahr 
für die Gesundheit dar, sowohl für sich selbst als auch für ihre Fähigkeit, die 
Übertragung von HIV und anderen Co- Infektionen. Wir untersuchten die Trends der 
Syphilis-Inzidenz in der SHCS und bewertet die Faktoren mit ihrer Häufigkeit und die 
Wirkung der ART auf sie. Wir fanden, dass in den letzten Jahren Syphilis-Inzidenz hat 
sich fast verdreifacht mit den wichtigsten Treibern Risikobereitschaft Verhalten bei 
jungen HIV-infizierten Personen. Wir fanden auch eine interessante Assoziation 
zwischen der Verabreichung von NVP und einer geringeren Syphilis-Inzidenz, die 
bisher nicht berichtet wurde und aus dem gleichen Grund keine mechanistische 
Erklärung hat. 
 
Angesichts dieser Feststellung, dass Nevirapin gegen ein Bakterium wirksam sein 
könnte und frühere Berichte über Azidothymidin auch gegen Bakterien wirksam sind. 
Wir evaluierten 25 HIV Antiretrovirale gegen gram-positive und gram-negative 
Bakterien, um ihre antibakterielle Wirkung zu bewerten. Wir fanden, dass drei der 25 
getesteten Antiretroviren (Efavirenz, Azidothymidin, 2', 3' Dideoxyinosin) 
antibakterielle Effekte gegen grampositive und gramnegative Bakterien haben. Die 
lange chronische Art der HIV-Behandlung unterstreicht die Bedeutung des 
Verständnisses der antibakteriellen Wirkungen von Antiretroviralen und ihrer 
möglichen Konsequenz auf die Veränderung der Darm-mikrobiota. 
 
Die letzte Grenze in HIV ist seine Beseitigung, die außergewöhnlich schwierig ist, da 
HIV ein anhaltendes Reservoir durch die Integration seines Genoms innerhalb der 
zellulären DNA etabliert. Die Merkmale dieser Integrationsstellen werden sowohl ex 
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vivo als auch in vivo unter Verwendung einer Bioinformatik-Pipeline untersucht, die 
mehrere bekannte Probleme der Integrationsstellenanalyse adressiert. Diese Analyse 
beleuchtet die Unterschiede der Integrationsmuster zwischen verschiedenen Zelltypen 
ex vivo. Darüber hinaus wurden die Integrationsmuster in HIV-infizierten Individuen 
direkt nach der Infektion und in Längsrichtung im Laufe der Jahre untersucht, wobei 
mehrere Ebenen der Auswahl des latenten Reservoirs unterzogen. Das erste davon tritt 
auf, wenn die infizierte Zelle von dem aktivierten in den ruhenden Zustand übergeht, 
und die zweite, wenn die ruhenden infizierten Zellen durch Behandlung unter Druck 
stehen. Unsere Erkenntnisse haben hier Auswirkungen auf die Erklärung der HIV-
Pathogenese sowie die Ausarbeitung zukünftiger Strategien zur Tilgung des latenten 
Reservoirs. 
 
Zusammenfassend wurde in dieser Arbeit HIV auf die Bevölkerung, individuelle, 
zelluläre und genomische Ebene untersucht, um einen weiteren Schritt für die HIV-
Prävention und Tilgung und mit der Hoffnung, dass diese Bemühungen helfen, einen 
Tag beenden die HIV-Pandemie.  
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Introduction	and	
Background	
 
The acquired immunodeficiency syndrome (AIDS) was first reported among men who 
have sex with men (MSM) in the United States in 19811. What was initially a limited 
outbreak of the human immunodeficiency virus (HIV), quickly became one of the most 
devastating pandemics of the past century claiming more than 35 million lives to date2. 
The HIV epidemic changed many facets of the culture, politics, and scientific practice 
that we now take for norms.  
 
An unknown unknown, Pre 1980 
The exact point at which HIV jumped hosts remains an active research topic. Generally, 
it is believed that HIV was transmitted to humans through infected bush-meat around 
1920 in central Africa3. Records of HIV and AIDS cases prior to 1980 are scarce given 
that symptoms upon acute HIV infection are unspecific mostly resembling a viral 
syndrome (“flu- or mononucleosis like”) 4 and its chronic phase until AIDS develops is 
largely asymptomatic5. 
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The search for the known unknown 1981-1986 
In the beginning of the 1980s several cases of the uncommon lung infection 
Pneumocystis carinii pneumonia (PCP) and Kaposi’s Sarcoma were reported in MSM 
and intravenous drug users (IDU) in the United States1, Europe6, and Africa7. Similar 
constellations were thereafter observed in the heterosexual partners of those 
individuals, implying that the culprit is heterosexually transmissible 
as well8. Soon thereafter, blood donation recipients (namely 
hemophiliacs) were noted to have presented with similar symptoms 
9. The CDC coined the term AIDS10 to refer to the aforementioned 
constellation of symptoms, before the causative agent was recognized 
as HIV (Box 1). In 1984 the Pasteur Institute and the National Cancer Institute jointly 
announced that the likely causative agent of AIDS is the Lymphadenopathy-Associated 
Virus/HTLV-III11; two of the many initial names for HIV, which became the official 
name as of 198612. The identification of the causative agent of AIDS, was accompanied 
by a then overly optimistic estimate that a vaccine would be developed in two years13. 
A prophecy that is yet to be realized after more than 30 years. 
 
The poor prognosis of an HIV infection mobilized massive efforts in the scientific field, 
that lead to the rapid development of the first commercially available HIV test in 1985 
(based on enzyme-linked immunosorbent assay)14. Within the same year, HIV was 
successfully cloned15, its genome sequenced16, and CD4 receptor was identified as its 
main target17. The latter finding strengthened the notion that CD4 
monitoring is crucial for the care of the infected, while sequencing 
of HIV paved the way for the understanding of HIVs life cycle, 
cross-species origin, diversity, and resistance. The study of the 
origin of HIV showed that there were multiple events were HIV-1 
CDC	AIDS	Definition	
1982	
“A	disease	at	least	
moderately	predictive	
of	a	defect	in	cell-
mediated	immunity,	
occurring	in	a	person	
with	a	no	known	
cause	for	diminished	
resistance	to	that	
disease.”10	
HIV	RT	Fidelity		
HIV	RT	enzyme	has	a	
high	transcription	error	
rate	(10-4	range)20,21.	This	
gave	rise	to	a	central	
problem	in	HIV	care,	that	
is,	treatment	failure	due	
to	resistance	mutation.	It	
is	also	the	reason	HIV	is	
exceptionally	suitable	for	
molecular	epidemiology	
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jumped hosts leading to four major groups (M, N, O, and P). Group M, and more 
specifically subtype B, dominates Switzerland, western Europe and the Americas18. 
While subtype C is responsible for almost 48% of HIV infections worldwide, with most 
of the cases taking place in sub-Saharan Africa and India18. The reason for this 
remarkable diversity of HIV is namely the low fidelity of its reverse transcriptase (RT) 
enzyme, frequent recombination19, and its high replication rate20,21. Unless otherwise 
stated, I hereafter refer to HIV-1 as HIV. 
 
By the end of 1986 HIV was reported in 85 countries and more than 38,401 people 
were diagnosed22. This period was one of the bleakest in the history of HIV where both 
HIV infected individuals and their caretakers felt helpless and powerless towards what 
seemed to be an invincible enemy, and where an HIV diagnosis was considered by 
many a death sentence. 
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Pre-HAART 1987-1994 
The beginning of this period marked the FDA approval of the first HIV drug zidovudine 
(AZT)23, and the first ray of hope. AZT was followed by several other nucleotide reverse 
transcriptase inhibitors (NRTIs) (zalcitabine, didanosine, stavudine), adding to the 
general optimism that a cure was not far. Over the course of those 7 years, HIV testing 
 
Box 1. HIV life cycle: HIV life cycle has been thoroughly covered in the literature 65, but we shortly touch 
upon it here. Briefly, HIV-1 binds to the CD4 cell receptor and co-receptors (CCR5 or CXCR4 depending on 
the virus tropism). The virus then fuses with the cell membrane of the host cell, and the capsid is uncoated 
allowing for the release of the viral RNA into the cytoplasm. The viral RNA is transcribed thereafter through 
the HIV reverse transcriptase enzyme, generating viral DNA. The viral DNA along with other viral and host 
proteins form the pre-integration complex, that is afterwards shuttled to the nucleus. There, the DNA 
through the action of the HIV integrase enzyme, is integrated in the host genome and thereafter transcribed 
and translated into the parts that make up the yet to be assembled virions. The viral protease enzyme is 
responsible for cleaving the translated polyprotein in the individual HIV proteins, which assemble along 
with the generated viral RNA to form the mature viruses. The mature viruses bud out and are then released. 
HIV antiretrovirals target one of four steps in HIV life cycle: viral fusion, reverse transcription of viral RNA 
to DNA, integration inhibition, and protease inhibition. HAART posed the notion that targeting multiple 
steps of the HIV life cycle is more effective in preventing viral replication. 
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became progressively more specific (Western blot based testing) and more accessible14. 
It was clear as the years passed that while NRTIs generally prolonged the life 
expectancy and increased the life quality of the HIV infected24, they were not sufficient 
to stop the eventual deterioration of the health state of HIV patients. The culprit for 
this deterioration was rapidly pinned down to be the low HIV RT fidelity and high 
replication rate of HIV, which gives rise to various mutants that are resistant to 
treatment25,26.  
 
The unfavorable prognosis of HIV and the stigma surrounding the 
people infected lent further importance to HIV genome sequencing. 
Criminal prosecution became commonplace 27, and pin pointing the 
source of infection was heavily dependent on genetic similarity (or the 
lack thereof) of the infecting virus28. The collective term that is mostly 
used for these studies is molecular epidemiology. 
 
 
The inability to eradicate HIV infections and its continuous ability to evade the 
immune system through mutations gave rise to the need of continuous monitoring of 
HIV patients in terms of CD4. Another aspect that called for this monitoring is the 
management of the side effects many of the early antiretrovirals had. (e.g. anemia from 
AZT). This constant need of monitoring lead to the birth of many cohort studies 
dedicated to HIV, including the Swiss HIV Cohort Study29 (SHCS, Section 1.1), from 
which the data in this thesis was obtained. 
 
Molecular	epidemiology		
The	study	of	viral	
transmission	between	
hosts	based	on	genetic	
sequence	relies	heavily	
on	the	variation	of	the	
genetic	constituent	of	
the	isolates	of	the	
examined	population66.	
The	low	fidelity	of	HIV	
RT	allows	for	the	
differentiation	of	
patients	infected	from	
distinct	sources,	and	
forms	the	basis	of	HIV	
molecular	epidemiology	
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The HAART Era 1995-2007 
In 1995 the FDA approved the first protease inhibitor (PI) (Saquinavir)30, and in the 
following year the first non-nucleoside transcriptase inhibitor (NNRTI) drug 
(Nevirapine31). The introduction of these new classes ushered the beginning of the 
HAART era: highly active antiretroviral treatment32,33. Along the years, several more 
antiretrovirals from the NRTI, NNRTI, and PI classes were introduced to the market 
with differences in potency, dosage frequency, and side effects. By the end of 2007, 
more than 30 antiretrovirals were on the market. Given the number of antiretrovirals, 
and the complex history behind their prescription, we dedicate section 1.2 of the 
introduction to cover the HAART period in the SHCS. This will also help give a better 
context of the three manuscripts addressing the collateral effects of ART in HIV 
infected individuals. 
 
HAART was a turning point in the HIV pandemic history, two years after its 
introduction AIDS related mortality dropped by more than 60% in the United states 
(from 50 000 to 18 000)34,35. With more potent and safer drugs on the market the life 
expectancy of HIV infected individuals is climbing towards that of the uninfected36,37, 
and HIV moved from being a terminal disease to a manageable chronic condition.  
 
Prevention and the search for a cure 2008-Present 
The history of major milestones in HIV prevention shies in comparison to that of HIV 
treatment. Behavioral prevention methods (e.g. needle exchange and safe sex) 
succeded and failed to varying degrees38. It took seven years after the approval of AZT 
to show its efficacy in preventing vertical transmission39. Another 11 years were needed 
for the next prevention milestone, recommending circumcision as a prevention 
measure40. And, another half a decade was needed to show that using Emtricitabine 
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and Tenofovir disoproxil fumarate provides 44%, and up to 90% protection (in high 
risk population41) against HIV acquisition in some high-risk populations42,43.  
 
The most important advance in HIV prevention came in 2011 where a randomized 
controlled trial demonstrated that starting treatment early for patients with CD4 cell 
count >350 in serodiscordant heterosexual and couples reduced transmission by 96% 
44. Moreover, in an observational study, there were no phylogenetically linked 
transmissions in 1166 heterosexual and MSM couples over a median of 1.3 years per 
couple. In other words, the risk of a virologically suppressed HIV infected individual 
transmitting the infection to a susceptible individual is very low. Before said 
randomized clinical trial, several groups reported similar observations in observational 
studies including a group of Swiss physician that released what is knowns as the Swiss 
statement in 200845.  This signaled the start of a new paradigm in HIV prevention, that 
is, “Treatment as prevention”46,47. 
 
The bulk of the past 30 years of HIV research has been focused on prevention and 
treatment strategies. However, more recently the last hurdle in front of us toward an 
HIV cure is being consistently challenged. The final frontier in HIV eradication is the 
presence of replication competent provirus in various CD4+ T lymphocytes, and other 
anatomical and cellular sanctuaries48,49. The features of these reservoirs and how it is 
created and maintained is under heavy investigation, because it is the stepping-stone 
towards the complete eradication of HIV from infected individuals50. 
 
The study of HIV integration site landscape requires sophisticated sequencing and 
bioinformatics techniques. After the successful sequencing of the junction between 
HIV and the human genome, the human part of the sequence needs to be mapped to 
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the human genome and annotated with all possible features present at the integration 
site. The characteristics of the integration landscape are believed to govern some of the 
features of HIV latency and how it is sustained. To that end, we embarked on the task 
of characterizing the integration site features of HIV ex-vivo and in-vivo, pioneerd by 
Schröder et al51.  
 
Ex-vivo, we studied the characteristic of monocytes, which are one of the secondary 
targets of HIV, and how they compare to CD4+ T-cells (Chapter 6). In-vivo, we studied 
the characteristics of integration sites at the different stages of infection (recent, 
chronic, late), on and off ART, in the recently infected/reactivated cells (activated CD4+ 
T-Cells), and in the latent reservoir represented by resting CD4+ T-cells (Chapter 7). 
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1.1 The Swiss HIV epidemic and the Swiss HIV Cohort Study (SHCS)  
Switzerland was one of the European countries hit hardest by the HIV epidemic 
evident by the higher than average HIV prevalence52, that persists to date. The HIV 
epidemic in Switzerland coincided with a rise in recreational drug use. Consequently, 
at the beginning of the epidemic the main driver of the epidemic was IDUs followed by 
MSM as a close second53. This contrasts with many western countries where MSM and 
HET drove the initial rise of the epidemic.  
 
Switzerland set an example in drug policies, by rapidly adopting risk reduction 
measures that lead to a rapid decline in IDU associated HIV cases, in what has been 
one of the most effective prevention measures in Switzerland53. A similar success in the 
MSM remains to take place54.  
  
Despite these remarkable efforts, HIV incidence in Switzerland remained largely 
unchanged for the past 15 years with occasional peaks (source: BAG Bulletin). While 
HIV incidence in IDU has been virtually non-existent in recent years, this does not 
apply to MSM, as they remain the main driver of HIV transmission in the SHCS54. In 
addition, the influx of immigrants led to the sustenance of HIV incidence in 
heterosexuals, and introduced a higher fraction of non-B subtype in Switzerland54. The 
fraction of patients undiagnosed, diagnosed and not in care, and diagnosed and in care 
remains an open question55.  
 
Early on in the HIV epidemic in Switzerland, the efforts to fight HIV were united under 
one umbrella to facilitate the understanding and seed collaborations all over the 
country29. That umbrella is the Swiss HIV Cohort Study (www.shcs.ch), one of the 
longest running and most comprehensive HIV cohorts in the world. The SHCS was 
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established in 1988 with ongoing recruitment of patients. It is a prospective 
observational open cohort study, including all transmission groups with bi-annual 
follow up visits. In these visits, many behavioral and social aspects are collected from 
the participating individuals, such as condom use, drug use, and social status. 
Additionally, the patients’ clinical picture is evaluated every 3 months, collecting 
among many other laboratory values CD4+ T-cell count and viral load. The diversity of 
the data collected allows for highly interdisciplinary research encompassing clinical, 
biological, epidemiological and sociological sciences. 
 
One of the most distinctive features of the SHCS is the presence of a biobank. This bio-
bank stores biological samples of the participants, which allows cutting edge research 
to be conducted long after the samples are collected. A prominent example of this is 
the retrospective partial pol viral genome sequencing of samples going back to 199556. 
These sequences are stored along with the now routinely conducted genotypic 
resistance test in the SHCS Drug Resistance Database, in addition to meta-data such 
as sampling date, subtype, and mutations. These sequences have been leveraged in 
many molecular epidemiological studies that helped in understanding HIV 
transmission in Switzerland, and consequently better target prevention strategies. The 
SHCS has been shown to be representative of the HIV epidemic in Switzerland evident 
by covering 53% of all HIV cases ever diagnosed in Switzerland, as well as 72% of 
patients receiving ART29. Finally, full antiretroviral treatment history is recorded for 
the respective patients. 
 
Despite this remarkable coverage, one cannot exclude the possibility of undetected 
outbreaks that are not represented in the SHCS. Starting from 2003, genotypic 
resistance tests became the standard of care in Switzerland. Given that HIV is a 
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reportable disease, the sequences were collected by the BAG 
from that year onward. The BAG sequence database has the 
unique feature that it includes all patients diagnosed with HIV 
in Switzerland, and not only those in the SHCS. This allowed 
us to shed some light on the outbreaks taking place outside of 
the SHCS, and evaluate the true coverage of the SHCS 
surveillance. We embarked on this task in the paper presented 
in Chapter 1 in this thesis, with the aid of phylogenetic techniques.  
 
One important aspect of any scientific finding and of an epidemiological study in 
particular is its generalizability to different settings. Efforts to assess the similarities 
between the epidemics of different countries and thus the potential applicability of 
their HIV-epidemiology findings are scarce in the literature. One example is the 
similarities and differences between the Swiss and the UK HIV epidemics. Several 
reports showed that they are rather different in terms of outbreak size and subtype 
distribution. However, these very reports used different definitions to define an 
outbreak. Therefore, in Chapter 2 of this thesis, a standardized bioinformatics pipeline 
was developed and applied to both the Swiss and the UK sequence data, in order to 
evaluate the degree of similarity or difference between the two underlying epidemics.  
 
  
Genotypic	resistance	test	
Sequencing	of	the	HIV	virus,	
and	based	on	the	sequence	
estimate	the	potential	activities	
of	the	different	drug	classes	PI,	
NRTI,	NNRTI,	and	INIs67.	The	
interpretation	of	the	algorithms	
predicting	activity	is	not	always	
in	concordance	and	
recommendations	are	regularly	
published68.	The	sequence	
could	also	be	used	to	
determine	the	virus	subtype,	
and	consequently	its	potential	
geographic	origin.	
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HIV Co-infections and the collateral effects of ART 
With the increase of the life expectancy of HIV infected population, deaths attributed 
to HIV or AIDS related factors dropped dramatically, and other comorbidities rose as 
the new perpetrators36. In the SHCS, non-AIDS related malignancies has taken the top 
rank as the number one cause of mortality, followed by hepatitis co-infection36.  
 
Most importantly, many of HIV’s coinfections facilitate its transmission (e.g. syphilis) 
and worsen its prognosis (e.g. Hepatitis B and C infections)57,58. This implies the rising 
need of better measure to control the spread of those co-infections. Even though most 
of the coinfections cause a minor elevation of HIV RNA viral load59,60, it has been 
shown that treating those infections and the consequent drop in the HIV RNA viral 
load (regardless of how minor it is) still has beneficial effect manifesting as slower HIV 
progression and lower transmission risk60,61.  
 
All of these factors pool into the same vein, there are more and more people living with 
HIV, and their life expectancy is increasing steadily, HIV comorbidities and healthy 
aging need to be the focus of our effort along with HIV prevention and eradication. To 
that end, we pursued three lines of investigation relating to HIV treatment and 
coinfections. The first is covered in Chapter 3 where the incidence of HBV was 
evaluated and to what degree does ART affect its incidence. More specifically, we 
assessed whether there are immunological, behavioral, or treatment related factors 
that affect HBV incidence. It has been shown that HBV replication is inhibited by some 
anti HIV drugs (Tenofovir, Emticitrabine, and Lamivudine)62,63. Of note is Tenofvir 
being one of the first line drugs in HBV mono-infections64. Similarly, we assessed the 
same factors for another coinfection that has been on the rise recently, that is, syphilis. 
For the case of syphilis, we aimed to find the determinants of its incidence and whether 
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some of them can be used for better targeting of prevention. In addition, given that 
syphilis incidence was decreasing at the beginning of the 2000s we evaluated the time 
trends associated with the observed increase in incidence and the factors driving it 
(Chapter 4). 
 
During our syphilis investigation, we observed an interesting previously unreported 
association of the drug Nevirapine with lower syphilis incidence. Having corrected for 
all the available confounders that could potentially spuriously give rise to such an 
association we pursued a direct evaluation of the effect of the different antiretrovirals 
on bacteria. Ideally, Treponema palladium, syphilis’ causative agent, should have been 
examined, yet T. palladium remains a bacterium that cannot be grown in axenic 
medium. Therefore, we tested 25 antiretroviral on two species, one a gram-positive 
(Bacillus subtilis) and the another gram-negative (Escherichia Coli) to assess the 
antibacterial effects of antiretrovirals (Chapter 5).  
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1.2 A 20 Years history of Highly Active Antiretrovirals in the Swiss 
HIV Cohort Study 
HIV treatment guidelines have changed dramatically in the past 20 years, for the 
presence of new, safer, more effective drugs, and to accommodate the progression of 
scientific evidence showing the advantages of early treatment. The IAS-USA published 
13 treatment guidelines to date (www.iasusa.org/guidelines). These frequently issued 
guidelines reflect the rapid pace with which HIV research progresses. The prescription 
trends in the Swiss HIV cohort study were always nimble to adapt these changes and 
in many cases, lead the way. The treatment start conditions over the years presents an 
interesting overview of these changing guidelines. We observed in the past decade a 
consistent linear increase of CD4 cell count at first ART prescription, and decrease of 
time between diagnosis and ART initiation. The past 20 years also witnessed the rise 
and fall of many antiretrovirals.  
 
We explore here the prescription trends in the SHCS between 1996-2016 in terms of at 
which CD4 cell count did treatment start over the years. In addition, we examine how 
the time between diagnosis and treatment start changed in the past two decades. 
Finally, we explore the prescription trends of the different antiretroviral drugs over the 
aforementioned period. 
 
The median time between diagnosis and ART start closely reflects the change in policy 
of HIV treatment over the years (Figure 1).  The “Hit hard and early” era witnessed 
shorter time between diagnosis and treatment (Figure 1), yet, shortly thereafter, to 
spare patients the side effects of antiretrovirals available at the time, health providers 
deferred treatment to later stages where CD4 cell count dropped <200 cells/ml 
(reflected in years 2000-2005; Figure 1). The introduction of safer treatments and the 
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mounting evidence of the advantages of early ART lead to the return of much shorter 
times between diagnosis and treatment, this trend continues to our present day (2006-
2016). The consistent increase of CD4 cell count at treatment initiation also reflects 
these trends (Figure 2). The ever increasing CD4 cell count at diagnosis could also 
reflect heightened awareness of high risk populations, and earlier presentation. 
 
 
Figure 1 In the 20 years we examined, the median time between diagnosis and ART start peaked in 
2005 and  has been dropping consistently ever since, in line with the updates of the treatment 
guildlines favoring earlier start for personal health and preventivtion 
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Figure 2 The median and interquartile range of CD4 cell count in patients starting treatment in 
the past 20 years in the SHCS. We see a clear trend towards liberating ART start from CD4 cell 
count as the years go. This in addition to figure one point towards earlier treatment at better 
health state. 
 
In terms of which drugs are prescribed most (newly starting, or switching), TDF has 
been the NRTI of choice in the SHCS since its introduction, with ETC following with a 
slight delay (Figure 3; NRTI). ABC and 3TC were also frequently prescribed but to a 
lesser extent. ABC/3TC recently overtook TDF/ETC as the more prescribed NRTI 
backbone owing to their co-formulation with DTG. DTG based regimens constituted 
44% of new prescriptions (start or switch) since its introduction in 2013. DTG, RPV, 
and DRV/r made up approximately 80% of new prescriptions in 2015. 
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Figure 3 The percentage of patients starting or switching their treatment to a different group of 
antiretrovirals per years from 1996-2015 
 
The picture is only slightly different when the proportion of days per year on a certain 
drug for the HIV infected population is considered. 3TC/ABC and TDF/ETC remain 
the most used NRTIs. Overall, NNRTI and INSTI have been eating away the market 
share of PIs. In absolute numbers, EFV is the most prescribed complement for NRTIs, 
yet losing more recently parts of its share to Rilpivirin. Interestingly, NVP has been 
holding a constant share of the market ever since its introduction (~8%). 
 
PIs were generally less popular in recent years, except for a slight increase caused by 
the introduction of Darunavir. Finally, LPV and ATV are consistently being disfavored 
in recent years. 
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Figure 4 Proportion of total time spent on treatment per drug 
 
Overall, the SHCS has been for the past 20 years very agile in adopting new research 
findings and treatment recommendation, and in many cases leading the way. It is 
hoped that the shorter time between diagnoses would further decrease HIV incidence 
in Switzerland, and the higher CD4 at treatment initiation would lead to a better long-
term prognosis for the HIV infected population. Generally, there is a strong trend of 
switching to safer antiretrovirals and the more convenient one pill a day regimens. 
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Genotypic Resistance Tests 
Sequences Reveal the Role of 
Marginalized Populations in HIV-1 
Transmission in Switzerland
Mohaned Shilaih1,2, Alex Marzel1,2, Wan Lin Yang1, Alexandra U. Scherrer1,2, Jörg Schüpbach2, 
Jürg Böni2, Sabine Yerly3, Hans H. Hirsch4, Vincent Aubert5, Matthias Cavassini6, 
Thomas Klimkait7, Pietro L. Vernazza8, Enos Bernasconi9, Hansjakob Furrer10, 
Huldrych F. Günthard1,2, Roger Kouyos1,2  & the Swiss HIV Cohort Study† 
Targeting hard-to-reach/marginalized populations is essential for preventing HIV-
transmission. A unique opportunity to identify such populations in Switzerland is provided 
by a database of all genotypic-resistance-tests from Switzerland, including both sequences 
from the Swiss HIV Cohort Study (SHCS) and non-cohort sequences. A phylogenetic tree was 
built using 11,127 SHCS and 2,875 Swiss non-SHCS sequences. Demographics were imputed 
for non-SHCS patients using a phylogenetic proximity approach. Factors associated with 
non-cohort outbreaks were determined using logistic regression. Non-B subtype (univariable 
odds-ratio (OR): 1.9; 95% confidence interval (CI): 1.8–2.1), female gender (OR: 1.6; 95% 
CI: 1.4–1.7), black ethnicity (OR: 1.9; 95% CI: 1.7–2.1) and heterosexual transmission group 
(OR:1.8; 95% CI: 1.6–2.0), were all associated with underrepresentation in the SHCS. We 
found 344 purely non-SHCS transmission clusters, however, these outbreaks were small 
(median 2, maximum 7 patients) with a strong overlap with the SHCS’. 65% of non-SHCS 
sequences were part of clusters composed of >= 50% SHCS sequences. Our data suggests 
that marginalized-populations are underrepresented in the SHCS. However, the limited 
size of outbreaks among non-SHCS patients in-care implies that no major HIV outbreak in 
Switzerland was missed by the SHCS surveillance. This study demonstrates the potential of 
sequence data to assess and extend the scope of infectious-disease surveillance.
One of the key challenges in HIV surveillance and more generally in infectious-disease epidemiology is that the 
sampled or surveyed population might not be representative of the target population, especially with respect to 
hard-to-reach/marginalized subgroups1,2. The Swiss HIV Cohort Study (SHCS) is one of the most comprehensive 
HIV cohorts, with an estimated coverage of at least 45% of the cumulative number of HIV-infected individuals in 
Switzerland, approximately 75% of HIV-patients on antiretroviral treatment, and as much as 80% of AIDS cases3. 
However, since enrolment into the SHCS is voluntary, the possibility remains that marginalized populations are 
underrepresented and that entire sub-epidemics might be missed by the cohort2,4.
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These issues are particularly important in the context of late presentation of HIV patients, which is a 
known public health challenge worldwide. Marginalized populations have been shown to be prone to pres-
ent late as demonstrated in the UK5 and Europe in general6. Late presentation is one of the hurdles against 
“treatment-as-prevention” efforts on the population scale7. Therefore, marginalized populations present a prime 
target for intervention and knowing their characteristics would help tailor better interventions8.
A unique opportunity to assess the presence of such “under-the-radar” populations is provided by geno-
typic resistance testing, which is universal in most industrialized countries (i.e. virtually every patient in care 
receives a resistance test). In our case, we use for Switzerland a database of all genotypic resistance tests (GRT) 
performed in Switzerland. This database includes both cohort and non-cohort patients and has been initiated by 
the Swiss-Federal-Social-Insurance Office (“BSV”) as a quality-control measure for HIV genotyping. All Swiss 
Laboratories which perform routine HIV resistance tests are obliged to submit sequence data along with minimal 
demographic information for patient de-duplication, into this database, which therefore contains also sequence 
data for patients that are not enrolled in the SHCS.
This uniquely complete sequence database allows for the assessment of how well the Swiss HIV epidemic is 
covered by the SHCS. Both an overall good representation and occasional representation gaps appear plausible for 
this setting: On the one hand, the very high coverage and systematic long-term follow-up of the SHCS argues for a 
very high representativeness; on the other hand, populations that fear deportation, persecution, or social rejection 
might be less willing to participate in cohorts9.
Molecular phylodynamics10 has been used extensively in the recent years to evaluate several features of epi-
demics11, with HIV being one of the more studied viruses in Switzerland12 Europe13, and the rest of the world14. 
We aim to further investigate the utility of sequence data (which is being rapidly accumulated worldwide) in 
extending the scope of epidemiological analysis and to assess the unavoidable gaps arising in classical epidemio-
logical surveillance with a focus on marginalized populations (in this study: all patients facing barriers for enrol-
ment). We leverage the versatile tool of molecular phylodynamics to examine whether cohort and non-cohort 
patients differ with respect to demographics, whether non-cohort patients constitute entire missed outbreaks, and 
whether missing demographic information can be inferred from clustering patterns.
Results
We obtained 4,294 non-SHCS HIV sequences from the BSV database collected between 2003 and 2014, of those, 
879 were deemed potential duplicates of SHCS patients and thus discarded. Of the remaining 3415, only the first 
sequence per patient was retained using the workflow delineated in the methods, for a total of 2875 non-SHCS 
sequences.
The resulting 2,875 non-SHCS sequences were added to the first sequence from the 11,127 SHCS patients 
with available sequences (out of 18,688 SHCS enrolled patients as of December 2014) for a total of 14,002 Swiss 
sequences (Table 1). These sequences were then used along with >27,000 background sequences (from the Los 
Alamos HIV sequence database, see methods) to construct a maximum likelihood phylogenetic tree.
Demographics analysis. SHCS collected demographics. We found that SHCS patients differ from 
non-cohort patients (with a sequence, hereafter referred to as non-cohort or non-SHCS for simplicity) in terms 
of viral subtype and demographics (Tables 1 and 2). SHCS patients were 29% females, compared to 36% in the 
non-SHCS. Thus, women were overrepresented among non-SHCS patients (univariable odds ratio (OR) 1.6; 
95% confidence interval (CI) 1.4, 1.7),). In regards to subtypes (Fig. 1), univariable analysis showed that non-B 
subtypes were overrepresented among non-SHCS patients (OR 1.9, 95% CI 1.8, 2.1).
Sequence based demographics inference. In order to determine transmission-group and ethnicity for non-cohort 
patients, we utilized phylogenetic clustering with cohort patients (for whom these demographic variables are 
known, see methods). This approach is based on the fact that patients in the same phylogenetic cluster tend 
to exhibit similar demography15. The method was validated by testing its predictive power on two subsets of 
cohort-sequences with known demographics (a random sample from the SHCS and a group of late enrollers, see 
methods).
Overall, the inference method performed well (up to 81% correct predictions), yet the performance was 
dependent on the demographic feature predicted and the genetic distance (i.e. the comprehensiveness of sam-
pling and the consequent tightness of social clusters). More complex models (Support vector machines) improved 
prediction by 3–6%, when taking into account the inferred demographic, the larger cluster demographics distri-
bution, cluster size, and overall genetic distance (results not shown).
The inferred demographics of the non-SHCS individuals were then compared to that of the SHCS (Table 2). 
In univariable analysis, we found an overrepresentation of heterosexuals (HET) (OR 1.80, 95% CI 1.63, 1.99; 
compared to MSM), and intravenous drug users (IDU) (OR 1.8, 95% CI 1.52, 2.1) in the non-SHCS, while other 
transmission-groups were not significantly different between the two populations. Black ethnicity was overrep-
resented among non-SHCS patients (OR 1.9, 95% CI 1.7, 2.1), while other ethnicities showed no difference. This 
finding is consistent with the above observation of non-B subtypes being more frequent in non-SHCS patients 
than in the SHCS, given that non-B subtypes are highly correlated with non-white ethnicities. All the covariates 
were similar in magnitude and significance in a multivariate model as well (Table 2).
Overall, these analyses reveal a robust overrepresentation of non-B (not imputed) subtypes and non-MSM 
transmission groups (imputed) among patients not enrolled in the cohort.
Clusters Analysis. To shed light on possible clusters of patients that are not enrolled in the SHCS we focused 
on clusters that were predominantly Swiss (>=80% SHCS and non-SHCS) without imposing bootstrap-support 
or genetic-distance criteria12. As previously suggested, such transmission clusters can be interpreted as separate 
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introductions of HIV-1 into Switzerland12. Alternative cluster definitions exhibited similar patterns (data not 
shown).
Cluster size distribution and clustering pattern comparison. We found a similar degree of clustering among 
SHCS and non-SHCS Swiss patients and a strong intermixing between the two populations. 1,645 clusters were 
composed of >= 80% Swiss sequences, encompassing 8,135 (73%) of the SHCS sequences, and 1,938 (67%) 
non-SHCS sequences. The median cluster size was 2 with an interquartile range between two and five (Figure S1).
Most non-SHCS patients belonged to mixed clusters (of SHCS and non-SHCS sequences) indicating a strong 
mixing between SHCS and non-SHCS patients. Specifically, 65% of clustered non-SHCS patients (1253) were part 
of outbreaks that consisted of >= 50% SHCS sequences (this threshold was chosen to account for the fact that the 
median cluster size is two).
Factors determining predominantly Swiss clusters. Univariable analyses revealed that non-SHCS Swiss sequences 
were less likely to be part of a Swiss transmission cluster in comparison to SHCS sequences (OR 0.8, 95% CI 0.7, 
0.9) however this association was not robust for adjustment (OR 1.0, 95% CI 0.9, 1.1). In both univariable and 
multivariable analysis, non-B subtype significantly decreased the chances of being in a cluster (OR 0.27, 95% CI 
0.25, 0.29), which was similarly reflected in black ethnicity and other non-white ethnicities having similarly lower 
odds of clustering. The only consistent association of transmission group was that IDUs were more likely to clus-
ter than other transmission groups, while HETs and other transmission groups showed no significant associations 
(all compared to MSM) (Table 3).
Characteristics of purely non-SHCS clusters. Importantly, we found 344 transmission clusters consisting only of 
non-SHCS patients. These clusters occurred frequently but were limited in size (Fig. 2) with a median size of 2 
patients, IQR: 2–2 and a maximum cluster of seven patients, thus suggesting a strong overlap between transmis-
sion chains among SHCS and non-SHCS populations. In particular, this implies the absence of long transmission 
chains in Switzerland occurring completely outside the SHCS. Finally, there were no apparent subtypes or demo-
graphical factors driving the non-SHCS outbreaks (Table 4).
SHCS
Swiss Sequences 
(SHCS and non-SHCS)
SHCS 
sequences
Non-SHCS 
sequences
Demographics
 Number of Patients 18688 14002 11127 2875
 Median Sample year – 2004 (IQR 1998–2008) 2002 (IQR 1997–2006)
2009 (IQR 
2006–2012)
Sex, No. (%)
Male 13458 (72%) 9794 (70%) 7956 (72%) 1838 (64%)
Female 5230 (28%) 4208 (30%) 3171 (29%) 1037 (36%)
Transmission groupb, No. (%)
MSM 6996 (37%) 5252 (38%) 4307 (39%) 945 (33%)
HET 6153 (33%) 5388 (38%) 3959 (36%) 1429 (50%)
IDU 4770 (26%) 2769 (20%) 2396 (21%) 373 (13%)
Other 372 (2%) 246 (2%) 206 (2%) 40 (1%)
NA 397 (2%) 347 (2%) 262 (2%) 88 (3%)
Ethnicityb, No. (%)
White 12614 (68%) 10449 (75%) 8623 (78%) 1826 (63%)
Black 1889 (10%) 2059 (15%) 1318 (12%) 741 (26%)
Otherc 931 (5%) 892 (6%) 657 (6%) 235 (8%)
NAc 3254 (17%) 602 (4%) 532 (5%) 73 (3%)
Subtype, No. (%)
Aa 624 (4%) 446 (4%) 178 (6%)
Ba 9907 (71%) 8440 (75%) 1467 (51%)
Ca 647 (5%) 416 (4%) 231 (8%)
01_AEa 546 (4%) 403 (4%) 143 (5%)
02_AGa 784 (6%) 448 (4%) 336 (12%)
Other Subtypesa 1494 (10%) 974 (9%) 520 (18%)
Table 1.  Baseline demographics and the demographics of sequences on the phylogenetic tree stratified 
by their membership in the SHCS, Switzerland, 1988–2014. Abbreviations: GRT: Genotypic resistance test, 
MSM: men who have sex with men, HET: heterosexual, IDU: intravenous drug users, NA: not applicable. 
aSubtypes can only be determined for patients with a GRT. bTransmission group and ethnicity for non-cohort 
patients were determined by our phylogenetic predictor (see methods) with no restrictions applied on distance 
and sampling year. cOther ethnicities encompass all non-white and non-black ethnicities (e.g. Asian), while 
NA refer to patients with no applicable ethnicity information. For non-SHCS “NA” inferred ethnicity refers to 
patients to whom the closes SHCS patient had no applicable ethnicity information.
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Discussion
In this study we used a database containing all GRTs performed in Switzerland (since 2003) to evaluate the 
coverage-especially systematic gaps in the coverage-of the SHCS. Despite having an overall excellent coverage 
(79% of GRTs were from SHCS patients), we found that non-SHCS patients deviate in terms of demographics 
in comparison to SHCS patients. The most significant of these differences was an overrepresentation of non-B 
subtypes among non-SHCS patients. As non-B subtypes dominate in Africa and east Asia16, and as these subtypes 
exhibit a low degree of clustering in our data, this suggests that patients who acquired the infection abroad or 
from persons originating from those geographical regions, are less likely to enroll in the cohort. Accordingly, 
we also found that black ethnicity was more frequent among non-SHCS patients. These differences in subtype 
distribution and ethnicity indicate that hard-to-reach, marginalized populations, or individuals infected abroad 
were less likely to enrol in the SHCS compared to Swiss or individuals infected in Switzerland. Our results also 
emphasises the deep intermingling between the two populations, as 65% of non-SHCS patients were within SHCS 
outbreaks. In summary, non-SHCS patients do not seem to play a significant role in sustaining HIV transmission 
outside of the cohort, but have significant contributions toward the propagation of non-B subtypes in Switzerland.
As part of the growing understanding that migrants and refugees, especially from HIV-endemic countries 
are a vulnerable population with specific health needs, the Swiss Federal Office of Public Health is currently con-
ducting a survey among Sub-Saharan African population in Switzerland to map and characterize the needs and 
attitudes of this population (http://afric-answer.weebly.com/, accessed 1/02/2016). Our work further emphasizes 
Variable Univariable OR (95% CI) Multivariable OR (95% CI)c
Transmission Group 
 MSM 1 (Reference)
 HET 1.80 (1.63, 1.99) 1.40 (1.22, 1.60)
 IDU 1.78 (1.52, 2.07) 2.24 (1.90, 2.65)
 Other 1.02 (0.70, 1.48) 0.89 (0.59, 1.31)
Subtypes
 Subtype B 1 (Reference)
 Non-B subtypes 1.94 (1.77, 2.13) 1.57 (1.39, 1.77)
Ethnicity
 White 1 (Reference)
 Black 1.90 (1.69, 2.13) NAb
 Other 1.11 (0.94, 1.32) NAb
Sex
 Male 1 (Reference)
 Female 1.56 (1.41, 1.73) 1.26 (1.12, 1.42)
Sample Year 1.17 (1.16, 1.19) 1.19 (1.17, 1.21)
Table 2.  Univariable and Multivariable logistic regression analysis of the non-SHCS demographics 
compared to the SHCSa (reference), Switzerland, 2003–2014. Abbreviations: MSM: men who have sex 
with men, HET: heterosexual, IDU: intravenous drug users, NA: not applicable. aCohort membership was the 
dependent variable with being in the SHCS as the base case. bEthnicity was not included in the multivariate 
model because of co-linearity with subtype. cAdjusting for potential confounders sex, sample year, subtype, and 
transmission group.
Figure 1. Subtypes Distribution in the overall Swiss patients analysed. The X-axis represents the proportion 
of the patients, while the breadth of the column reflects the number of Swiss patients per subtype.
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Variable Univariable OR (95% CI) Multivariable OR (95% CI)b
Cohort Membership (Baseline SHCS)
SHCS 1 (Reference)
Non-SHCS 0.79 (0.72, 0.88) 1.02 (0.91, 1.14)
Transmission Group 
 MSM 1 (Reference)
 HET 0.41 (0.37, 0.46) 0.92 (0.80, 1.06)
 IDU 1.45 (1.19, 1.77) 1.66 (1.35, 2.05)
 Other 0.51 (0.36, 0.73) 0.83 (0.57, 1.23)
Subtypes
 Subtype B 1 (Reference)
 Non-B subtypes 0.25 (0.22, 0.27) 0.30 (0.26, 0.34)
Ethnicity
 White 1 (Reference)
 Black 0.26 (0.23, 0.28) NAa
 Other 0.46 (0.4, 0.53) NAa
Sex
 Male 1 (Reference)
 Female 0.49 (1.52, 1.78) 0.75 (0.66, 0.85)
Sample Year 0.98 (0.98, 0.99) 0.98 (0.97, 1.00)
Table 3.  Univariable and Multivariable logistic regression analysis of factors associated with clustering of 
Swiss sequences. Abbreviations: MSM: men who have sex with men, HET: heterosexual, IDU: intravenous drug 
users, NA: not applicable. aEthnicity was not included in the multivariate model because of co-linearity with 
subtype. bAdjusting for: sex, sample year, subtype, and transmission group.
Figure 2. A boxplot of the size distribution of pure SHCS clusters (transmission clusters consisting only of 
SHCS sequences) and pure non-SHCS clusters SHCS (transmission clusters consisting only of Swiss non-
SHCS sequences). 
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that stigmatization, criminalization, and racial discrimination of patients with HIV are potential obstacles in the 
battle against the HIV pandemic9.
Our sequence-based approach also validated previous independently-derived results about the representa-
tiveness of the SHCS3,17. Our finding that overall 79% of patients with a GRT are enrolled in the SHCS, agrees 
with previous studies3 showing that approximately 75% of patients on ART in Switzerland are in the SHCS. 
Furthermore, we also found an underrepresentation of non-B subtypes, which is in good qualitative and quanti-
tative agreement with the results from previous studies who also found that migrants were less likely to enrol in 
the SHCS4,18.
Despite the differences in the demographics and subtypes, there was no evidence of large outbreaks consisting 
of purely non-cohort patients (we found a single maximal cluster of 7 patients) (Fig. 2). Theoretically, one cannot 
rule out that the absence of larger clusters is caused by systematic sample collection bias (for GRTs) that only cap-
tures far linked parts of transmission chains, thus leading to smaller observed clusters19. However, this is highly 
unlikely given the universal coverage of the Swiss Health Care System, the fact that genotypic drug resistance 
testing is part of the standard of care, and the high probability that patients will seek care when they reach the 
AIDS phase (or often earlier). Furthermore, even for subtype CRF02_AG, the subtype with the worst representa-
tiveness, 57% of patients with GRT are enrolled in the SHCS (Table 1), and non-SHCS clusters are characterized 
by similar demographics than Swiss-transmission clusters in general. Altogether, this indicates that the sampling 
gaps of the SHCS are not substantial and even sub-epidemics containing non-enrollers are covered (at the very 
least, partly).
It should be noted that not all HIV positive patients have a genotypic HIV resistance test; thus, there may 
be fraction of diagnosed patients that are not part of the BSV database and hence not in our study population. 
For example, there may be a tendency to obtain resistance testing preferentially for patients that are considered 
eligible for treatment because of low CD4 cell counts, or pregnancy. However, it is likely that such effects have 
decreased in recent years, as GRTs close to the time of diagnosis have become the standard of care in Switzerland 
since approximately 2003. In addition, a large part of non-SHCS patients is also cared for in the SHCS cen-
tres, thus the same high medical standards are in place for this population and thus no bias towards less resist-
ance testing is expected4. Thus the population of patients with a GRT corresponds closely to the population of 
HIV-patients in care and especially to the population of patients on ART.
We employed a BLAST-based method to retrieve background sequences. The study’s outcomes were 
unchanged compared to including the entire Los Alamos pol sequences (results not shown). Using fewer 
sequences allowed for smaller trees that take less computational time to be built, thus enabling running the anal-
ysis several times as new sequences are added to the SHCS drug resistance database.
In this study, we utilized a liberal cluster definition (80% Swiss with no bootstrap support or genetic distance 
limitations), which allowed us to capture the maximal number of outbreaks from non-SHCS patients. For the 
purpose of this study (i.e. excluding large outbreaks among non-cohort patients), this cluster definition is con-
servative as it treats all possible clusters as true ones. Therefore this approach has the maximal possible sensitiv-
ity in detecting outbreaks outside the SHCS. Moreover, our findings remained robust under alternative cluster 
definitions (combinations of bootstrap support values (70%, 95%) and genetic distances (1.5% and 4.5%). The 
non-SHCS clusters found were comparable to those found under the presented cluster definition. The SHCS IQR 
and maximum cluster size remained stable at all combinations strict and liberal, reflecting the robustness of those 
Variable Univariable OR (95% CI) Multivariable OR (95% CI)b
Transmission Group
 MSM 1 (Reference)
 HET 1.11 (0.93, 1.33) 1.10 (0.88,1.39)
 IDU 1.34 (1.03,1.73) 1.44 (1.10,1.87)
 Other 1.57 (0.80,3.00) 1.61 (0.81,3.09)
Subtypes
 Subtype B 1 (Reference)
 Non-B subtypes 1.06 (0.90,1.25) 1.12 (0.91,1.39)
Ethnicity
 White 1 (Reference)
 Black 1.08 (0.90,1.30) NAa
 Other 0.68 (0.50,0.93) NAa
Sex
 Female 1 (Reference)
 Male 1.10 (0.93, 1.30) 1.18 (0.98, 1.42)
Sample Year
1.02 (0.99, 1.04) 1.02 (1.00, 1.05)
Table 4.  Univariable and Multivariable logistic regression of Factors affecting The Clustering of 
Predominantly Non-SHCS Sequences. Abbreviations: MSM: men who have sex with men, HET: heterosexual, 
IDU: intravenous drug users, NA: not applicable. aEthnicity was not included in the multivariate model because 
of co-linearity with subtype. bAdjusting for: sex, sample year, subtype, and transmission group.
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clusters. Thus despite the lack of a consensus for cluster definitions in molecular epidemiology20–22, our findings 
are robust in this regard.
We also presented a sequence-based method for inferring demographics information for patients with no 
such data available. This method allowed for the characterization of the demographics of non-SHCS patients and, 
more generally, proves to be a potential method for extending the coverage of other cohorts by using sequence 
data from non-cohort individuals (especially given the ever increasing ubiquity of sequencing data). It should be 
noted that the general problems associated with imputation (see for example23) also apply here. As with all infer-
ence methods, the quality of the training set plays a vital role in the prediction performance. In our data, some 
of the patients had uncertainties about the route of infection HET or IDU (7% of the all patients). This was in 
return reflected in the predictor performance where MSM membership was better predicted than HET and IDU. 
In addition, there are limitations to the correspondence of the HIV phylogenetic tree and the true underlying 
structure of the transmission chain, which might affect the prediction performance21,24. Despite the imperfect 
performance of the predictor, and given the difficulties associated with evaluating multinomial classification25, the 
predictor still provides some information about an otherwise completely unlit part of the population. Finally, the 
imperfect performance of the predictor does not affect the other major results of our analysis (overrepresentation 
of non-B subtypes among non-cohort patients; no large outbreaks completely outside the cohort). Therefore this 
method could allow the identification of sub-populations who are underrepresented in cohorts and who may 
therefore profit from additional recruitment and care efforts.
More generally, this work highlights the utility of molecular epidemiology in extending and testing the scope 
of classical epidemiological data. As sequencing pathogens from a large and representative number of patient 
samples becomes increasingly affordable, the situation we have encountered with the SHCS and the Swiss HIV 
epidemic will become more frequent: such a situation is characterized by high-quality and detailed epidemio-
logical data available for a limited number of patients and sequence data available beyond this group. Our work 
further demonstrates that in this setting sequence data can be used to approximate some of the missing epidemio-
logical information, to assess how well the available epidemiological data captures the spread of an infectious dis-
ease (in particular to test whether a cohort misses entire outbreaks), and to identify marginalized subpopulations.
Methods
Ethics statement. Participants in the SHCS provided written informed consent and the SHCS, this study, 
all associated experimental and non-experimental protocols has been approved and is in accordance with local 
ethics committees’ guidelines in the respective study centres (Kantonale Ethik-Kommission Zurich, Basel, Bern, 
Lugano, St Gallen, Geneva and Lausanne). In addition, the Kantonale Ethik-Kommission Zurich approved of the 
present analysis (approval number 29/14).
Patients data. The SHCS-drug-resistance database is part of the SHCS, which is a national cohort study that 
started in 1988 with ongoing enrolment and semi-annual follow up visits3. The SHCS-drug-resistance database 
contains 21,623 sequences (July 2014) belonging to 11,127 patients. Genotypic resistance tests are done routinely 
when the patient is first diagnosed, upon a viral-load test, or if virus rebound is observed during ART; in addition 
retrospective sequencing from the SHCS bio-bank was performed to maximize representativeness. Only the ear-
liest sequence of every SHCS patient was included in the phylogenetic tree, and only from patients belonging to 
MSM, HET, and IDU transmission groups (covering 96% of HIV cases in the SHCS). Further information about 
the sequences and their availability can be found in the supplementary material.
The BSV database started collecting genotypic resistance tests in 2003 as they became part of the standard of 
care in Switzerland; the analysis was hence restricted to data collected after 2003 from the SHCS as well. As some 
non-cohort patients choose to partake in the SHCS after having been tested and deposited in the BSV-database, 
suspected duplicate records between non-SHCS and the SHCS were discarded. A non-SHCS sequence was sus-
pected to be part of the SHCS (and hence discarded) if it matched an SHCS patient record on sex and birthdate, 
and their sequences formed a monophyletic clade.
It is plausible that the same non-SHCS patient might have several sequences in the BSV database, therefore, 
in order to keep only the single earliest sequence per non-SHCS patient, we assumed that two sequences with the 
same sex and birthdate and a genetic distance of <2% belonged to the same patient. We choose this conservative 
cut-off based on Hightower et al.26 finding that the genetic diversity of HIV pol gene sequence in patients followed 
longitudinally for a median of 1.8 years was less than 1%, and the median time for SHCS patients between the last 
negative HIV test and registration being 3.1 years. Technically, a graph was created for every group of sequences 
sharing the same sex and birthdate with edge-lengths being the genetic distance between two sequences. Edges 
were dissolved if they carried a genetic distance >2% (indicating that the two vertices/sequences were likely not 
from the same patient). Isolated vertices were considered unique patients while only the sequence with the earli-
est sampling date was retained from the connected vertices in the graph.
Phylogenetic tree construction. To identify transmission clusters, we first pooled the Swiss sequences 
with non-Swiss sequences from the Los-Alamos sequence database27. Specifically, we considered all non-Swiss 
sequences available in the Los-Alamos sequence database which spanned the protease and reverse transcriptase 
genes. Of those, only a single sequence per patient was kept provided that the sequence spanned at least 850 
nucleotides of the protease and reverse transcriptase (positions 2253–3870 of the HXB2 reference sequence, 
114,609 sequences (April/2014)). After excluding Swiss sequences present in the Los Alamos Database, for every 
Swiss sequence, the ten closest sequences were retrieved using BLAST (Standalone 2.2.28+28). Overall, 27,803 
foreign sequences were pooled with the Swiss sequences for the final phylogenetic tree construction.
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Next, the Stanford and International Antiviral Society-USA drug resistance mutations lists were consulted and 
the major drug resistance mutations were removed29,30 to avoid the potentially distorting effect of ART-driven 
convergent evolution.
Sequences were aligned to HXB2 using Muscle (V3.731, default settings) respectively and the phylogenetic tree 
was constructed using FastTree 2.132 with the Generalized time-reversible model and the CAT approximation 
(which has been shown to be better or as accurate as other maximum-likelihood phylogenetic inference meth-
ods33). Bootstrap-support values for clusters were derived from 100 bootstrap trees (using FastTree 2.132 and 
GNU Parallel34).
Clusters extraction and demographics prediction. Clusters were defined as monophyletic sub-trees 
with at least 80% Swiss sequences (SHCS and non-SHCS)12. In addition, sensitivity analysis was performed with 
other cluster definitions (combinations of bootstrap support values (70%, 95%) and inter-cluster genetic distances 
(1.5 and 4.5%)). Clusters were extracted (using Ape35, Caper36, R37) so that every Swiss sequence could maximally 
be present once: if a sequence was part of two clusters one of which is nested within the other, only the larger 
cluster was kept.
For the SHCS sequences, the patients’ demographics were available in the SHCS-database. For Swiss 
non-SHCS patients, sex and birthdate were provided with the sequences in the BSV-database, other demo-
graphic variables (transmission group, ethnicity) were inferred using phylogenetic proximity. Starting from a 
given non-SHCS tip the tree was traversed up to the parent node then down to the nearest (based on cophenetic 
distance) SHCS child node with known demographics. If no child node with known demographic were to be 
found from this node, then the tree was climbed up to the following parent, and the previous process repeated 
recursively until an SHCS patient with known demographics is found (R code present with supplementary mate-
rials). This method was validated on two sets. The first consisted of randomly chosen SHCS patients matching the 
number of non-SHCS patients (2,875 and for whom demographics was known) with 10-folds cross validation. 
For the second test set, we approximated the non-SHCS populations by choosing SHCS patients who were found 
to be HIV-positive at least three years prior to enrolment in the SHCS; those patients were termed “late-enrollers”. 
As this group also experienced barriers to enrolment in the SHCS, it represents a better approximation for the 
non-cohort population.
These analyses were performed using uni- and multivariable logistic regression adjusting for the following 
potential confounders: sex, sample year, subtype, and transmission group.
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Phylogenetic clustering approaches can elucidate HIV transmission dynamics. Comparisons across 
countries are essential for evaluating public health policies. Here, we used a standardised approach 
to compare the UK HIV Drug Resistance Database and the Swiss HIV Cohort Study while maintaining 
data-protection requirements. Clusters were identified in subtype A1, B and C pol phylogenies. We 
generated degree distributions for each risk group and compared distributions between countries 
using Kolmogorov-Smirnov (KS) tests, Degree Distribution Quantification and Comparison (DDQC) 
and bootstrapping. We used logistic regression to predict cluster membership based on country, 
sampling date, risk group, ethnicity and sex. We analysed >8,000 Swiss and >30,000 UK subtype B 
sequences. At 4.5% genetic distance, the UK was more clustered and MSM and heterosexual degree 
distributions differed significantly by the KS test. The KS test is sensitive to variation in network scale, 
and jackknifing the UK MSM dataset to the size of the Swiss dataset removed the difference. Only 
heterosexuals varied based on the DDQC, due to UK male heterosexuals who clustered exclusively 
with MSM. Their removal eliminated this difference. In conclusion, the UK and Swiss HIV epidemics 
have similar underlying dynamics and observed differences in clustering are mainly due to different 
population sizes.
Despite huge advances in prevention and treatment, the global burden of HIV continues to rise and novel 
approaches are required to eliminate the virus. Phylogenetic analyses of HIV genetic sequences enable detailed 
reconstructions of historical and current HIV transmission. As such, phylogenetics can help identify populations 
at risk and better tailor public health interventions.
The UK and Switzerland have two of the most extensive HIV sequence databases in the world: the UK HIV 
Drug Resistance Database (UK HIV RDB) and the Swiss HIV Cohort Study (SHCS), which contain pol sequences 
from at least 60% of diagnosed patients within each country. These databases have allowed Switzerland and the 
UK to lead the way in population-level HIV research, including HIV phylogenetics. Phylogenetic analyses of HIV 
in these densely sampled epidemics have been used to estimate epidemic parameters including times between 
transmissions according to risk group1,2, crossover between risk groups3–5 and the relative contributions of local 
versus imported infections5.
HIV was introduced into UK men who have sex with men (MSM) around 19806, probably from the USA7. 
Until the early 1990 s the epidemic was dominated by the transmission of subtype B among MSM and people who 
inject drugs (PWID). Six large reconstructed MSM transmission chains reflect independent introductions. The 
MSM epidemic displayed exponential growth in the 1980 s then stabilised in the 1990 s but continues to be highly 
clustered8. In the 1990 s, cases among heterosexuals became more common9 and non-B subtypes increased10,11. 
1University of Edinburgh, Edinburgh, UK. 2Division of Infectious Diseases and Hospital Epidemiology, University 
Hospital Zurich, University of Zurich, Zurich, Switzerland. 3Institute of Medical Virology, University of Zurich, Zurich, 
Switzerland. ͺMRC Clinical Trials Unit, London, UK. 5Laboratory of Virology and AIDS Center, Geneva University 
Hospital, Geneva, Switzerland. 6Department Biomedicine-Petersplatz, University of Basel, Basel, Switzerland. 
ͽDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, 
Switzerland. 8Public Health England, London, UK. *These authors contributed equally to this work. Correspondence 
and requests for materials should be addressed to M.L.R.-C. (email: Manon.Ragonnet@ed.ac.uk)
Receie: 1Ϳ a 2016
Accepte: 2ͽ u 2016
Puise: 1Ϳ eptemer 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:32251 | DOI: 10.1038/srep32251
Within MSM clusters, 25% of transmissions occur within 6 months of infection2. Heterosexuals in the UK display 
far less clustering and slower epidemic dynamics: only 2% of transmissions occur within 6 months of infection1. 
Currently, 100,000 people are living with HIV (0.15% prevalence), one quarter of whom are unaware of their 
infection12. Highly Active Antiretroviral Therapy (HAART) became available to residents in 1996 and to all in 
2012. HIV positive people on successful treatment in the UK have normal life expectancy13.
Switzerland had the highest HIV prevalence in Europe in the 1980 s14. HIV initially spread among MSM and 
PWID15 with heterosexual transmission starting to play a role after the mid-1980 s. The number of new diagnoses 
declined in the 1990 s, owing to needle exchange, heightened awareness, wide-scale testing, and the introduction 
of HAART in 1996. The number of new HIV diagnoses in Switzerland has fluctuated since 2000 with no clear time 
trends. The MSM and PWID epidemics display limited overlap. The heterosexual subtype B epidemic appears to 
be reseeded by PWID, migration, and (to a limited extent) MSM, with the importance of PWID in driving new 
infections decreasing over time3,5,16 (less than 3 PWID infections per year in the last 5 years17). Meanwhile only 
25% of non-B infections arise within Swiss-specific clusters, indicating a growing role for immigration5.
One important focus of phylogenetic analyses is on clusters: groups of sequences more related to each other 
than to the rest of the tree. Clustered sequences represent epidemiologically linked infections with short durations 
of time between transmissions and thus clusters represent the leading edge of the epidemic. High clustering of 
sequences within a country indicates rapid transmission and a bias towards within-country transmission.
Despite the two countries sharing similar epidemic histories, separate analyses have suggested different struc-
tures of the two countries’ epidemics, including distinct proportions of clustered sequences. In the UK, 24%, 40% 
and 22% of patients infected with HIV-1 subtypes B17, A1 and C12, respectively, cluster, whereas the numbers for 
Switzerland are 55%, 21% and 16%3,5. Clearly these differences arise in part due to distinct cluster definitions: the 
SHCS defines a cluster as ≥ 10 sequences supported by > 80% bootstrap3, while the UK studies defined clusters by 
a genetic distance (GD) ≤ 4.5% and bootstrap ≥ 90%2. Variable cluster definitions are a common problem in the 
literature. Bootstraps from 70% to 99% are used, in combination with GD from 1.5% to 4.5%. Another reason for 
the disparity could be differences in sampling procedures. However it is also possible that the contact and trans-
mission processes between Switzerland and the UK differ. Given these observed differences, it is unclear to what 
extent findings from one country can be applied to the other, and more importantly whether results from either 
can be extended to other less densely sampled European epidemics.
Because access to data from national cohorts is subject to restrictions, and because analyses have been con-
ducted according to in-house bioinformatics pipelines, the differences between the two epidemics have never 
been elucidated. Here, we present an analysis conducted in parallel on the two epidemics using a standardised 
approach. We hypothesised that because of its geography, the Swiss epidemic might be more integrated into the 
European epidemic and less clustered because of unsampled links in Swiss transmission chains. Using the same 
cluster definition, we compared the cluster distributions (the number and sizes of clusters) of the two countries 
as an indicator of underlying epidemic dynamics. We determined whether clustering was affected by risk group 
and ethnicity and compared the degree distributions (the number of linked partners) of heterosexual, MSM and 
PWID to test whether differences between countries were down to any specific risk group. Finally, we tested 
whether the UK and Swiss epidemics intermingled with the same foreign countries through sequence analysis.
Results
Baseline demographics. HIV pol sequences were retrieved from the SHCS drug resistance database18 
(SHCS DRDB, 2014) and from the UK HIV RDB (sequences up to mid-2013). Closely related sequences were 
obtained from the Los Alamos National Laboratory (LANL) database as described in the Methods. In the final 
analyses, the Swiss datasets contained 1,374 subtype A1 sequences (435 Swiss, 939 LANL), 15,043 B (8,390 Swiss, 
6,653 LANL) and 1,571 C (419 Swiss, 1,152 LANL). The UK datasets comprised 4,421 A1 (2,507 UK, 1,914 
LANL), 38,863 B (31,450 UK, 7,413 LANL) and 22,027 C (15,815 UK, 6,212 LANL). The Swiss epidemic com-
prised more PWID, fewer heterosexuals and more patients of White ethnicity (Table 1). These differences were in 
part a result of the different subtype composition across the two countries, but even within subtype B there were 
notable differences, with proportionally more cases among heterosexuals and PWID in Switzerland.
In both countries individuals for whom sequence and epidemiological data were available broadly matched 
the characteristics of the HIV diagnosed population as a whole, in terms of risk group, sex, ethnicity and age 
distribution19,20. Swiss sequence dates go back to 1995 owing to retrospective sequencing of samples from the 
SHCS Bio-bank21.
Sex Female
UK CH
A1 B C A1 B C
1442 (57.5%) 2327 (7.4%) 3869 (62.2%) 269 (62%) 1812 (22%) 237 (57%)
Risk
MSM 170 (6.8%) 22157 (70.4%) 660 (4.2%) 21 (5%) 3914 (47%) 25 (6%)
HET 1718 (68.5%) 3399 (10.8%) 11893 (75.2%) 366 (84%) 2626 (31%) 357 (85%)
PWID 92 (3.7%) 873 (2.8%) 128 (0.8%) 12 (3%) 1553 (19%) 9 (2%)
Other/NA 527 (21%) 5021 (16%) 3134 (19.8%) 36 (8%) 287 (3%) 28 (7%)
Ethnicity White 494 (19.7%) 22724 (72.3%) 1724 (10.9%) 194 (45%) 7333 (87%) 118 (28%)
Total 2507 31450 15815 435 8390 419
Table 1.  Baseline demographics of the two datasets.
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Difference in clustering. Maximum likelihood phylogenetic trees were constructed and clusters were 
selected22 at a range of genetic distance (GD) and bootstrap thresholds. A significantly larger proportion of 
UK subtype B sequences clustered in the uncorrected analysis at all thresholds (Supplementary Table 1, Fig. 1). 
Concordantly, the UK was more clustered in the univariate analysis (Table 2) with odds for being in a cluster 4 
times higher at 4.5% GD. At 4.5% GD, subtypes C and A1 were also more clustered in the UK, but there was no 
significant difference at 1.5% GD. The subsequent analysis focused mainly on subtype B.
Because of the difference in sampling time distributions and demographics between the two subtype B data-
sets, we considered the logistic regression adjusting for those variables. More recent samples were much more 
likely to cluster than older samples (Table 3) and when the model was adjusted for sample date, the Swiss epi-
demic was more clustered than the UK epidemic at 1.5% GD. At 4.5% GD, clustering remained higher for the UK 
but the strength of the association was halved compared with the univariate model. The effect of risk group and 
ethnicity on clustering was consistent across the two countries, with MSM in both countries showing the highest 
propensity for clustering.
Degree Distributions. Degree distributions for each country and risk group were generated based on cluster 
size distributions and compositions. For example a cluster containing 3 heterosexuals is equivalent to 3 hetero-
sexuals each with degree 2. Statistical frameworks exist to formally compare degree distributions23–25 and include 
bootstrapping to simulate the effect of the sampling process and test the robustness of conclusions. Degree dis-
tributions for the populations as a whole and for each risk group were compared using the Kolmogorov-Smirnov 
(KS) tests24 and the Degree Distribution Quantification and Comparison (DDQC) algorithm23. Based on the KS 
test, there was no difference between the two countries at 1.5% GD. At 4.5% GD, distributions differed signifi-
cantly for HET, MSM and the population as a whole, but not for PWID (Supplementary Table 2). The difference 
appeared to be driven by the longer tail of the UK distributions (Fig. 2), indicating the existence of larger clusters 
in the UK. The UK epidemic thus comprised not only a higher proportion of sequences in clusters, but also clus-
ters were larger.
Because the KS test is sensitive to network size, we applied the DDQC, which is robust to differences in scale. 
The DDQC measures the distance between networks based on features extracted from their degree distributions. 
However, it does not indicate whether distances calculated are significant or not. In order to generate null dis-
tributions, the UK and Swiss degree distributions were compared to themselves through bootstrapping. The UK 
and Swiss degree distributions were each bootstrapped 100 times to simulate the effect of sampling (see Methods) 
and the DDQC distance calculated between the true data and each bootstrap replicate (Fig. 3). Between country 
DDQC values were considered significant if they exceeded the 95% percentile of the within country DDQC 
Figure 1. Proportion of UK (pink) and Swiss (blue) sequences in clusters at different genetic distance (1.5% 
and 4.5%) and bootstrap (70%, 80%, 90%, 95%) thresholds. CH - Switzerland.
Bootstrap
Genetic 
Distance Covariates OR 2.5% 97.5%
0.7 0.015 UK 1.316 1.243 1.394
0.8 0.015 UK 1.335 1.258 1.418
0.9 0.015 UK 1.396 1.308 1.492
0.95 0.015 UK 1.444 1.345 1.551
0.7 0.045 UK 5.001 4.745 5.272
0.8 0.045 UK 4.119 3.904 4.347
0.9 0.045 UK 3.942 3.722 4.176
0.95 0.045 UK 3.176 2.986 3.381
Table 2.  Unadjusted logistic regression for the comparison of the degree of patients clustering between the 
UK and Switzerland (Subtype B). OR: odds-ratio.
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values (one-sided test). The DDQC distance was higher than expected only for heterosexuals at 4.5% GD (95th 
percentile DDQC = 0.97, observed HET DDQC = 1.22).
We hypothesised that the difference highlighted by the KS test at 4.5% might be the result of a difference in 
scale between the two epidemics. The UK population (and the HIV+ population) is much larger than that of 
Switzerland and so the pool of partners available is bigger. To examine the effect of epidemic size on clustering 
and degree distributions, we down-sampled the UK subtype B datasets to match the size of the Swiss datasets. In 
parallel, the Swiss datasets were bootstrap sampled with replacement. When these equal-sized resampled datasets 
were compared, the UK and Swiss degree distributions overlapped for the population as a whole and for the MSM 
population, but not for heterosexuals (Fig. 4).
In the true and the jack-knife sampled UK heterosexual population, we observed male heterosexuals with 
high degree (> 20) not present in the Swiss data (Fig. 4). The largest exclusively heterosexual cluster in the UK 
comprised 27 individuals (bootstrap = 0.9, GD = 4.5%); all heterosexuals with higher degree were in clusters 
dominated by MSM. When we dropped heterosexuals with degree > 26 from the UK sample (125 individuals out 
of a total of 1556 heterosexuals), the DDQC distance between the two networks fell within its null distribution 
(DDQC = 0.17, Fig. 3).
Cross border transmission. We investigated intermingling between national and foreign sequences by 
removing the 80% national criterion. We used a tight GD threshold (1.5%, 70% bootstrap) to capture close trans-
mission partners. At this threshold, Swiss sequences clustered with 162 non-Swiss sequences and UK sequences 
clustered with 353 non-UK sequences. For Switzerland, Western European countries provided over 75% of 
the links. For the UK, 50% of close links were with other European countries and 20% originated from other 
Anglophone countries: Australia, Canada and the USA (Supplementary Figure 1).
Discussion
The aim of this study was to compare epidemic dynamics between the two most densely sampled HIV epidemics, 
the UK and Switzerland, while adhering to data governance procedures and privacy protection requirements. We 
found that the fraction of sequences in transmission clusters was similar between the UK and Switzerland for a 
strict GD threshold (1.5%) but that they differed at a more relaxed GD threshold (4.5%). This suggests that the 
two epidemics resemble each other at a micro-level but differ at a macro-level. Because a statistical framework 
for comparing cluster distributions directly is lacking, we generated degree distributions based on cluster sizes 
and compared them through formal statistical tests: the KS test, the DDQC and bootstrapping. Based on the 
KS test, there were differences between the UK and Swiss subtype B degree distributions at 4.5% GD. However, 
downsampling the UK dataset to the size of the Swiss dataset rendered this difference insignificant in MSM and 
the population as a whole, but not heterosexuals (Fig. 4). In parallel, only heterosexuals showed a significant dif-
ference based on the DDQC test, which corrects for network size.
The degree distribution of UK heterosexuals had a long tail representing male heterosexuals clustered exclu-
sively with MSM. Previous UK analyses have demonstrated that a proportion of self-reported male heterosexuals 
are likely to have been infected through sex with men26, which appears to be the case here. When those high 
degree heterosexuals were removed from the dataset, the UK and Swiss no longer differed. Male heterosexuals 
who have sex with men are likely to also have sex with women and provide a bridge between MSM and heterosex-
ual epidemics. This is a likely route for the spread of non-B subtypes among MSM in the UK4. More detailed anal-
yses of the Swiss epidemic have found little overlap between the MSM and HET epidemics3; however, the Swiss 
heterosexual with the highest degree was similarly part of a HET/MSM cluster comprising 36 individuals, while 
Bootstrap
Genetic 
Distance Covariates OR 2.5% 97.5%
0.7 0.015
UK 0.66 0.617 0.705
Sample year 1.138 1.131 1.145
0.8 0.015
UK 0.665 0.621 0.713
Sample year 1.142 1.134 1.149
0.9 0.015
UK 0.694 0.645 0.749
Sample year 1.146 1.138 1.154
0.95 0.015
UK 0.706 0.651 0.765
Sample year 1.153 1.144 1.162
0.7 0.045
UK 2.692 2.538 2.856
Sample year 1.134 1.128 1.14
0.8 0.045
UK 2.12 1.996 2.252
Sample year 1.145 1.139 1.151
0.9 0.045
UK 1.968 1.846 2.099
Sample year 1.156 1.15 1.163
0.95 0.045
UK 1.551 1.448 1.662
Sample year 1.161 1.154 1.168
Table 3.  Logistic regression for the comparison of the degree of patients clustering between the UK and 
Switzerland, corrected for sample year (Subtype B). OR: odds-ratio.
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the largest exclusively heterosexual cluster contained only 9. In fact, 47% of UK and 38% of Swiss heterosexuals 
were in HET/MSM clusters. The present analysis cannot determine whether bridging is more common in the UK 
or whether risk group classification is assessed more thoroughly in Switzerland.
There was more overlap between PWID and heterosexuals in Switzerland than in the UK (23% vs 12%), but 
the difference in PWID degree distributions was not significant. Although this could be due to sample size, the 
stemming of the heterosexual epidemic through PWID in Switzerland is likely to be an old process3 while the 
bridging between HET and MSM in the UK is ongoing4,26.
Our findings were consistent across bootstrap thresholds. At 1.5% GD, we found no difference between the 
degree distributions of the Swiss and UK epidemics. At tight thresholds mostly pairs and recently infected patients 
are captured and these groupings are similar across the two countries. At 4.5% GD, the UK was more clustered and 
so the UK HIV RDB is more likely to capture larger transmission chains. However, the downsampled UK epidemic 
degree distribution overlapped with the Swiss degree distribution. While the proportion of clustered individuals in 
the UK is higher, the difference is seemingly due to the UK greater epidemic size rather than because of differences 
Figure 2. Degree distributions of the UK (pink) and Swiss (blue) subtype B epidemics. MSM - men who 
have sex with men, HET - heterosexuals. Cluster definition was: genetic distance = 4.5% and bootstrap = 90%. 
Note that the proportion of individuals of each degree is shown rather than the absolute number of individuals 
of each degree. The number of clustered individuals was much larger in the UK than in Switzerland.
Figure 3. DDQC distances within and between countries. DDQC – Degree Distribution Quantification and 
Comparison, CH - Switzerland, MSM - men who have sex with men, HET - heterosexuals. PWID – people 
who inject drugs. Cluster definition was: genetic distance = 4.5% and bootstrap = 90%. In order to generate 
null distributions of the expected values for the DDQC, we bootstrapped the Swiss and UK distributions and 
calculated DDQC values comparing the original datasets to their bootstrap samples (in blue and pink). The top 
of the coloured bars represent the mean distance of within country comparisons and the whiskers represent 
the 95% percentiles. The DDQC distance was then calculated between the UK and Swiss degree distributions 
(black triangles). The distance between countries was considered significant if it exceeded the 95% percentile 
from the simulated values, which was the case only for HET at 4.5% GD (indicated by *). When we removed 
heterosexuals who were likely to have been infected through sex with men from the UK dataset, the DDQC 
distance between the UK and Swiss HET degree distributions fell within the simulated null distribution (orange 
triangle).
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in contact or transmission processes. Both countries are similarly integrated into global unsampled epidemics, and 
this study underlines the importance of HIV public health interventions at the European and global levels.
Transmission between European countries has been analysed in more depth elsewhere27. In agreement 
with that analysis, we found Spain to be a major mixing partner for both Switzerland and the UK. Germany 
and the Czech Republic were also identified as significant. We found increased linkage between the UK and 
other Anglophone countries. In Switzerland strong segregation has been observed between German and 
French-speaking regions3 and this language-dependency of HIV transmission warrants investigation at the global 
scale.
Both countries have noted the subtype diversification of their respective epidemics9,28, yet the difference in 
size between the UK and Swiss subtype A1 and C datasets (18,000 vs 900, respectively) rendered a comparison 
meaningless. In Switzerland fewer than 25% of non-B infections were acquired in the country5, whereas in the 
UK over 50% of infections in individuals born abroad are thought to have occurred in the UK11. Local non-B 
non-heterosexual transmission appears far more extensive in the UK4.
Although degree distributions are a blunt tool for elucidating the dynamics of an epidemic29, they allowed 
us to apply statistically robust methods to compare the two epidemics without the need for exchanging sensitive 
data. Sequences from national databases were never exchanged and while this precluded a combined phylogenetic 
analysis of UK and Swiss sequences, one of the strengths of the study stems from undertaking such an analysis 
without compromising patient privacy. A second issue, the distributions of sample dates differing between the 
two cohorts, arose because the SHCS has conducted extensive retrospective sequencing on patients diagnosed 
early on in the epidemic and for whom samples had been stored. The SHCS coverage of older samples explains 
in part the lower clustering observed in Switzerland. However, clustering remained significantly higher in the 
UK at 4.5% GD after sample date was adjusted for. Thirdly, international comparisons were based on the LANL 
database which is in essence a large-scale convenience sample and not necessarily representative. We suggest the 
apparently important contribution of the Czech Republic to both epidemics may arise from recent submission of 
large numbers of sequences from that country.
In conclusion, we showed that apparent major differences in clustering patterns between the UK and 
Switzerland subtype B epidemics can be explained for the most part by differences in size and sampling time. 
This is the first study leveraging the vast amounts of data available in multiple national HIV databases. We made 
use of data without breaching data governance procedures and highlighted that transmission trends in these two 
countries are driven by similar underlying factors. From a methodological perspective, our study highlights the 
importance of using the same cluster-detection algorithm and correcting for demographic factors when compar-
ing clustering patterns across settings.
Methods
Data. Switzerland. 9,232 HIV pol sequences were retrieved from the SHCS DRDB. The SHCS DRDB aggre-
gates all HIV resistance tests for patients of the SHCS. SmartGene is responsible for data storage and management 
(http://www.smartgene.com). The DRDB is part of the SHCS, which is an ongoing national clinical cohort of 
HIV patients aged 16 and above with biannual follow up (http://www.shcs.ch)20. Sequences were assigned sub-
types using REGA30,31; subtypes B (91%), A1 (5%), and C (5%) were analysed. The SHCS has been approved by 
the ethics committees of all participating institutions, and written, informed consent has been obtained from 
participants.
UK. 63,065 HIV pol sequences were obtained from the UK HIV RDB (http://www.hivrdb.org). Sequences cover 
protease and 900 bases of reverse transcriptase. After age, sex, risk group and ethnicity were attached, the data 
Figure 4. Jack-knife and bootstrap sampled degree distributions of the UK (pink) and Swiss (blue) 
epidemics. UK subtype B degree distribution for men who have sex with men (MSM), heterosexuals (HET) and 
the population as a whole (all) were jack-knife sampled 100 times to match the size of the Swiss epidemics (in 
light pink). The Swiss epidemic was bootstrapped 100 times to its full size (in light blue). Degree distributions 
are shown on a double-logged scale. Samples overlapped for MSM and the dataset as a whole, but not for HET. 
Where Swiss replicates cannot be seen they are covered by the UK replicates.
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were anonymised and delinked. Subtypes were assigned using SCUEAL32 and REGA30,31. The three most com-
mon subtypes were B (48.6%), C (24.4%), and A1 (4.0%). Ethical approval was given by the London Multicentre 
Research Ethics Committee (MREC/01/2/10; 5 April 2001).
As submission of the UK and Swiss sequence datasets to public databases would permit transmission network 
identification and thus risk breaching patient confidentiality, we have followed earlier practice3,33. A random 
sample of 10% of each subtype and country has been submitted to Genbank (accession numbers available in 
supplementary material).
Background sequences. All pol (HXB2 positions 2253–3870) sequences of HIV subtype A1, B, and C longer than 
900 bases were retrieved from LANL (January 2014). To limit the size of alignments, the ten closest sequences 
to each of the local (UK and Swiss) sequences were selected using Viroblast34. For this step, UK sequences were 
removed from LANL alignments before the UK Viroblast run, and Swiss LANL sequences were removed before 
the Swiss run.
Only the earliest available sequence for each individual was used. All sequences were stripped of 44 sites asso-
ciated with drug resistance based on the 2013 International AIDS Society list35.
Tree Building and Cluster Picking. Duplicate sequences were removed. Maximum likelihood phyloge-
netic trees were constructed for each country and subtype separately (six trees in total) using FastTree v2.036 with 
100 bootstraps. Initially clusters were selected for further analysis if they were supported by bootstrap thresholds 
of 70%, 80%, 90% and 95% and maximum GD of 1.5% or 4.5% (8 thresholds total)22. Of the initially identified 
clusters, those in the Swiss trees were further selected to contain at least 80% SHCS sequences, and clusters in 
the UK trees at least 80% UK sequences. In a separate analysis, we examined all clusters with at least one UK or 
Swiss sequence (within the respective datasets) to investigate mixing between national and foreign sequences. The 
automated pipeline included analysis with the Cluster Picker and Cluster Matcher22 as well as processing through 
python and R scripts (available upon request). The Cluster Picker was upgraded to recognise IUPAC nucleotide 
ambiguity codes as matches (version available upon request from the authors), increasing clustering by around 
15% in both datasets.
From the Cluster Picker and Cluster Matcher output files, we generated degree distributions (the number of 
links for each node). As files contained risk group composition for each cluster, it was possible to break down 
degree distribution by risk group. Nodes were sampled with replacement from the network with information 
on their cluster membership. Nodes sampled with the same cluster membership were linked together in each 
bootstrapped network, so that clusters sometimes increased in size, sometimes decreased in size or otherwise 
disappeared, and degree distribution was re-estimated each time. Jack-knife resampling where the number of 
nodes sampled was smaller than the full network size was also performed.
Statistical analysis. The number of sequences clustering at different thresholds between the two epidemics 
was compared using Fisher’s exact test with Bonferroni correction (24 comparisons across clustering thresholds 
and subtypes). Degree distributions were compared using the KS test24 and the DDQC algorithm23. The KS test is 
a nonparametric test which compares the cumulative distribution of two samples to estimate whether they have 
been drawn from the same distribution and is frequently used to compare degree distributions25. The DDQC was 
developed specifically to compare degree distributions and corrects for differences in population size while the 
KS test does not. The DDQC extracts a vector of eight values from degree distributions for comparison. In brief, 
the range of node degrees is divided into eight regions based on the minimum, maximum, mean and standard 
deviation of the degree distribution. The probability of the degree of any node being contained within each inter-
val is calculated. The distance between two networks is the sum of the absolute differences for each of the eight 
features extracted.
The UK subtype B dataset used here was 3.75 times larger than the Swiss dataset; the UK MSM dataset was 5.7 
times larger and the UK heterosexual dataset was 1.3 times larger (Table 1). To investigate the effect of the differ-
ence in size of the pool of possible infectors, the UK dataset was jack-knife sampled to the size of the Swiss dataset. 
One hundred jack-knife replicates were generated, and in each replicate the degree distribution was re-estimated 
based on the links present in the sample.
A logistic regression model was used to characterise the factors influencing clustering in the two countries. 
The model was applied with cluster membership as the outcome variable and with the country of origin (UK 
or Switzerland) as the main exposure variable. Sampling dates, risk group, sex, and ethnicity were adjusted for. 
Statistical analyses were conducted in R37.
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Background. Hepatitis B virus (HBV) has a detrimental effect on human immunodeﬁciency virus (HIV) natural course, and
HBV vaccination is less effective in the HIV infected. We examine the protective effect of dually active antiretroviral therapy
(DAART) for HIV/HBV (tenofovir, lamivudine, and emtricitabine) in a large cohort encompassing heterosexuals, men who have
sex with men, and intravenous drug users who are HIV infected yet susceptible to HBV, with comprehensive follow-up data about
risky behavior and immunological proﬁles.
Methods. We deﬁned an incident HBV infection as the presence of any of HBV serological markers (hepatitis B surface antigen,
anti–hepatitis B core antibodies, or HBV DNA) after a negative baseline test result for anti–hepatitis B core antibodies. Patients with
positive anti-hepatitis B surface antigen serology were excluded. Cox proportional hazards models were used, with an incident case of
HBV infection as the outcome variable.
Results. We analyzed 1716 eligible patients from the Swiss HIV Cohort Study with 177 incident HBV cases. DAART was neg-
atively associated with incident HBV infection (hazard ratio [HR], 0.4; 95% conﬁdence interval [CI], .2–.6). This protective associ-
ation was robust to adjustment (HR, 0.3; 95% CI, .2–.5) for condomless sex, square-root–transformed CD4 cell count, drug use, and
patient demographics. Condomless sex (HR, 1.9; 95% CI, 1.4–2.6), being a man who has sex with men (2.7; 1.7–4.2), and being an
intravenous drug user (3.8; 2.4–6.1) were all associated with a higher hazard of contracting HBV.
Conclusions. Our study suggests that DAART, independently of CD4 cell count and risky behavior, has a potentially strong
public health impact, including pre-exposure prophylaxis of HBV coinfection in the HIV infected.
Keywords. HBV prevention; HIV coinfection; tenofovir; lamivudine; emtricitabine.
The prevention of hepatitis B virus (HBV) transmission in in-
dividuals infected with human immunodeﬁciency virus (HIV)
is important because both viruses share common transmission
modes and have detrimental effects on each other’s natural
course of infection [1–3]. HBV is a worldwide leading cause
of chronic hepatitis, responsible for roughly half of deaths due
to hepatocellular carcinoma and a third of those related to liver
cirrhosis [4]. It is estimated that, globally, HBV affects 10% of all
HIV-1–infected individuals [5, 6]. In addition, HBV and hepa-
titis C virus together are responsible for approximately 15% of
deaths in HIV-infected patients in the Swiss HIV Cohort Study
(SHCS) [7].
Vaccination against HBV remains the mainstay of preventing
HBV acquisition both in HIV-infected and uninfected individ-
uals. However, owing to the effect of HIV on the immune sys-
tem, mounting and maintaining a protective immune response
against HBV is sometimes unattainable, with success rates be-
tween 18% and 71% [8–10].
Given the unfavorable course of HIV/HBV coinfections, it is of
great public health value to prevent HBV acquisition in HIV-
infected individuals. Earlier studies focused on the protective ef-
fect of dually acting HIV-1 antiretroviral drugs (tenofovir [TDF],
lamivudine [3TC], and emtricitabine [FTC]) [11–14] against
HBV,mainly inmenwho have sex withmen (MSM). Considering
that heterosexual transmission remains the main driver of HIV
propagation in sub-Saharan Africa and many parts of Asia [15],
intravenous drug use is responsible for 30% of HIV cases outside
sub-Saharan Africa [16], and the highest HBV burden lies in sub-
Saharan Africa and Southeast Asia [17], it is of great importance
to evaluate the protective effect of dually active antiretroviral ther-
apy (DAART) in all 3 of these major transmission groups.
Consequently, in the current study, we examined the effect
of DAART-containing regimens (TDF, 3TC, and FTC) in
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protecting against incident HBV infections in heterosexuals
(HET), MSM, and intravenous drug users (IDU). Our study
has among the largest number of HBV-susceptible HIV-
positive individuals and incident cases examined so far in the
context of the protective effects of antiretroviral therapy
(ART), and it is unique in its generalizability, because it consid-
ers the 3 main transmission groups. Using the SHCS’s compre-
hensive longitudinal data on patients’ sexual behavior, drug use,
and immunological and ART status, we aim to quantify the
effects of DAART and disentangle the effects of the aforemen-
tioned factors from DAART’s direct effect, which would pro-
vide a more concrete estimate of the degree of protection
DAART confers against incident HBV infections. A strong
protective effect would call for early treatment initiation and,
especially, for favoring regimens containing DAART in settings
where rates of vaccination or vaccination success are low and
HBV is common. We hypothesize that DAART has a protective
effect against HBV but that the magnitude of the association
could be modiﬁed, masked, or confounded by behavioral,
demographic, and immunological factors.
METHODS
Patients
The SHCS is an ongoing, prospective, national observational
cohort study with biannual follow-up visits, and it started
in 1988. Written informed consent was obtained from all pa-
tients. CD4 and CD8 cell counts and HIV-1 viral load are col-
lected continuously (in general every 3 months). In addition,
detailed treatment/ART history is recorded for each patient.
Age, transmission group, and ethnicity are also recorded,
along with condom usage. In particular, at each of the biannual
follow-up visits, individuals were asked, concerning in the
preceding 6 months (1) whether they had occasional partners,
(2) whether they had sex with an occasional partner, and (3) how
often they used condoms. The SHCS has an excellent coverage,
including >70% of patients receiving ART in Switzerland [7].
The study population included all HIV-1–infected individu-
als taking part in the SHCS from 1992 to 2014 who were tested
more than once for one or more of the following HBV markers:
hepatitis B surface antigen, anti–hepatitis B core antibodies
(anti-HBc), or HBV DNA. Next, patients positive for any of
the aforementioned HBV markers at baseline were excluded
from the analysis (borderline test results were considered posi-
tive). Successful vaccination is highly protective against HBV
infection. Accordingly, patients with positive anti-hepatitis B
surface antigen (anti-HBs) serology at baseline were excluded.
For patients in whom positive anti-HBs results occurred during
follow-up, only the time at risk before the ﬁrst positive anti-HBs
result was included. An incident case patient was then deﬁned
as a person in whom any of the 3 HBV markers of interest
turned positive after a negative anti-HBc result at least at
baseline.
An isolated positive anti-HBc serology has been linked to
several factors, including the assay method, the viral strain,
and the immunological status of the patient [18], and its clinical
and physiological signiﬁcance remains unclear. Hence, we per-
formed a sensitivity analysis excluding patients with an isolated
positive anti-HBc serological results to assess the robustness of
the associations. In all analyses, only patients with an observa-
tion time >6 months were examined.
Statistical Methods
We used both univariable and multivariable Cox proportional
hazards models to address our hypothesis. The outcome vari-
able in the analysis was an incident case of HBV infection,
and the main explanatory variable was the proportion of
observation time with the patient receiving ART, calculated
by dividing the number of months a patient received ART by
the number of months he or she was observed (later further sub-
divided into individual DAART and ART regimens). In a sensi-
tivity analysis, we also determined the proportion of observation
time during ART when a patient’s viral load was suppressed (ie,
<400 copies/mL) or nonsuppressed. Given the longitudinal na-
ture of the data and the fact that the outcome variable (HBV in-
fection) cannot be observed exactly (unlike death, for example),
as a sensitivity analysis, we used a parametric interval-censored
model with time-varying covariates [19] (see SupplementaryMa-
terial for methods, R code, and simulated data).
The covariates tested were the CD4 and CD8 cell counts clos-
est to infection or censoring time, because both are implicated
in the natural course of both HBV and HIV [20, 21]. Both
counts were square-root transformed, which provides more
normally distributed values and variance stabilization. Having
had unprotected sex (occasional or with stable partner), as re-
ported by the patient (during follow-up before censoring or the
event) was taken as a proxy for risky behavior. We also con-
sidered baseline CD4 and CD8 cell counts, age at enrollment,
history of drug use, ethnicity, and an interaction term of sex
with transmission group (ie, male-HET, female-HET, male-
MSM, male-IDU, or female-IDU), as well as the nadir CD4
cell count, calculated as the lowest count observed during the
observation time for an individual patient.
RESULTS
Starting with all SHCS patients registered (December 2014;
N = 18 663), we kept only those who had a negative baseline
HBV serological result, had ≥1 test after baseline, and who be-
longed to one of the major transmission groups (MSM, HET, or
IDU) (n = 1716), Figure 1. The risk group distribution was 936
HET (54%), 220 IDU (13%), and 612 MSM (33%). A total of
4532 individuals were excluded owing to the unavailability of
their HBV tests; these patients were mostly recruited early in
the cohort (median year, 1990; interquartile range [IQR],
1988–1992), and 95% died or were lost to follow-up by 1996.
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The total number of incident HBV cases was 177, of which 86
(49%) occurred in MSM. Patient observation time started from
the date of the ﬁrst negative test results and ended the last time
the patient was tested or when an event occurred. Most patients
had only 2 tests (n = 1129; 66%; IQR 2–3 tests), and the median
(IQR) time between tests was 29 (12–58) months (Table 1). The
total observation time was 10 682 person-years. The overall
incidence rate per 1000 person-years was 16 (95% conﬁdence
interval [CI], 14–19). The transmission group incidence rates
were as follows, per 1000 person-years: HET, 9 (95% CI, 6–11);
IDU, 28 (21–38); and MSM, 25 (21–31).
Both univariable and multivariable analysis showed a strong
reduction in the risk of acquiring HBV for patients receiving
DAART. In univariable analysis, DAART had a protective effect
against HBV acquisition, with a hazard ratio (HR) of 0.4 (95%
CI, .2–.6), whereas other ART regimens had none (HR, 1.63;
95% CI, .94–2.81) (Figure 2 and Table 2). Furthermore, the ex-
clusion of patients with isolated positive anti-HBc serology did
not affect the associations (HR, 0.4; 95% CI, .2–.8). The propor-
tion of time a patient was receiving DAART with an HIV RNA
viral load <400 copies/mL showed similar protective effect (HR,
0.4; 95% CI, .2–.6), while receiving DAART without suppres-
sion offered no signiﬁcant protection (0.6; .2–1.7). Other non-
DAART antiretrovirals showed no protective effect even with
suppression (HR, 1.4; 95% CI, .70–2.7); moreover, being on
non-DAART regimens and not being suppressed was associated
with higher HBV incidence (3.4; 1.2–10.0), but this association
was not signiﬁcant in the multivariable model (2.0; .5–7.5).
The log-likelihood ratio (LLR) test showed no signiﬁcant
Table 1. Baseline Characteristics of the 1716 Patients Eligible for the
Study Based on Their HBV Status
Characteristic
Patients, No. (%)a
Incident HBV
Infection (n = 177)
No Incident HBV
Infection (n = 1539)
Sex
Male 141 (80) 971 (63)
Female 36 (20) 568 (37)
Transmission group
HET 49 (28) 887 (58)
IDU 42 (24) 178 (12)
MSM 86 (48) 474 (31)
CD4 cell count, median (IQR),
cells/mL
429 (265–636) 432 (271–625)
Age at registration, median (IQR), y 33 (27–38) 33 (28–40)
HIV-1 RNA, median (IQR), log10
copies/mL
3.5 (2.1–4.7) 3.4 (2.0–4.4)
Ethnicity
White 151 (85) 1246 (81)
Black 10 (6) 170 (11)
Hispano-American 6 (3) 52 (3)
Asian 6 (3) 30 (2)
Other/unknown 4 (3) 41 (3)
Proportion of observation time on treatment, median (IQR), %
DAART 35 (0–80) 60 (15–94)
Non-DAART 0 (0–30) 0 (0–14)
Year of enrollment, median (IQR) 1996 (1992–2001) 1998 (1994–2003)
Tests performed, median (IQR), No. 2 (2–2) 2 (2–3)
Observation time, median (IQR), mo 59 (32–99) 66 (34–111)
History of drug use 2 (1) 16 (1)
Year of ART initiation, median (IQR) 1997 (1996–2002) 1998 (1996–2004)
Year of infection, median (IQR) 2006 (2002–2010) . . .
Abbreviations: ART, antiretroviral therapy; DAART, dually active ART; HBV, hepatitis B virus;
HET, heterosexuals; HIV, human immunodeficiency virus; IDU, intravenous drug users;
IQR, interquartile range; MSM, men who have sex with men.
a Data represent No. (%) unless otherwise specified.
Figure 1. Patient selection flowchart. Abbreviations: Anti-HBC, anti–hepatitis B
core antibodies; HBV, hepatitis B virus; HET, heterosexuals; IDU, intravenous drug
users; MSM, men who have sex with men; SHCS, Swiss HIV Cohort Study.
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difference between the unadjusted model with DAART only
and the model with DAART conditional on suppression
(P = .29); however, the difference was borderline signiﬁcant
when the adjusted models were compared (P = .055).
The univariable analysis also demonstrated a higher
burden of incident cases in MSM and IDU than in HET
(Table 2). Compared with the male-HET group, the female-
HET group had lower odds of acquiring HBV (HR, 0.5; 95%
CI, .3–1.0).
Self-reported risky sexual behavior was associated with high-
er risk of acquiring HBV. A history of condomless sex was as-
sociated with higher HBV acquisition risk (HR, 1.9; 95% CI,
1.4–2.6), whereas having used intravenous drugs at any point
during the observation time was not (HR, 1.0; 95% CI, .2–3.8).
We examined the square-root–transformed (√) CD4 cell
count closest to the HBV coinfection date as a proxy for the
immune-mediated effect of ART on HBV, and a protective as-
sociation was observed, but it was not statistically signiﬁcant
(HR, 0.98; 95% CI, .96–1.002). Neither the baseline √CD4
cell count nor √CD8 cell count had an inﬂuence on the risk
of HBV acquisition. Using non–square-root–transformed
CD4 and CD8 cell counts did not alter the associations.
One notable observation was the stronger protective effect of
DAART in patients with CD4 cell count nadir ≥200 × 106/mL
(635 patients; 38%). In those patients, the HR for DAART’s
protective effect was 0.2 (95% CI, .1–.5) in the univariable
and 0.1 (CI, .1–.4) in the multivariable model. DAART also
had a protective effect in patients with a CD4 cell count nadir
<200 × 106/mL (1062 patients; 62%), but this was signiﬁcant
only in the univariable model (univariable HR, 0.5 [95% CI,
.3–.8]; multivariable HR, 0.5 [.2–1.1]). The difference in
DAART’s effect between patients with CD4 cell count nadirs
≥200 versus ≤200 106/mL was not statistically signiﬁcant in a
multivariable Cox model with an interaction term between
the proportion of time receiving DAART and the nadir CD4
cell count.
The adjusted analysis displayed the same direction of asso-
ciation in terms of the protective effect of DAART (HR, 0.3;
95% CI, .2–.6; Table 2). √CD4 was not signiﬁcant in the mul-
tivariable model (HR, 1.0; 95% CI, .98–1.03), but condomless
sex remained signiﬁcant (1.9; 1.4–2.6). The protective associa-
tion of DAARTwas not affected by adjusting for these variables.
The protective association of DAART was also robust to model
choice, as evident in a sensitivity analysis using an interval-
censored parametric survival model with an exponential hazard
function and ﬁxed and time-varying covariates (univariable
HR, 0.5 [95% CI, .3–.6]; adjusted HR, 0.5 [.4–.7]).
In univariable analysis, the hazard of HBV acquisition for
patients receiving 2-agent DAART (TDF plus 3TC or TDF
plus FTC) was half that of patients receiving single-agent
DAART (TDF or 3TC alone; FTC was not prescribed alone)
(unadjusted HR for 2-agent DAART, 0.2 [95% CI, .1–.6]; un-
adjusted HR for single-agent DAART, 0.4 [.3–.7]). The protec-
tive effect of dual therapy was further strengthened after
adjustment (adjusted HR for 2-agent DAART, 0.1 [95% CI,
.0–.3]; adjusted HR for single-agent DAART, 0.4 [.2–.6]).
We tested the statistical signiﬁcance of the reduction of
risk for 2- versus single-agent DAART regimens using the
likelihood-ratio test, and obtained P values of .17 and .01 for
the univariable and adjusted models, respectively.
Figure 2. Hazard ratios (HRs) of the different factors influencing hepatitis B virus (HBV) incidence. Adjusted model covariates are shown in Table 2. Results for antiretroviral
therapy (ART; human immunodeficiency virus only) and dually active ART (DAART) represent proportion of observation time. Abbreviations: CI, confidence interval; HET, het-
erosexuals; IDU, intravenous drug users; MSM, men who have sex with men.
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After demonstrating an overall strong protective effect
of DAART against HBV coinfections, we went further to disen-
tangle the effects of the different DAART regimens (Table 3).
DAART regimens containing TDF in combination with 3TC
or FTC displayed the strongest protective effect against HBV
(adjusted HR, 0.03 [95% CI, .0–.4] and 0.2 [.1–.5], respectively).
Furthermore, DAART regimens containing 3TC as the only du-
ally active substance were comparable to regimens with TDF as
the only dually active substance (Table 3). TDF-only regimens
had wide CIs because of the short observation time for patients
receiving TDF monotherapy. In the unadjusted model there was
no signiﬁcant difference in the LLR test comparing all DAART
combined versus individual DAART regimens (P = .1), but the
difference was statistically signiﬁcant in the adjusted model
(P = .01).
DISCUSSION
In this study we analyzed a large cohort of HIV-1–infected
individuals at risk of acquiring HBV, to evaluate the protective
effect of DAART in the 3 major HIV transmission groups
(HET, IDU, and MSM). We conﬁrm earlier reports about the
protective effect of DAART, and we report a strong protective
effect of all DAART [11–14] in said risk groups. We also
show that risky sexual behavior plays a key role in the acquisi-
tion of HBV infection because it independently increases the
risk even in patients receiving DAART; however, it does not
seem to be a confounder of DAART’s protective effect. Finally,
we found that the immune status close to infection time, as
measured by CD4 cell count, was not a main actor inﬂuencing
the risk of HBV acquisition for patients receiving DAART.
However, DAART had a higher protective effect in patients
with a better long-term immunological status (represented by
nadir CD4 cell count ≥200 × 106/mL).
Our ﬁndings conﬁrm the importance of viral suppression
(and the implicit adherence) in reaching the protective effect
of DAART [11]. We observed that the protective effect of
Table 2. Univariable and Multivariable Cox Proportional Hazards Models
for the Factors Associated With HBV Incidence
Covariate
HR (95% CI)
Univariable Analysis
Multivariable Analysis
of Complete Cases
Only (n = 1697)
Proportion of observation time on treatment
DAART 0.38 (.25–.58) 0.32 (.18–.58)
ART 1.63 (.94–2.81) 1.12 (.55–2.30)
Sex interaction with transmission group
Male-HET 1 (Reference) 1 (Reference)
Male-IDU 2.67 (1.57–4.53) 2.81 (1.56–5.06)
Male-MSM 2.24 (1.46–3.44) 2.33 (1.46–3.72)
Female-HET 0.55 (.31–.97) 0.47 (.25–.88)
Female-IDU 2.01 (1.07–3.77) 2.71 (1.38–5.31)
Ethnicity
White 1 (Reference) 1 (Reference)
Black 0.62 (.33–1.18) 1.52 (.71–3.26)
Hispano-American 1.03 (.46–2.34) 1.53 (.66–3.53)
Asian 1.77 (.78–4.01) 2.37 (.96–5.85)
Other/unknown 1.38 (.51–3.74) 1.18 (.42–3.31)
Age at cohort enrolment 1.00 (.98–1.02) 1.01 (.99–1.03)
History of condomless sexa 1.92 (1.41–2.61) 1.89 (1.36–2.63)
Registration year 1.04 (1.01–1.07) 1.06 (1.03–1.10)
√CD4 cell count at test time 0.98 (.96–1.00) 1.00 (.98–1.03)
√CD8 cell count at test timeb 1.01 (.99–1.03) 1.00 (.98–1.03)
√Baseline CD4 cell count 1.00 (.92–1.01) 0.98 (.95–1.00)
History of IDUc 0.92 (.23–3.73) . . .
Abbreviations: √, square-root–transformed; ART, antiretroviral therapy; CI, confidence
interval; DAART, dually active ART; HBV, hepatitis B virus; HET, heterosexuals; HR, hazard
ratio; IDU, intravenous drug users; MSM, men who have sex with men.
a Values missing in 17 patients.
b Values missing in 3 patients.
c Excluded for possible collinearity with IDU transmission group.
Table 3. Univariable and Multivariable Cox Proportional Hazards Models
for the Factors Associated With HBV Incidence
Covariate
HR (95% CI)
Univariable Analysis
Multivariable Analysis
in Complete Cases
Only (n = 1697)
Proportion of observation time on treatment
TDF 0.56 (.12–2.56) 0.23 (.04–1.14)
3TC 0.42 (.28–.68) 0.41 (.22–.75)
TDF + 3TC 0.02 (.00–.34) 0.03 (.00–.43)
TDF + FTC 0.42 (.14–1.22) 0.16 (.05–.55)
Other ART regimens 1.02 (.57–1.80) 1.17 (.57–2.40)
Sex interaction with transmission group
Male-HET 1 (Reference) 1 (Reference)
Male-IDU 2.67 (1.57–4.53) 2.83 (1.57–5.09)
Male-MSM 2.24 (1.46–3.44) 2.33 (1.46–3.71)
Female-HET 0.55 (.31–.97) 0.47 (.25–.88)
Female-IDU 2.01 (1.07–3.77) 2.69 (1.37–5.26)
Ethnicity
White 1 (Reference) 1 (Reference)
Black 0.62 (.33–1.18) 1.50 (.70–3.22)
Hispano-American 1.03 (.46–2.34) 1.55 (.67–3.60)
Asian 1.77 (.78–4.01) 2.35 (.95–5.81)
Other/unknown 1.38 (.51–3.74) 1.18 (.42–3.29)
Age at cohort enrollment 1.00 (.98–1.02) 1.01 (.99–1.03)
History of condomless sexa 1.92 (1.41–2.61) 1.96 (1.41–2.73)
Registration year 1.04 (1.01–1.07) 1.08 (1.04–1.11)
√CD4 cell count at test time 0.98 (.96–1.00) 1.00 (.97–1.03)
√CD8 cell count at test timeb 1.01 (.99–1.03) 1.00 (.98–1.02)
√Baseline CD4 cell count 1.00 (.92–1.01) 0.98 (.96–1.00)
Abbreviations:√, square-root–transformed; 3TC, lamivudine; ART, antiretroviral therapy; CI,
confidence article; FTC, emtricitabine; HBV, hepatitis B virus; HET, heterosexuals; HR,
hazard ratio; IDU, intravenous drug users; MSM, men who have sex with men; TDF,
tenofovir.
a Values missing in 17 patients.
b Values missing in 3 patients.
HBV Prophylaxis Using HIV/HBVActive ART • JID 2016:214 (15 August) • 603
 at Universitaet Zuerich on October 17, 2016
http://jid.oxfordjournals.org/
Downloaded from 
DAART was absent in the phases in which individuals were not
virologically suppressed. This further underlines a direct effect
of DAART, because treatment failure is associated with poor ad-
herence [22, 23] and generally with low plasma levels of antire-
trovirals. For non-DAART regimens, we found an increase in
the hazard of an HBV infection in nonsuppressed individuals,
but this association was not robust to adjustment (multivariable
HR, 2.0; 95% CI, .5–7.5). On a speculative note, this could re-
ﬂect the fact that lower adherence is associated with more risky
behavior [24, 25] and hence a higher HBV incidence.
The lack of a statistically signiﬁcant difference in the LLR be-
tween the models with or without suppression could indicate a
power issue, given the short periods patients are usually not
suppressed (and receiving ART or DAART). This is further
supported by the fact that the likelihood ratio test result was
borderline signiﬁcant (P = .055) when the adjusted models
were compared. Fortunately, 96% of patients receiving ART in
the SHCS are suppressed, so this problem is less concerning in
our setting [26]. The Joint United Nations Programme on HIV/
AIDS gap report [16] showed that 76% of patients receiving
ART achieved viral suppression, yet the bigger problem re-
mains: 47% of the HIV infected are unaware of their positive
status.
Our ﬁndings also suggest that 2-agent DAART regimens (ie,
TDF plus FTC or 3TC) are superior to single-agent DAART
regimens in protecting against incident HBV. This ﬁnding
may be relevant for optimizing ART regimens in settings
where HBV incidence is high and vaccination coverage or re-
sponse is low. One caveat is that the majority of observation
time with one drug was with 3TC, with the observation time
for TDF alone being much shorter (no patient was prescribed
FTC alone). Thus, it is plausible that the observed enhancement
of protection is due to TDF. The likelihood ratio test showed
that this difference was present only in the adjusted model, im-
plying that other factors (eg, immunological status and risk be-
havior) could have confounded the association in the
unadjusted model.
Previous ﬁndings [12, 14] suggest a superior protection for
TDF compared with 3TC-containing regimens. We did not ob-
serve a clear superiority of TDF over 3TC regimens in our data,
as shown by the likelihood ratio test and the overlapping CIs of
the respective regimens. However, this could be due to the dif-
ferent ways treatment was accounted for in the different studies.
Gatanaga et al [14] pooled TDF-plus-FTC regimens along with
other TDF regimens and did not encode the treatment as pro-
portion of observation time, whereas Heuft et al [12] adopted
treatment averaging with categorization (detailed in the next
paragraph).
As with all observational studies, ours has limitations. The
longitudinal and periodic nature of the data collection gives
rise to uncertainty as to the precise date of HBV infection
(Supplementary Figure S1). Interval-censored models with
time-varying covariates account for this varying exposure
(ie, treatment changes). However, these models are scarcely
described or used in the literature [19]. Heuft et al [12] shared
the same concerns about the interval-censored nature of
the data, but they circumvented this problem by coding for
the different treatments as proportion of observation time
with the respective treatments, with <20% equivalent to no
treatment and higher percentages equivalent to receiving a
certain treatment. This method of handling treatment indeed
avoids some issues related to treatment changes and interruptions
but remains problematic because patients who have received
DAART for 21% of their observation time would are considered
equal to for example those who received DAART since their di-
agnosis (ie 100% of their observation time) (as discussed in [12]).
To further assess the issue of unknown HBV infection times,
we considered a parametric survival model with ﬁxed and time-
varying covariates. This model showed a similar protective ef-
fect of ART, though the magnitude was slightly smaller than
with the Cox proportional hazards model. The estimates of
both models are in line with earlier reports [11–14].
Data on HBV incidence in Switzerland remain scarce, but it
is plausible that it is on the decline, because vaccination against
HBV was ramped up and better harm reduction interventions
were used for IDU, particularly needle exchange programs [27].
To account for this potential confounding, we performed a sen-
sitivity analysis correcting for calendar time, and the protective
effect of DAART remained robust (unadjusted HR, 0.4 [95%
CI, .2–.6]; adjusted HR, 0.3 [.2–.5]).
Black ethnicity remains underrepresented in studies address-
ing the protective effect of ART against. Both our study and that
of Heuft et al [12] take place in a majority-white population, and
those of Gatanaga et al [14] and Sheng et al [13] both comprised
an Asian majority. The consistency of the ﬁndings in previously
conducted studies and ours, however, suggests that the ﬁndings
are independent of ethnicity. Moreover, given the evidence and
plausibility of a direct drug-mediated effect, it is also unlikely
that this protection depends on ethnicity.
In our analysis, 70 patients were considered positive based only
on an isolated anti-HBc serological result. Their exclusion did not
alter the protective DAART association (data not shown), sug-
gesting that this serological proﬁle is probably caused by HIV co-
infection [18, 28] and not by false-positive laboratory results, as
some studies suggested [18]. Isolated anti-HBc serology in
HIV-infected individuals are usually caused by a recently resolved
infection with low or undetected anti-HBs.
One interesting population that we were unable to examine
is patients who were vaccinated but did not mount an immune
response. Such an analysis was not possible using the SHCS data
set, because the SHCS does not collect patients’ vaccination
records.
One modeling study concluded [29] that even with 100% vac-
cination uptake by all susceptible patients, a large fraction
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of patients would remain at risk of HBV acquisition, owing
to the lower vaccination response in HIV-infected patients.
Hence, our retrospective observational study suggests that
DAART—after additional conﬁrmation in a randomized-
controlled setting—might be worth serious consideration as
an additional means of ﬁghting HBV infections in HIV-infected
individuals, in general and especially in settings where HBV
vaccination uptake is low. Moreover, our study adds to the
growing body of evidence that early ART initiation [30], regard-
less of CD4 cell counts, has a strong beneﬁcial public health im-
pact, including preexposure prophylaxis of HBV coinfections.
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Abstract 
Background 
After several years of steady decline, syphilis is reemerging globally as a public health 
hazard, especially among people living with HIV. Syphilis resurgence is observed 
mainly in men-who-have-sex-with-men (MSM), yet other transmission groups are 
affected too. In this manuscript we study the factors associated with syphilis incidence 
in the Swiss HIV cohort study in the era of highly effective antiretrovirals.  
 
Methods 
Using parametric interval censored models with time fixed and varying covariates, we 
studied the immunological, behavioral, and treatment related elements associated with 
syphilis incidence in three transmission groups: MSM, heterosexuals and intravenous-
drug-users.  
 
Results 
Syphilis incidence has been increasing annually with up to 74 incident cases per 
thousand-person-years in 2013, with MSM being the population with the highest 
burden (92% of cases). While antiretroviral treatment in general did not affect syphilis 
incidence, Nevirapine was associated with lower hazard of syphilis incidence 
(multivariable hazard ratio 0.5, 95% confidence-interval 0.2-1.0). We observed that 
risky behavior (sexual and drug related) and younger age were associated with higher 
syphilis incidence. Moreover, time updated CD4, nadir CD4, and CD8 cell counts were 
not associated with syphilis incidence. Finally, testing frequency higher than the 
recommended once a year routine-testing was associated with a twofold higher risk of 
acquiring syphilis.  
 
Conclusions 
Condomless sex is the main driver of syphilis resurgence in the SHCS and antiretroviral 
treatment and immune reconstitution provide no protection against syphilis. This 
entails targeted interventions and frequent screening of high-risk populations. The 
possible protective association of Nevirapine against syphilis incidence warrants 
further clinical, epidemiological, and microbiological investigation.  
Introduction 
Syphilis is a reemerging public health hazard that has been on the rise in recent years 
globally [1], and locally in Switzerland [2]. This is particularly the case for the HIV 
infected population, with one review placing the mean prevalence of syphilis in the HIV 
infected population at 9.5% [3]. The importance of syphilis as a coinfection in the HIV 
infected does not only stem from the negative effect of syphilis on HIV natural course 
(manifested as temporary CD4 cell count drop and HIV viral load elevation [4,5]), but 
also from the enhancement of HIV transmission in individuals coinfected with syphilis 
[6]. The fact that 60% of syphilis cases are asymptomatic [2], and that it enhances HIV 
transmission and other co-infections (e.g. Hepatitis B [7] and Hepatitis C [8]), places 
syphilis coinfection in the forefront of HIV-transmission and public health concerns.  
 
Antiretroviral therapy (ART) has been shown to affect HIV and some of its coinfections 
through three main axes: immunological, behavioral, and direct. On the 
immunological front, ART enhances immune reconstitution in the HIV infected 
leading to an enhanced protection against pathogens [9]. More generally, there is a 
strong interaction between the immune system and syphilis (e.g. a low CD4 cell count 
is associated with a higher likelihood of developing neuro syphilis [5]). 
 
On the behavioral side, ART influences sexual-risk behavior differently depending on 
the setting [10], with some evidence pointing toward no change in sexual-risk behavior, 
and other suggesting risk compensation [11]. In the Swiss HIV Cohort Study (SHCS) it 
has been observed that there is a trend of increasing condomless sex in all transmission 
groups. This increase was especially evident in men-who-have-sex-with-men (MSM), 
with evidence that both individuals in stable and casual relationships are using 
condoms less frequently [12]. Similar patterns of increase of condomless sex among 
MSM have been observed in the United States as well [13]. 
 
Finally, ART has a direct effect on HIV coinfections including herpes simplex virus type 
2 [14], and Hepatitis B Virus [15]. In addition, ART has been shown to have a wide 
array of targets and functions including activity as anti-tumor, antibacterial, 
antifungal, anti-malarial, anti-SARS, and anti-Influenza [16].  
 
Despite several studies examining the interaction between ART and syphilis in HIV 
infected individuals the relationship remains unclear, with associations spanning the 
entire spectrum, some positive, others negative, and some showing no influence. 
Several studies suggest that HIV-positive persons taking ART may have better overall 
treatment response, including a better outcome in neuro-syphilis [17–19], lower rates 
of syphilis serological failure [20], shorter time to serological response [21], and lower 
adjusted incidence [22]. In contrast, other studies suggest that ART has no influence 
on syphilis incidence [23],[24] or increases it [25–27]; and some suggesting no effect 
on treatment or serological failure [28,29].  
 
In the light of this complex nature of syphilis coinfection in HIV positive individuals, 
we aimed to examine the factors affecting syphilis incidence in the SHCS. We used a 
large cohort of men who have sex with men (MSM) from the SHCS with comprehensive 
longitudinal data on sexual behavior, treatment regimens and continuation, 
demographics, treatment response, and immunological profiles. In addition, we briefly 
assessed the incidence of syphilis in other important transmission groups 
(heterosexuals (HET), and intravenous drug users (IDU)). We aimed to further 
disentangle the association between ART and syphilis, and evaluate whether it is due 
to immunological factors, behavioral aspects, time trends, or the direct effect of ART. 
  
Methods 
The SHCS is a prospective cohort with ongoing enrollment for HIV-infected 
individuals in Switzerland since 1988. Clinical, laboratory, and socio-demographics 
information are collected every six months. This includes information about sexual 
behavior in terms of having a stable or occasional partner(s) in the past six months, 
and if so, whether sex was with or without a condom. All participants provided 
informed consent and the study was approved and is conducted per the guidelines of 
the ethical committees of the respective participating center (e.g. for Zürich center, the 
Ethical Commission of the Canton of Zurich approved the study). The SHCS Study was 
shown to be highly representative of the HIV infected population in Switzerland; 
including hard-to-reach populations [30]. 
 
Annual syphilis testing ceased as of 1998 owing to a steady decline in the syphilis 
infection rate in Switzerland and an internal analysis that revealed that syphilis testing 
every two years imparted no decrement in incidence [2]. Syphlis testing was restarted 
in 2004, hence only tests taking place thereafter were included here.  
 
Syphilis testing in the SHCS can be divided into two categories: non-treponemal and 
treponemal. The non-treponemal branch contains either Venereal Diseases Research 
Laboratory or Rapid plasma regains; and the treponemal branch includes: Treponema 
pallidum particle agglutination assay/ Treponema pallidum hemagglutination assay, 
Liaison (CLIA), and Architect (CMIA). 
 
Only individuals with a negative baseline test by both methods were included in the 
analysis. Individuals with missing tests in either arm were excluded, and a case was 
considered positive only if both markers turned positive [31]. A positive treponemal 
test with a negative non-treponemal test were considered evidence for previous 
infections and those individuals/observation time were excluded. 
 
The analysis was conducted for available individuals meeting the aforementioned 
criteria from 2004-2014. Owing to the limited number of cases in HET and IDU, the 
analysis was later restricted to MSM as they account for the vast majority of syphilis 
cases. This would also allow for a more homogenous population (and consequently a 
comparable risky behavior). The observation time was defined as the time between the 
first negative test and either the first positive syphilis test or the last negative test the 
individuals had. Finally, only individuals who were observed for a year or more were 
analyzed. Of note is that the transmission group is defined in the SHCS as the most 
probable route of infection as declared by the patient in conjunction with the clinician. 
 
Statistical analysis 
Given the inherent interval censored nature of syphilis incidence (imprecise knowledge 
of the exact point of time where the infection occurred), we utilized univariable and 
multivariable parametric-interval-censored models with time-fixed and varying 
covariates and an exponential hazard function (implemented in [15]). We tested the 
association of antiretroviral treatment (exposure) and syphilis incidence (outcome 
variable) coded in several hierarchical ways. First, antiretroviral treatment as a binary 
variable, then ART divided into four classes of (nucleotide-reverse-transcriptase 
inhibitors (NRTI), non-nucleotide reverse-transcriptase inhibitors (NNRTI), protease 
inhibitors (PI), and other HIV antiretroviral drug classes (integrase and fusion 
inhibitors, primarily Raltegravir (87%)). And finally the individual drugs for the 
NNRTI class (as it showed a trending protective association Table S1). The exposure 
was subsequently subdivided into ART treated and suppressed (HIV RNA <=50 
copies/mL) or ART treated and non-suppressed.   
 
The univariable analysis was constructed to include variables most likely to influence 
syphilis incidence based on the literature and clinicians’ evaluation. The following 
covariates were examined in the univariable models: square root transformed CD4, 
CD8, and nadir CD4 cell count (lowest observed CD4 since enrollment). In addition, 
baseline CD4 cell count <200 (binary), log transformed HIV RNA copies/mL, smoking, 
drug use (binary, reflecting no drug use, and any drug use intravenous or otherwise) 
reporting of condomless sex with a stable or occasional partner (binary), ethnicity 
(binary non-white or white, with white as the reference level), age at infection 
(continuous per 5 years), and education (attended a higher education institution, 
binary).  
 
The inclusion criteria for the multivariable analysis were based on clinical relevance, 
significance in the univariable analysis (P-value ≤ 0.10), and in case of highly 
correlated variables, one representative (HIV RNA viral load and ART, ART was 
chosen). The variables included were: immunity markers (CD4 and nadir CD4), 
behavioral markers (condomless sex with occasional partner, testing rate per year), 
treatment, demographics (age at infection, ethnicity, and last center of follow up), and 
calendar year (to account for the time trends of incidence).   
 
As sensitivity analyses, the associations were estimated using a Weibull hazard 
function and Cox proportional hazard models.  
 
Analyses were conducted in Stata 14.1 (Stata Corp.) and R 3.3.1.   
Results 
A total of 3,575 individuals were routinely tested for syphilis once or more, following a 
negative baseline test between 2004-2014 (median observation start year 2005, IQR 
2004-2007) (Table 1). There were 226 incident syphilis cases reported in 19,041 person 
years. The incidence rate was 26.8 cases per thousand-person years for MSM (95% 
confidence interval (95% CI) 23.5-30.8), 1.3 (0.49-3.5) for IDU, and 1.8 (1.1-3.0) for 
HET. This corresponded to 207 (92%) syphilis cases in MSM, 4 (2%) in IDU, and 15 
(6%) in HET. 
 
During the study period (2004-2014), we found a significant increase of syphilis 
incidence over time (Pearson correlation between annual incidence and year 0.9, P 
<0.01; Figure 1, 2). We did not observe a clear elevation of syphilis incidence 
immediately after the year 2008 (the year of the so-called Swiss statement [32]). The 
incidence rate of syphilis increased two fold by 2012, and a similar trend was reflected 
in the hazard of acquiring syphilis estimated by the model described in the methods 
(Figures 3). In addition, we observed that the MSM population is the one affected most 
by syphilis, and accounts for the majority of incident cases (92%). Finally, the number 
of cases in IDU has remained constantly low over time, while that of HET is apparently 
increasing, yet the overall low number of cases does not allow for conclusive 
assessment. That is particularly the case considering that 2 of the 19 cases in IDU and 
HET transmission group identify as bisexual, and another individual identifies as 
homosexual.  
 Figure 1. The number of unique SHCS patients tested per year and the number of syphilis tests they 
underwent are shown for the period 2005-2014. Syphilis incidence is also shown in the different 
transmission group (MSM: men who have sex with men, HET: heterosexuals, IDU: intravenous 
drug users) 
 
Hereafter, we focus on the MSM population, as it is the group with the highest 
incidence, and in which public health interventions would have the strongest impact.  
 
We observed no association between being on ART and syphilis incidence (univariable 
HR 1.2, 95% CI 0.8-1.9). Breaking down ART treatment into individual drug classes 
revealed that NNRTI could potentially have a protective association against syphilis 
(HR 0.9, 95% CI 0.7-1.2) Table S1. Indeed, we found that Nevirapine was associated 
with lower syphilis incidence (multivariable HR 0.5, 95%CI 0.2-1.0) (Table 3). We also 
observed that the protective association of NVP was tightly coupled to suppression 
(plasma RNA <=50) (NVP and suppressed HR 0.4, 95% CI 0.2-0.9).  No protective 
effect of NVP was present in non-suppressed patients on NVP (HR 1.0, 95% CI 0.1-
7.9). Furthermore, the effect of NVP did not seem to be mediated by immune markers 
as NVP’s association remained even after adjusting for these variables (among others, 
Tables 2 and 3). There was no change in the associations between boosted and non-
boosted PI. 
 
 
Figure 2. Incidence rate of syphilis in the SHCS 2005-2014, cases per 1000 person years (blue line 
is a natural cubic spline fitted to the incidence rate with the grey area shows 95% CI). The red dots 
represent the number of incident cases per year (the red line is the fitted cubic line of the number 
of cases) 
 
Regarding demographics, we observed a decrease in syphilis incidence with increasing 
age (univariable HR 0.8, 95% CI 0.7-0.8). In addition, syphilis incidence was 
associated with neither ethnicity nor education (higher than high school) Table 3.  
 
Figure 3 Hazard ratio of syphilis acquisition compared to the year of the Swiss statement 
release(2008) in MSM. Estimates with 95% confidence intervals are shown (with a fitted natural 
cubic spline with 95% CI) 
On the behavioral side, we observed that generally risk behavior is associated with 
higher incidence of syphilis. A history of condomless sex with an occasional partner 
increased the hazard of acquiring syphilis (univariable HR 4.6, 95% CI 3.1-6.50). 
Interestingly, condomless sex with a stable partner was also associated with higher 
incidence of syphilis (univariable HR 1.4, 95% CI 0.9-2.1); however this association 
was not significant. While individuals who reported being in a stable partnership were 
generally less likely to engage in condomless sex with occasional partners (OR 0.24, 
95% CI 0.24-0.25), 12% reported such behavior. We also observed that drug use was 
associated with higher incidence of syphilis (Drug use -intravenous or otherwise- HR 
11.6, 95% CI 2.1-65), however the number of individuals reporting drug-use were low, 
and the proportion of observation time in which they used was small (9 individuals for 
0.07% of the observation time; hence this covariate was not included in the 
multivariable model as a risk-behavior marker). Moreover, smoking was associated 
with an increased syphilis incidence yet the association was not statistically significant 
(HR 1.3, 95% CI 0.9-1.7, Table 2 and 3). Finally, we also observed that individuals who 
tested more frequently for syphilis had a higher propensity to be infected (univariable 
HR 2.7, 05% CI 1.9-3.8).  
 
The immunological status represented by square root transformed CD4, CD8, and 
nadir CD4 cell count did not seem to influence syphilis incidence (Tables 2 and 3).  
 
The estimates were qualitatively similar when using a Cox proportional hazard model 
or a Weibull hazard function for the current model (results not shown).  
 
  
Table 1 General characteristics of eligible MSM SHCS patients at enrollment 
 Patients with an 
incident Syphilis 
infection (N. = 207) 
Patients with no 
incident Syphilis 
infection (N. = 1312) 
CD4+ cell count, 
cells/mm3, median (IQR)  
473 (342-621) 460 (324-625) 
Age at infection, median 
(IQR) 
42 (37-48) 46 (40-52) 
HIV-1 RNA, log10 
copies/mL, median (IQR) 
2.8 (0.0-4.56) 1.7 (0.0-4.2) 
Ethnicity N. (%)    
White 187 (90) 1207 (92) 
Non-White 20 (10) 105 (8) 
Year of observation start, 
median (IQR) 
2006 (2004-2008) 2005 (2004-2008) 
Percentage smokers at 
infection or censoring 
48 40 
Infection year, median 
(IQR) 
2011 (2009-2013) - 
Testing rate per year, 
median (IQR) 
1.2 (0.9-1.6) 1.2 (1.0-1.4) 
 
  
Table 2 Univariable analysis of Factors Associated with Syphilis Incidence in MSM 
Variable HR 2.5% 97.5% 
NRTI 1.41 0.91 2.20 
NNRTI 0.87 0.65 1.17 
Other Drugs 1.49 0.93 2.40 
PI 1.09 0.82 1.46 
ART 1.20 0.77 1.86 
√CD4 1.02 0.99 1.05 
√CD8 1.01 0.99 1.03 
√CD3 1.01 0.99 1.03 
√Nadir CD4 
1.04 1.01 1.07 
Log10 HIV RNA 
0.98 0.89 1.08 
Smoking 
1.25 0.94 1.67 
Drug Use 11.63 2.09 64.90 
Condomless sex with a stable 
partner 1.38 0.92 2.06 
Condomless sex with an occasional 
partner 4.55 3.18 6.50 
Testing rate per year 2.70 1.93 3.76 
Age at infection (per 5 years) 0.70 0.65 0.76 
Ethnicity (non-white) 1.26 0.79 2.00 
Education (higher than high school) 1.23 0.75 2.04 
Calendar Year 
1.24 1.17 1.31 
Center (out of Zurich) 
1.04 0.79 1.37 
  
  
Table 3 Multivariable analysis of Factors Associated with Syphilis Incidence in MSM 
 HR 95% CI 
NRTI 1.48 0.83 2.64 
Other Drugs 1.38 0.80 2.39 
PI 1.19 0.77 1.83 
NVP 0.45 0.21 0.96 
EFV 1.02 0.64 1.63 
RPV* 0.00 0.00 Inf* 
ETV 0.68 0.34 1.37 
√CD4a 0.99 0.95 1.02 
√Nadir CD4 1.00 0.97 1.04 
Condomless sex with an 
occasional partnerc 3.74 2.61 5.36 
Calendar Year 1.22 1.14 1.31 
Age at infection (per 5 years) 0.75 0.69 0.81 
Ethnicity  0.88 0.55 1.41 
Center 1.30 0.96 1.77 
Testing rate per year 1.80 1.28 2.53 
                                 *few patients are on RPV hence the lack of an estimate 
                                   
 
 
  
Discussion 
In this study we report on the factors associated with syphilis incidence in the era of 
highly effective ART in the SHCS. Most prominently, we observe a steady increase of 
syphilis incidence, with the highest burden falling on MSM. We show that risk behavior 
(be it sexual or drug use) and being of younger age are all associated with a higher risk 
of contracting syphilis; while being on NVP was associated with a lower risk.  
 
We observed no association between being on ART and syphilis incidence (HR 1.2, 95% 
CI 0.8-1.9). This implies that immune reconstitution does not provide significant 
protection against syphilis. We show that the protective effect of NVP is only present 
in individuals with viral suppression, in other words, only NVP that achieved viral 
suppression (<=50 HIV RNA copies/mL) conferred a protective effect. The fact that 
protection is only achieved by NVP and suppression suggests the necessity of 
consistent drug administration and adherence for NVP to exhibit its potential 
protective effect against syphilis. To our knowledge, there are no known mechanistic 
effects for NVP against Treponema palladium. Given the observational nature of our 
study, one cannot exclude the contribution of unobserved confounders to the observed 
association. Nonetheless, there are reports of other antiretrovirals being effective 
against both gram positive and gram negative bacteria (Shilaih et al submitted). T. 
pallidum remains one of the bacteria that cannot be grown in axenic medium and 
requires laborious infection of animals (rabbits) to be studied; therefore it is highly 
challenging to evaluate the effect of NVP experimentally. We strived to select a 
homogenous sample of individuals to minimize demographic and behavioral influence 
on the associations (hence the focus on MSM), however this does not rule out the 
potential presence of other factors not accounted for by the chosen covariates. In other 
words, we cannot rule out that the NVP effect is owing to patients receiving NVP being 
different from the overall study population in ways not captured by the covariates 
included in the multivariable analysis.  
 
Generally, we observed a lower overall incidence rate of syphilis in the SHCS than that 
of HIV infected MSM in Canada [33], the Netherland [34], and the United States [22] 
(27/thousand-person years for the SHCS compared to 42, 46, and 62 respectively). On 
the same note, we observed that the syphilis incidence rate in recent years has 
consistently climbed; from 25-35 per thousand-person years between 2009 and 2011, 
to 60-74 in 2012-2014 (Figure 2). Similar increases have been reported in other 
countries [1,22,34]. Generally, syphilis incidence remains very high in MSM worldwide 
and in the SHCS. These increases in syphilis incidence are consistent with the 
previously reported trend of more condomless sex in the SHCS [12] and in other 
countries [13].  
 
Condomless sex remains one of the strongest drivers of syphilis incidence in the SHCS, 
consequently better risk reduction measures are needed. For example, it has been 
shown that patients who had an episode of syphilis at one point are three times as likely 
be re-infected [33], implying a continued risky behavior tendencies in some 
populations. Such individuals are prime targets for more frequent screening and other 
supportive therapy. We observed that individuals who get tested more frequently (i.e. 
more than the one time of routine screening per year) are 2-3 times more probable to 
get infected with syphilis. These individuals are tested -most likely- more often due to 
their self-reported risky sexual behavior (with testing initiated either by themselves or 
by the clinician), and underline the importance of frequently testing in high risk 
groups. One possible strategy is adopting more frequent syphilis testing, as several 
studies have demonstrated the benefit of screening for syphilis every three months 
compared to 6 or 12 months [35]. The observation that younger age is associated with 
higher syphilis incidence should help targeting intervention efforts. 
 
Our findings matches the reported syphilis-incidence trends in non-HIV infected MSM 
in Switzerland (BAG Bulletin 2011-2014). This implies that the behavior leading to 
syphilis infection is not exclusive to HIV-infected individuals. A high syphilis incidence 
together with the untreated HIV-infected individuals (mostly undiagnosed) could be 
one of the factors contributing to the still relatively high rate of new HIV-infections 
seen in Switzerland, despite almost fulfilling the WHO 90-90-90 criteria [36]. Yet, it is 
needless to say that the root cause of both syphilis and HIV incidence remains risky 
behavior. Taken together with our earlier study of condomless sex  in the SHCS [12], it 
is clear that risky behavior correlates strongly with an increase of incidence of STIs. 
One of the challenges that will face any STI prevention measure in a high risk 
population is communicating that the efficacy of HIV treatment as prevention and pre-
exposure prophylaxis does not extend beyond HIV, and that one remains vulnerable to 
other STIs by engaging in condomless sex. A recent meta-analysis showed that MSM 
receiving pre-exposure prophylaxis were between 11.2-44.6 times more likely to get 
infected with an STI, with syphilis being the STI with the highest likelihood to occur 
(44.6) [37]. 
 
One factor that could benefit from further investigation is the study of the circulating 
strains of syphilis over the past years. Multiple reports indicate that there are several 
circulating T. pallidum strains with different genetic profiles [38] (e.g. Azithromycin 
resistant variants [39]). This could imply that the increase in syphilis incidence, while 
readily explainable by an increase of risky behavior could be further fueled by a shift in 
the circulating strains of T. pallidum that are more transmissible or pathogenic 
(unfortunately such data is not available in Switzerland). 
 
This study demonstrates that syphilis incidence has been continuously increasing with 
the main driver being high risk taking behavior. In addition, we demonstrate that 
generally ART does not provide a protective effect against syphilis. Moreover, we found 
an unexpected but intriguing protective association of NVP against syphilis incidence. 
Given these findings, more frequent screening targeted for MSM is needed to limit 
syphilis spread (and other STIs) and the probable consequent increase of HIV 
infections. Finally, the observed protective association of NVP against syphilis is worth 
further investigation epidemiologically and potentially in other settings such as 
prospective clinical trials. NVP, if proven effective against syphilis, could be 
recommended to high risk individuals, for its potential to reduce HIV transmission and 
syphilis acquisition. 
  
Conflict of interest 
H. F. G. has been an adviser and/or consultant for Gilead, Merck and Jansen and has 
received unrestricted research and educational grants from Roche, Jansen, Gilead, and 
Merck Sharp and Dohme  
Financial support 
This work was supported by the Swiss National Science Foundation (grants 
33CS30_148522, grants 324730-159868 to H. F. G., and grants PZ00P3-142411and 
BSSGI0_155851 to R. K.); the SHCS (projects 470, 528, 569, 683, and 760); the SHCS 
Research Foundation;  and the University of Zurich’s Clinical Research Priority 
Program (Viral Infectious Diseases: Zurich Primary HIV Infection Study to H. F. G. 
and D. L. B.).  
  
1.  Patton ME, Su JR, Nelson R, Weinstock H. Primary and secondary syphilis--United 
States, 2005-2013. MMWR. Morb. Mortal. Wkly. Rep. 2014; 63:402–6.  
2.  Thurnheer MC, Weber R, Toutous-Trellu L, et al. Occurrence, risk factors, diagnosis and 
treatment of syphilis in the prospective observational Swiss HIV Cohort Study. AIDS 
2010; 24:1907–16.  
3.  Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections 
in people living with HIV/AIDS: systematic review with implications for using HIV 
treatments for prevention. Sex. Transm. Infect. 2011; 87:183–90.  
4.  Buchacz K, Patel P, Taylor M, et al. Syphilis increases HIV viral load and decreases 
CD4 cell counts in HIV-infected patients with new syphilis infections. AIDS 2004; 
18:2075–9.  
5.  Sadiq ST, McSorley J, Copas AJ, et al. The effects of early syphilis on CD4 counts and 
HIV-1 RNA viral loads in blood and semen. Sex. Transm. Infect. 2005; 81:380–5.  
6.  Solomon MM, Mayer KH, Glidden D V, et al. Syphilis predicts HIV incidence among 
men and transgender women who have sex with men in a preexposure prophylaxis trial. 
Clin. Infect. Dis. 2014; 59:1020–6.  
7.  Tien PC, Kovacs A, Bacchetti P, et al. Association between syphilis, antibodies to herpes 
simplex virus type 2, and recreational drug use and hepatitis B virus infection in the 
Women’s Interagency HIV Study. Clin. Infect. Dis. 2004; 39:1363–70.  
8.  Wandeler G, Gsponer T, Bregenzer A, et al. Hepatitis C virus infections in the Swiss 
HIV Cohort Study: a rapidly evolving epidemic. Clin. Infect. Dis. 2012; 55:1408–16.  
9.  Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy 
on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997; 
277:112–6.  
10.  Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk 
behavior: a meta-analytic review. JAMA 2004; 292:224–36.  
11.  Doyle JS, Degenhardt L, Pedrana AE, et al. Effects of HIV antiretroviral therapy on 
sexual and injecting risk-taking behavior: a systematic review and meta-analysis. Clin. 
Infect. Dis. 2014; 59:1483–94.  
12.  Kouyos RD, Hasse B, Calmy A, et al. Increases in Condomless Sex in the Swiss HIV 
Cohort Study. Open forum Infect. Dis. 2015; 2:ofv077.  
13.  Paz-Bailey G, Mendoza M, Finlayson T, et al. Trends in condom use among men who 
have sex with men in the united states: the role of antiretroviral therapy and sero-adaptive 
strategies. AIDS 2016;  
14.  Celum C, Morrow RA, Donnell D, et al. Daily oral tenofovir and emtricitabine-tenofovir 
preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among 
heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized 
trial. Ann. Intern. Med. 2014; 161:11–9.  
15.  Shilaih M, Marzel A, Scherrer AU, et al. Dually Active HIV/HBV Antiretrovirals Protect 
Against Incident Hepatitis B Infections: Potential for Prophylaxis. J. Infect. Dis. 2016;  
16.  Mastrolorenzo A, Rusconi S, Scozzafava A, Barbaro G, Supuran C. Inhibitors of HIV-1 
Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral 
Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease 
Inhibitors. Curr. Med. Chem. 2007; 14:2734–2748.  
17.  Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. 
Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22:1145–51.  
18.  Marra CM, Maxwell CL, Tantalo LC, Sahi SK, Lukehart SA. Normalization of serum 
rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical 
abnormalities after treatment of neurosyphilis. Clin. Infect. Dis. 2008; 47:893–9.  
19.  Dumaresq J, Langevin S, Gagnon S, et al. Clinical Prediction and Diagnosis of 
Neurosyphilis in HIV-Infected Patients with Early Syphilis. J. Clin. Microbiol. 2013; 
51:4060–4066.  
20.  Ghanem KG, Moore RD, Rompalo AM, Erbelding EJ, Zenilman JM, Gebo KA. 
Antiretroviral therapy is associated with reduced serologic failure rates for syphilis 
among HIV-infected patients. Clin. Infect. Dis. 2008; 47:258–65.  
21.  González-López JJ, Guerrero MLF, Luján R, Tostado SF, de Górgolas M, Requena L. 
Factors determining serologic response to treatment in patients with syphilis. Clin. 
Infect. Dis. 2009; 49:1505–11.  
22.  Horberg MA, Ranatunga DK, Quesenberry CP, Klein DB, Silverberg MJ. Syphilis 
epidemiology and clinical outcomes in HIV-infected and HIV-uninfected patients in 
Kaiser Permanente Northern California. Sex. Transm. Dis. 2010; 37:53–8.  
23.  Adolf R, Bercht F, Aronis ML, Lunardi LW, Schechter M, Sprinz E. Prevalence and risk 
factors associated with syphilis in a cohort of HIV positive individuals in Brazil. AIDS 
Care 2012; 24:252–8.  
24.  Huang Y-F, Nelson KE, Lin Y-T, Yang C-H, Chang F-Y, Lew-Ting C-Y. Syphilis 
among men who have sex with men (MSM) in Taiwan: its association with HIV 
prevalence, awareness of HIV status, and use of antiretroviral therapy. AIDS Behav. 
2013; 17:1406–14.  
25.  Park WB, Jang H-C, Kim S-H, et al. Effect of highly active antiretroviral therapy on 
incidence of early syphilis in HIV-infected patients. Sex. Transm. Dis. 2008; 35:304–6.  
26.  Hu Q, Xu J, Zou H, et al. Risk factors associated with prevalent and incident syphilis 
among an HIV-infected cohort in Northeast China. BMC Infect. Dis. 2014; 14:658.  
27.  Kukanok S, Kiertiburanakul S. Prevalence of positive syphilis serology among HIV-
infected patients: role for routine screening in Thailand. Southeast Asian J. Trop. Med. 
Public Health 2014; 45:435–41.  
28.  Wang Y-J, Chi C-Y, Chou C-H, et al. Syphilis and neurosyphilis in human 
immunodeficiency virus-infected patients: a retrospective study at a teaching hospital in 
Taiwan. J. Microbiol. Immunol. Infect. 2012; 45:337–42.  
29.  Jinno S, Anker B, Kaur P, Bristow CC, Klausner JD. Predictors of serological failure 
after treatment in HIV-infected patients with early syphilis in the emerging era of 
universal antiretroviral therapy use. BMC Infect. Dis. 2013; 13:605.  
30.  Shilaih M, Marzel A, Yang WL, et al. Genotypic Resistance Tests Sequences Reveal the 
Role of Marginalized Populations in HIV-1 Transmission in Switzerland. Sci. Rep. 2016; 
6:27580.  
31.  Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. 
MMWR. Recomm. Rep. 2015; 64:1–137.  
32.  Cohen MS. HIV treatment as prevention and &quot;the Swiss statement&quot;: in for a 
dime, in for a dollar? Clin. Infect. Dis. 2010; 51:1323–4.  
33.  Burchell AN, Allen VG, Gardner SL, et al. High incidence of diagnosis with syphilis co-
infection among men who have sex with men in an HIV cohort in Ontario, Canada. BMC 
Infect. Dis. 2015; 15:356.  
34.  Branger J, van der Meer JTM, van Ketel RJ, Jurriaans S, Prins JM. High incidence of 
asymptomatic syphilis in HIV-infected MSM justifies routine screening. Sex. Transm. 
Dis. 2009; 36:84–5.  
35.  Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for Syphilis: Updated Evidence 
Report and Systematic Review for the US Preventive Services Task Force. JAMA 2016; 
315:2328–37.  
36.  Kohler P, Schmidt AJ, Cavassini M, et al. The HIV care cascade in Switzerland: reaching 
the UNAIDS/WHO targets for patients diagnosed with HIV. AIDS 2015;  
37.  Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for human 
immunodeficiency virus and sexually transmitted infection acquisition among men who 
have sex with men. AIDS 2016;  
38.  Marra CM, Sahi SK, Tantalo LC, et al. Enhanced molecular typing of treponema 
pallidum: geographical distribution of strain types and association with neurosyphilis. J. 
Infect. Dis. 2010; 202:1380–8.  
39.  Mitchell SJ, Engelman J, Kent CK, Lukehart SA, Godornes C, Klausner JD. 
Azithromycin-resistant syphilis infection: San Francisco, California, 2000-2004. Clin. 
Infect. Dis. 2006; 42:337–45.  
 
  
 Supplementary material 
Table S1 Multivariable analysis of Factors Associated with Syphilis Incidence in MSM 
 HR             95% CI 
NRTI 1.56 0.89 2.73 
Other Drugs 1.30 0.78 2.16 
PI 1.13 0.74 1.71 
NNRTI 0.78 0.51 1.18 
√CD4a 0.99 0.95 1.02 
√Nadir CD4 1.00 0.97 1.04 
Condomless sex with an 
occasional partnerc 3.72 2.59 5.35 
Calendar Year 1.20 1.13 1.29 
Age at infection (per 5 years) 0.74 0.68 0.81 
Ethnicity  0.93 0.58 1.49 
Center 1.30 0.96 1.77 
Testing rate per year 1.81 1.29 2.54 
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Abstract  
The direct effect of antiretrovirals on the gut microbiota of HIV infected individuals has been 
largely overlooked in microbiome studies. We tested 25 antiretrovirals on Bacillus subtilis 
and Escherichia coli using a broth-microdilution assay to assess antiretrovirals’ antibacterial 
effects. We found that several widely used antiretrovirals (Efavirenz, Zidovudine, 2',3'-
Dideoxyinosine) have in-vitro antibacterial activity against both gram-positive and gram-
negative commensal bacteria. Given the increasing number of individuals on antiretrovirals, 
and the lifelong nature of HIV treatment, this could have wide-implications including 
explanation of HIV-linked host microbiome alterations, emergence or prophylaxis of bacterial 
co-infections, indirect selection for drug resistance, and potentially drug repositioning. 
 
Keywords: Antibacterial; HIV; Antiretrovirals; Dysbiosis; Microbiome  
Background 
There are 35 million people living with HIV in the world, 42% of them are on antiretrovirals, 
with an ever increasing life expectancy, accordingly chronic manifestations of HIV infections 
and ART have become a key focus of health care and research. The consistent observation 
that HIV infection is associated with gut microbiome dysbiosis that is not restored upon ART 
administration remains an open questions in HIV research (1). 
 
Recently, there have been several reports discussing the microbiota of untreated HIV patients, 
and the differences between their microbiota, that of HIV negatives, and that of  HIV 
positives on ART (2–5). One aspect that might not have been adequately addressed is the 
potential disruption of the microbiota by ART itself. Despite their general high specificity, 
antiretrovirals are not devoid of off-target effects, as demonstrated by multiple reports of 
antibacterial (6), antiviral (7,8), antifungal (9), and anti-cancer activity (9). 
 
Generally, the disruption of the microbiota by prescription drugs is an emerging issue in 
medicine (10,11). In this report we demonstrate that some widely prescribed antiretrovirals 
exhibit an in vitro antibacterial effect, which potentially could lead to modification of the gut 
microbiota in HIV treatment. 
 
As examples for gram-positive and gram-negative bacterial species, we considered Bacillus 
subtilis and Escherichia coli, respectively. 25 antiretroviral drugs were tested for their 
antibacterial activity using a broth microdilution assay to determine minimum inhibitory 
concentration (MIC, see methods). In addition, three of the most prescribed 
regimens/combinations in the Swiss HIV cohort study were tested for their antibacterial effect 
(Table 1).   
Methods 
Minimal inhibitory concentrations were determined by a microdilution assay. E. coli 
K12 MG1655 and B. subtilis 168 were grown in calcium-adjusted Mueller-Hinton 
Broth (Sigma-Aldrich #90922). All antiretrovirals were kindly provided by the AIDS 
Reagent Program, Division of AIDS, NIAID, NIH. Stock solutions of the compounds 
were prepared in appropriate solvents at concentrations between 2.56mg/ml and 
10.24mg/ml (Table 1). Two-fold serial dilutions were prepared and 5µl of these 
dilutions were transferred to 96-well plates and inoculated with 95µl of fresh dilution 
of an overnight culture of E. coli MG1655 or B. subtilis 168. The inoculum was diluted 
to achieve an inoculum size of approximately 105 – 106 colony forming units per ml. 
Wells containing no compound and wells containing no bacteria were included as 
growth and negative controls. The final concentration of solvent was ≤2.5% v/v. All 
solvents were tested separately and none of the solvents showed antibacterial activity 
at this concentration. Additionally, as a positive control at least one of four antibiotics 
(ampicillin, ciprofloxacin, kanamycin and chloramphenicol) was tested at the same 
time. After incubation at 37°C for 18-24h optical density of the wells was measured at 
595nm in a Tecan Infinite M200 spectrophotometer (Tecan, Männedorf, 
Switzerland). The MIC was defined as the lowest concentration showing > 90% of 
growth inhibition compared to control wells. The assay was repeated three times for 
each compound. 
 
Additional references pertaining to the content of the manuscript are listed in the 
supplementary material.  
Results and Discussion 
As expected, most of the antiretroviral compounds did not show any antibacterial activity 
against either bacterium. However, three of the 25 tested drugs showed a MIC consistent with 
an antibacterial activity within the examined range of concentrations. Efavirenz (EFV) had an 
MIC of 16µg/ml against B. subtilis, while 2',3'-Dideoxyinosine (DDI) and Zidovudine (AZT) 
had an MIC of 16-32µg/ml and 0.016 – 0.125 µg/ml (respectively) against E. coli. Among the 
three tested drug combinations (Table 1), only the combination containing EFV 
(Emtricitabine (FTC)/ Tenofovir disoproxil fumarate (TDF)/EFV) showed an antibacterial 
effect, yet the MIC found does not indicate a synergistic effect between the constituting drugs. 
 
Even though these findings are naturally limited by the fact that only two bacteria species are 
considered, it provides a proof of principle for the antibacterial effect of one of the most 
prescribed antiretrovirals (EFV). This raises several important issues for HIV treatment and 
beyond. Generally, the results imply the possibility that ART directly affects the microbiome 
through its antibacterial activity. Given that EFV is estimated globally to constitute 63% of 
prescribed NNRTIs by 2016 (12), a complete understanding of its (side)effects is crucial. 
Here, we demonstrated, for the first time, that EFV has an antibacterial effect against Bacillus 
subtilis, a bacterial species found in the human gut and a known probiotic, with an MIC that 
could lead to full or partial antibacterial activity depending on the compartment in question. 
The reported MIC of EFV (16µg/mL)  is well within the estimated gut lumen EFV 
concentration (1578µg/mL) (13), half of that reported in some intracellular compartments of 
the gut (14), and only 2-3 folds higher than the average reported peak plasma concentration 
(15). 
 
Potentially, such antibacterial activity could affect health by disrupting the microbiome, by 
protecting against infection or colonization with bacterial pathogens, or by indirectly selecting 
for resistance (16) (for example in concomitant infections or in commensal bacteria (17), as is 
known for other compounds with antibacterial activity (17)).  
 
Early in the HIV epidemic, AZT was shown to possess antibacterial effect against several 
bacterial strains, including E. coli (6). Here we report, in addition to our novel observation 
regarding EFV, that another nucleoside analogue (DDI) has similar activity on E. coli in-vitro. 
The mechanism of AZT antibacterial effect has been suggested to be DNA chain termination 
(6). On the gut microbiota front, one may speculate that the gastrointestinal symptoms that 
patients on DDI and AZT exhibit could be associated with the disruption of the microbiota 
because they target one of the most abundant gram negative species, E. coli. Despite being 
less prescribed as an antiretroviral in developed countries, 31% of adults are expected to be on 
AZT by 2017 (18), and both AZT and DDI are on the WHO “Model List of Essential 
Medicines”, therefore, their potential effects on the gut microbiota remain of great importance 
for a large number of HIV infected individuals. While reports on AZT gut concentration are 
scarce, the MIC reported by others, and here, are within the known AZT plasma concentration 
(19), which is the more conservative limit. The MIC of DDI also lies within two standard 
deviations from its reported peak plasma concentration. 
 
It is plausible that other antiretroviral drugs (that did not show activity in our assessment) 
could have potential antibacterial activity, yet requiring pre-activation or metabolism. This is 
conceivable given that several ART are pro-drugs (e.g. NRTIs require triphosphorylation to 
be active, and Tenofovir requires to be freed from its ester tenofovir disoproxil fumarate(20)), 
and others are complex molecules that undergo extensive metabolism in the human body(20), 
and lead to structurally diverse metabolites. For example, it has been shown that AZT requires 
pre-activation to exhibit its antibacterial activity (6), and that it is sensitive to the medium 
composition. 
 In conclusion, here we demonstrate that several antiretroviral drugs exhibit antibacterial 
activity in vitro against gram positive and gram negative bacteria. Surely, in no way does our 
report claim a causative explanation of dysbiosis in the treated HIV individuals, but it does 
hint to a biologically plausible mechanism, and calls for deeper examination of these effects 
on the microbiota, and HIV bacterial co-infections both in future and in already published 
work. In addition, these molecules could potentially create new opportunities for drug 
discovery, and repurposing, which in the light of global sharp increases in multidrug resistant 
bacteria might open new doors to treat those pan-resistant species.  
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Table 1: Minimum Inhibitory concentration (MIC) of 25 antiretrovirals and 3 combinations of 
antiretrovirals against E. coli and B. subtilis. Reported values are the range of three replicates. 
Bold indicates compounds with observed MIC at the given concentration.  
   
 MIC (µg/ml) 
 
Compound Abbr. Solvent E. coli MG1655 B. subtilis 168 
Entry- &  Fusion-Inhibitors 
 
 
   Trimeris/RocheT-20 ENF PBS >128 >128 
 Maraviroc MVC DMSO >256 >256 
Integrase Strand Transfer Inhibitors 
 Raltegravir RAL H2O >128 >128 
Non-Nucleoside Reverse-Transcriptase Inhibitors 
 Efavirenz EFV Methanol >128 16 
 Etravirine (TMC125) ETV Methanol >64 >64 
 Nevirapine NVP DMSO >256 >256 
 Rilpivirine (TMC278) RPV DMSO >256 >256 
Nucleoside Reverse-Transcriptase Inhibitors 
 2',3'-Dideoxycytidine DDC H2O >256 >256 
 2',3'-Dideoxyinosine DDI DMSO 16-32 >256 
 Abacavir ABC DMSO >256 >256 
 Emtricitabine FTC H2O >256 >256 
 Lamivudine 3TC H2O >256 >256 
 Stavudine D4T H2O >256 >256 
 Tenofovir TAF H2O >128 >128 
 Tenofovir disoproxil fumarate TDF H2O >256 >256 
 Zidovudine AZT DMSO 0.016-0.125 >256 
Protease Inhibitors 
 Amprenavir APV DMSO >256 >256 
 Atazanavir Sulfate ATV H2O >128 >128 
 Darunavir DRV DMSO >256 >256 
 Indinavir Sulfate IDV H2O >256 >256 
 Lopinavir LPV DMSO >256 >256 
 Nelfinavir NFV DMSO >256 >256 
 Ritonavir RTV DMSO >256 >256 
 Saquinavir SQV DMSO >256 >256 
 Tipranavir TPV Ethyl Acetate >256 >256 
Combinations 
 
 
   2FTC:6EFV:3TDF 
 
 >96:192:64 6:12:4-12:24:8 
 8FTC:RPV:12TDF 
 
 >192:16:128 >192:16:128 
 2FTC:8DRV:RTV:TDF 
 
 >96:32:256:64 >96:32:256:64 
Solvents 
 H2O   >2.5% (v/v) >2.5% (v/v) 
 PBS   >2.5% (v/v) >2.5% (v/v) 
 DMSO   >2.5% (v/v) >2.5% (v/v) 
 Ethyl Acetate   >2.5% (v/v) >2.5% (v/v) 
 Methanol   >2.5% (v/v) >2.5% (v/v) 
Antibiotics 
 Ampicillin AMP H2O <5 - 5 <5 
 Ciprofloxacin CIP 1N NaOH <0.5 <0.5 
 Kanamycin KAN H2O <1.5 – 1.5 <1.5 
 Chloramphenicol CAM 95% Ethanol 3 1.5 
 
 VII 
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Monocyte-derived macrophages 
exhibit distinct and more restricted 
HIV-1 integration site repertoire 
than CD4+ T cells
Yik Lim Kok1,2,*, Valentina Vongrad1,2,*, Mohaned Shilaih1,2,*, Francesca Di Giallonardo3, 
Herbert Kuster1,2, Roger Kouyos1,2, Huldrych F. Günthard1,2 & Karin J. Metzner1,2
The host genetic landscape surrounding integrated HIV-1 has an impact on the fate of the provirus. 
Studies analysing HIV-1 integration sites in macrophages are scarce. We studied HIV-1 integration 
site patterns in monocyte-derived macrophages (MDMs) and activated CD4+ T cells derived from 
seven antiretroviral therapy (ART)-treated HIV-1-infected individuals whose cells were infected ex 
vivo with autologous HIV-1 isolated during the acute phase of infection. A total of 1,484 unique HIV-1 
integration sites were analysed. Their distribution in the human genome and genetic features, and the 
effects of HIV-1 integrase polymorphisms on the nucleotide selection specificity at these sites were 
indistinguishable between the two cell types, and among HIV-1 isolates. However, the repertoires of 
HIV-1-hosting gene clusters overlapped to a higher extent in MDMs than in CD4+ T cells. The frequencies 
of HIV-1 integration events in genes encoding HIV-1-interacting proteins were also different between 
the two cell types. Lastly, HIV-1-hosting genes linked to clonal expansion of latently HIV-1-infected 
CD4+ T cells were over-represented in gene hotspots identified in CD4+ T cells but not in those identified 
in MDMs. Taken together, the repertoire of genes targeted by HIV-1 in MDMs is distinct from and more 
restricted than that of CD4+ T cells.
The human immunodeficiency virus-1 (HIV-1) mainly infects cells that express CD4 and the co-receptor CCR5 
or CXCR4, i.e. CD4+ T cells and macrophages1–6. The phenotypes as a result of an HIV-1 infection in mac-
rophages differ considerably from those of CD4+ T cells. For instance, macrophages are more resistant to HIV-1 
cytopathic effects7,8. Specialized macrophages are widely distributed in various tissues, including anatomical 
sanctuaries. Indeed, HIV-1 has been detected in microglial cells of the central nervous system9–11. The involve-
ment of HIV-1-infected macrophages, especially in the central nervous system, leading to the pathogenesis of 
HIV-1-associated diseases has been shown in various studies (reviewed in12).
Although it is conceivable that the different cellular physiology of macrophages in contrast to that of CD4+ 
T cells may contribute to the observed difference in productivity of the HIV-1 provirus in these two cell types, a 
multitude of studies, both in vivo and in vitro, have shown that the host genetic landscape surrounding the pro-
virus does have an impact on the subsequent fate of the provirus. Earlier integration site studies have established 
the host genetic requirements for HIV-1 integration: (i) HIV-1 favours integration into active transcription units 
in gene-dense regions but disfavours centromeric alphoid repeats and human endogenous retrovirus (HERV) ele-
ments13–15, (ii) Alu repetitive elements are over-represented at HIV-1 integration sites14–17, (iii) HIV-1 provirus is 
flanked by the duplicated weakly conserved palindromic sequence 5′ –GT(A/T)AC–3′13,15,17 and (iv) HIV-1 does 
not have a preference in transcription orientation relative to the gene into which it is integrated14,17.
Studies of HIV-1 integration site patterns in macrophages are scarce. This is partly due to the number of 
HIV-1-infected macrophages that can be recovered from blood samples of HIV-1-infected individuals 
is too low for HIV-1 integration site analysis, and obtaining them from other tissues is too invasive. Hence, 
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ex vivo infection of primary monocyte-derived macrophages (MDMs) is a practical solution. The study of Barr 
et al.18 examined HIV-1 integration site patterns in MDMs and compared them with those in CD4+ T cells 
obtained from other studies. They observed that HIV-1 integration events are found more often in long intergenic 
regions and, correspondingly, less often in gene-dense regions in MDMs compared to CD4+ T cells. In the study 
of Wellensiek et al.19, although they had examined HIV-1 integration site patterns in MDMs and CD4+ T cells, 
they focussed on the differences between adult and neonatal cells of each cell type rather than between cell types. 
To date, a systematic comparison of HIV-1 integration site patterns between MDMs and CD4+ T cells derived 
from the same experimental settings has never been done.
Here, we extended the characterization of HIV-1 integration site patterns in MDMs and CD4+ T cells in 
an experimental setting that mimics the in vivo situation. We used MDMs and CD4+ T cells derived from 
ART-treated HIV-1-infected individuals and infected these cells ex vivo with the individuals’ autologous HIV-1 
isolated during the acute phase of their HIV-1 infection. We focussed on other aspects of HIV-1 integration site 
patterns, e.g. structural and functional gene clusters formed by HIV-1-hosting genes and the frequencies of HIV-1 
integration events in certain gene subsets, and compared these features between the two cell types. We also exam-
ined the effects of two naturally occurring amino acid polymorphisms in the HIV-1 integrase on its nucleotide 
selection specificity at HIV-1 integration sites in primary cells. We showed that the repertoire of genes targeted by 
HIV-1 in MDMs was distinct and more restricted than that of CD4+ T cells.
Results
Characteristics of study participants and their autologous primary HIV-1 isolates. At the time 
of autologous HIV-1 isolation, the study participants were infected with HIV-1 for an estimated 15–153 days 
(Supplementary Table S1). All HIV-1-infected individuals are enrolled in the Zurich Primary HIV Infection 
(ZPHI) study20 and six of seven HIV-1-infected individuals started early ART during the acute phase of infection. 
The replication capacities of these primary HIV-1 isolates in MDMs were most comparable to that of HIV-1JR-FL, 
a macrophage-tropic strain. The replication capacity of primary HIV-1 isolate 6 in MDMs was consistently the 
highest among the seven primary HIV-1 isolates (Supplementary Figure S1). All primary HIV-1 isolates were also 
replication competent in CD4+ T cells (Supplementary Figure S2).
At the time of MDMs and CD4+ T cell isolation from HIV-1-infected individuals, viral suppression ranged 
from 2.8–7.8 years (mean = 4.7 yr) (Supplementary Table S1). These cells were then infected ex vivo with autol-
ogous primary HIV-1 isolates or heterologous HIV-1 isolates. The non-restrictive linear amplification-mediated 
polymerase chain reaction (nrLAM-PCR)21 was used to amplify the 5′ HIV-1 integration junctions, which were 
analysed using our new Integration Site Analysis Pipeline (InStAP) (Supplementary Figure S3). Prior to these 
experiments, CD4+ T cells from three ART-treated HIV-1-infected individuals were activated and monitored 
for HIV-1 outgrowth. Reactivation of HIV-1 from latently infected cells did not occur within 7–8 days (data not 
shown). Thus, we are certain that the HIV-1 integration sites amplified from CD4+ T cells after two days of acti-
vation and a further two days of ex vivo infection were the result of these ex vivo infections. More importantly, no 
HIV-1 integration sites were found in mock infected cell samples of HIV-1-infected individuals.
The basic genetic requirements for HIV-1 integration were similar among individual HIV-1 iso-
lates and between MDMs and CD4+ T cells. We obtained a total of 1,484 unique HIV-1 integration sites, 
derived from the seven selected HIV-1-infected individuals whose MDMs (n = 987) and CD4+ T cells (n = 497) 
were infected ex vivo with autologous primary HIV-1 isolates and heterologous HIV-1 isolates (Supplementary 
Table S2). Of these, 783 (79.3%) and 431 (86.7%) integration sites were found within genes in MDMs and CD4+ 
T cells, respectively. HIV-1 integration sites were also found mainly in gene-dense regions and away from cen-
tromeres, Giemsa dark regions, and the p arms of acrocentric chromosomes in both MDMs and CD4+ T cells 
(Fig. 1). The genic distribution and genetic profiles of HIV-1 integration sites were consistent with previous stud-
ies14,18,22, and they were indistinguishable between MDMs and CD4+ T cells, as well as between pooled autologous 
and heterologous HIV-1 isolates (Supplementary Figure S4). These basic genetic requirements for HIV-1 integra-
tion were also similar among individual HIV-1 isolates (Supplementary Figure S5).
Amino acid residue polymorphisms in HIV-1 integrase altered its nucleotide selection spec-
ificity in primary cells but not the genetic patterns of HIV-1 integration sites. Recent reports 
have identified the amino acid residues in the HIV-1 integrase that dictate the nucleotide selection specificity 
at integration sites, i.e. S119, T122, R231, and K258, in cell lines23,24. Since the full-length genomes of all well 
characterized primary HIV-1 isolates were sequenced, we could analyse these amino acid residues of our seven 
primary HIV-1 isolates and two clonal HIV-1 strains. Six HIV-1 isolates had the most common amino acid res-
idues in all four positions. Primary HIV-1 isolates 2 and 6 exhibited a polymorphism at positions 122 (T122I) 
and 119 (S119P), respectively. These two polymorphisms were present concurrently in primary HIV-1 isolate 5 
(Supplementary Figure S6). We investigated the effects of S119P and T122I polymorphisms on the nucleotide 
selection specificity at HIV-1 integration sites independently by analysing the 20 nucleotide positions immedi-
ately upstream of HIV-1 integration junctions (nucleotide position 0) in both MDMs and CD4+ T cells.
We analysed two nucleotide positions that were previously reported to be altered by the S119P HIV-1 integrase 
variant23. S119P resulted in a significantly increased preference for adenines at positions − 8 (p < 0.0001) and − 9 
(p < 0.01) in both MDMs and CD4+ T cells (Fig. 2a), consistent with previous report23. T122I significantly decreased 
the preference of HIV-1 for thymines at position − 8 in MDMs (p < 0.0001) (Fig. 2b), similar to the previously 
reported T122K23. Nonetheless, a consistent decrease in preference of HIV-1 for thymines at positions − 4 and − 8 was 
observed in both MDMs and CD4+ T cells (Fig. 2b). Primary HIV-1 isolate 5, which exhibited both polymorphisms 
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Figure 1. Chromosomal distribution of HIV-1 integration sites in monocyte-derived macrophages and 
CD4+ T cells infected ex vivo. Inner red lines indicate the position at which HIV-1 was found and outer blue 
peaks indicate gene densities. In each chromosome, red bands indicate centromeres, darker bands are AT-rich, 
and lighter bands are GC-rich.
Figure 2. Conservation and frequency plots of 20 host nucleotides upstream of integrated HIV-1. (a) Left 
panel shows the nucleotide selection specificity of HIV-1 with a serine residue at position 119 of the HIV-1 
integrase protein in a T122 background. Right panel shows the nucleotide selection specificity of HIV-1 with 
serine substituted by a proline residue at position 119 of the HIV-1 integrase protein in a T122 background.  
(b) Left panel shows the nucleotide selection specificity of HIV-1 with a threonine residue at position 122 of the 
HIV-1 integrase protein in an S119 background. Right panel shows the nucleotide selection specificity of HIV-1 
with threonine substituted by an isoleucine residue at position 122 of the HIV-1 integrase protein in an S119 
background. χ 2 test: *p < 0.01 and **p < 0.0001 compared to the same nucleotide positions in the left panel.
www.nature.com/scientificreports/
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in its integrase, could not be analysed due to the lack of sufficient HIV-1 integration sites. Both polymorphisms (S119P 
and T122I) dictated the nucleotide selection specificity at HIV-1 integration sites in primary cells.
The repertoire of HIV-1-hosting genes in MDMs was more restricted and distinct from that 
of CD4+ T cells. Next, we assessed whether the annotated features of HIV-1-hosting genes, e.g. involve-
ment in cellular and molecular processes, were different between the two cell types using the Database for 
Annotation, Visualization and Integrated Discovery (DAVID)25,26. The majority of HIV-1-hosting gene clusters 
over-represented in the human genome had annotations associated with structural motifs and domains of DNA 
and proteins in both cell types (Supplementary Figure S7). However, these gene clusters were more diverse in 
CD4+ T cells, which was also the case in most other categories of gene clusters (data not shown). MDMs had more 
over-represented gene clusters that were associated with protein metabolism, regulation, and transport whereas 
the proportion of over-represented gene clusters associated with a variety of other cellular processes, e.g. regula-
tion of apoptosis, was higher in CD4+ T cells (Supplementary Figure S7). There were also gene clusters that were 
observed exclusively in either cell type, e.g. deubiquitination and regulation of axonogenesis in MDMs whereas T 
cell receptor signalling and cell cycle progression in CD4+ T cells (data not shown), which concordantly reflected 
the cellular and molecular functions of the corresponding cell types.
As the diversity of structural and functional HIV-1-hosting gene clusters appeared to be higher in CD4+ 
T cells, we investigated further the extent to which these gene clusters overlap between cell types in order to 
estimate the relative size of the repertoire of genes accessible to HIV-1 for integration. For this purpose, we ana-
lysed the top 40 gene clusters of each data set, including both over-represented and not over-represented gene 
clusters in the human genome. We scored gene clusters having the same or highly similar annotations between 
data sets, and observed that the gene cluster overlap was the highest (47.5%) between MDM/HIV-1autologous and 
MDM/HIV-1heterologous, and decreased by 7.5–15% between MDMs and CD4+ T cells. As expected, between CD4+ 
T cell/HIV-1autologous and CD4+ T cell/HIV-1heterologous, the extent of overlap was lower (32.5%) (Table 1). This 
apparent trend of gene cluster overlaps was reproducible when we included HIV-1 integration site data sets from 
two other studies: the one other publicly available MDM data set (n = 754)18 and another CD4+ T cell data set 
(n = 534)27 (Table 1). Furthermore, to confirm the quality and comparability among data sets, we used a human 
T-lymphotropic virus-1 (HTLV-1) integration site data set from the study of Meekings et al.28 as a denominator 
control (Table 1). All six HIV-1 integration site data sets overlapped to similarly low extents with that of HTLV-1.
Due to the unequal number of HIV-1 integration sites recovered from each HIV-1-infected individual’s sam-
ple infected ex vivo, the observed results could have been driven mainly by samples of two individuals with 
the highest number of recovered HIV-1 integration sites, i.e. individuals 1 and 6 (Supplementary Table S2). To 
address this issue, we performed two analyses: (i) the proportion of HIV-1 integration sites forming the top 40 
gene clusters were compared with the proportion of HIV-1 integration sites recovered from each HIV-1-infected 
individual’s sample and (ii) gene clusters formed with data from individuals 1 or 6 only, and when removed, were 
Data set 1 Data set 2
Top 40 DAVID 
gene cluster 
overlap (%)
MDM/HIV-1a
MDM/HIV-1h 47.5
CD4+ T cell/HIV-1a 32.5
CD4+ T cell/HIV-1h 37.5
MDM/HIV-1h
CD4+ T cell/HIV-1a 37.5
CD4+ T cell/HIV-1h 40.0
CD4+ T cell/HIV-1a CD4+ T cell/HIV-1h 32.5
MDMs18
MDM/HIV-1a 37.5
MDM/HIV-1h 37.5
CD4+ T cell/HIV-1a 27.5
CD4+ T cell/HIV-1h 22.5
CD4+ T cells27
MDM/HIV-1a 37.5
MDM/HIV-1h 37.5
CD4+ T cell/HIV-1a 32.5
CD4+ T cell/HIV-1h 27.5
 HTLV-128
MDM/HIV-1a 22.5
MDM/HIV-1h 20.0
CD4+ T cell/HIV-1a 17.5
CD4+ T cell/HIV-1h 20.0
MDMs18 25.0
CD4+ T cells27 25.0
Table 1.  DAVID structural and functional gene clusters overlap between data sets. HIV-1- and HTLV-
1-hosting genes were clustered based on their structural and functional annotations using DAVID. The top 
40 clusters from all data sets were compared and clusters having the same or highly similar annotations 
were scored. MDM: Monocyte-derived macrophages; a: autologous; h: heterologous; HTLV-1: Human 
T-lymphotropic virus-1.
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compared with the entire corresponding data sets. A high correlation (R2 = 0.9774) was observed between the 
proportion of HIV-1 integration sites forming the top 40 gene clusters and that of HIV-1 integration sites recov-
ered from each HIV-1-infected individual’s sample, indicating that each individual’s sample contributed towards 
the formation of the top 40 gene clusters, and the extent of their contributions were concordant with the pro-
portion of HIV-1 integration sites recovered (Supplementary Figure S8). Additionally, data sets containing only 
HIV-1 integration sites derived from HIV-1-infected individuals 1 or 6 versus data sets without these HIV-1 inte-
gration sites overlapped with the entire corresponding data set to comparable levels (Supplementary Table S3), 
demonstrating our observations were neither HIV-1-infected individual-specific nor skewed by these two indi-
viduals who had the highest number of recovered HIV-1 integration sites.
Using the National Centre for Biotechnology Information (NCBI) database of published protein interactions 
between HIV-1 and its cellular host29, we investigated the frequency of HIV-1 integration events in a subset of 
genes encoding HIV-1-interacting proteins. We hypothesized that this frequency would be different between 
MDMs and CD4+ T cells given the lower HIV-1-hosting gene cluster overlap between them (Table 1). Here, we 
expanded our analysis and included a total of 11 HIV-1 integration site data sets: two MDM data sets (n = 987) 
and two CD4+ T cell data sets (n = 497) derived from this study and one other MDM data set (n = 754) and six 
other CD4+ T cell data sets (n = 7,557) obtained elsewhere14,18,27,30–33 (Table 2). We observed an increase of HIV-1 
integration events in genes encoding HIV-1-interacting proteins in MDMs (1.2×) and a significant increase in 
CD4+ T cells (1.4×, p < 0.001) compared to three sets of 5,000 random genes generated in silico (Fig. 3). As the 
CD4+ T cell data sets were derived from both activated and resting states, we further tested if the difference in 
cellular activation states in CD4+ T cells would have an influence on the frequency of HIV-1 integration into 
genes encoding HIV-1-interacting proteins; no significant difference was observed (data not shown). Though 
quantitatively modest, there was a significant difference (p < 0.05) between MDMs and CD4+ T cells (Fig. 3).
Cell type Virus
Number of 
integration sites 
reported Source
MDMs HIV-1 987 This study
CD4+ T cells HIV-1 497 This study
MDMs HIV-1 754 18
CD4+ T cells HIV-1 457 32
CD4+ T cells HIV-1 2661 33
CD4+ T cells HIV-1 2410 30
PBMCs HIV-1 534 27
SupT1 cells HIV-1 524 14
Jurkat cells HIV-1 971 31
Jurkat cells and 
PBMCs HTLV-1 579 28
Table 2.  Data sets examined in this study.
Figure 3. Frequency of HIV-1 integration events in genes encoding HIV-1-interacting proteins. A total of 
three MDM data sets (two derived from this study; closed circles) and eight CD4+ T cell data sets (two derived 
from this study; closed squares) were compared to three sets of 5,000 random genes generated in silico. Details 
of data sets derived from other studies (open symbols) are found in Table 2. HTLV-1 integration site data set 
served as an independent control. Two-tailed Mann-Whitney U test with 95% confidence interval was used to 
test for statistical significance.
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Given the consistent trend of gene cluster overlaps, a rigorous assessment to show the robustness of our anal-
ysis, and a significantly different (p < 0.05) over-representation of HIV-1 integration events in genes encoding 
HIV-1-interacting proteins between MDMs and CD4+ T cells, we demonstrated that the repertoires of genes 
accessible to HIV-1 for integration in MDMs and CD4+ T cells were distinct and that of MDMs’ was more 
restricted.
Genes linked to clonal expansion of latently HIV-1-infected CD4+ T cells were targeted more 
frequently in CD4+ T cells but not monocyte-derived macrophages. Expansion of the viral reser-
voir by means of clonal expansion of latently HIV-1-infected CD4+ T cells harbouring HIV-1 proviruses in genes 
of certain functional nature has recently been suggested27,30,32. These genes are referred to as genes linked to clonal 
expansion of latently HIV-1-infected CD4+ T cells here.
We compiled genes linked to clonal expansion of latently HIV-1-infected CD4+ T cells identified in two stud-
ies27,30 and collapsed them into a total of 196 unique genes. Next, we divided each HIV-1 integration site data 
set into two groups; one containing unique protein-coding genes in which HIV-1 was found ≥ 2 times, i.e. gene 
hotspots (Fig. 4) and the other, only once (Fig. 5a). We included seven HIV-1 integration site data sets for this 
analysis: two derived from this study (data sets of the same cell type combined; n = 1,484) and one other MDM 
data set (n = 754) and four other CD4+ T cell data sets (n = 4,613) obtained elsewhere14,18,31–33 (Table 2),
By comparing the frequencies of HIV-1-hosting genes linked to clonal expansion of latently HIV-1-infected 
CD4+ T cells in gene hotspots and genes with single HIV-1 integration events, we observed a highly significant 
increase of genes linked to clonal expansion of latently HIV-1-infected CD4+ T cells in gene hotspots in CD4+ T 
cells (2.5× , p < 0.001), but not in MDMs (Fig. 5b), showing again that the repertoires of genes accessible to HIV-1 
for integration in the two cell types were distinct.
Gene hotspots identified for HIV-1 integration. We identified a total of 75 (9.5%) and 33 (7.7%) genes 
in which HIV-1 was found ≥ 2 times in MDMs and CD4+ T cells, respectively (Fig. 4). Furthermore, ~70% of 
these genes were identified in ≥ 2 HIV-1-infected individuals. As the probability of getting the same gene ≥ 2 
times in multiple data sets was low34, these genes were considered as hotspots for HIV-1 integration here. Three 
gene hotspots were identified ≥ 4 times in both cell types, i.e. MECP2, KANSL1, and UBE2G1, and they were also 
listed in other studies (Table 3). In most cases, HIV-1 proviruses integrated into the same introns (Table 3), and 
they spanned 36 kb, 139 kb, and 22 kb in MECP2, KANSL1, and UBE2G1, respectively.
Discussion
We compared HIV-1 integration sites patterns between macrophages and CD4+ T cells derived from seven 
ART-treated HIV-1-infected individuals whose cells were infected ex vivo with autologous, as well as heterol-
ogous, primary HIV-1 isolates generated during the acute phase of infection. This unique experimental set-up 
allowed us to replicate the in vivo situation for the examination of HIV-1 integration site patterns arising from the 
two major cellular targets of HIV-1 and potentially among different HIV-1 isolates.
Figure 4. Gene hotspots for HIV-1 integration identified in MDMs and CD4+ T cells. Genes in which 
at least two independent HIV-1 integration events were identified in MDMs (n = 75) and CD4+ T cells 
(n = 33) are shown along with the HIV-1-infected individuals’ samples from which these HIV-1-hosting gene 
hotspots were identified. HIV-1-infected individuals’ samples are colour-coded and strand widths are directly 
proportional to the number of independent integration sites. Underlined in red are gene hotspots that were 
identified at least four times in both cell types.
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The various genetic features at HIV-1 integration sites were similar among different HIV-1 isolates, regardless 
of whether the virus was autologous or heterologous. However, given that the gene clusters consistently over-
lapped to a higher extent in MDMs, the repertoire of genes accessible to HIV-1 for integration in MDMs appeared 
to be more restricted than and distinct from that of CD4+ T cells. This distinction between the two cell types was 
again reflected in the different frequencies of HIV-1-hosting genes in two gene subsets: genes encoding HIV-
1-interacting proteins and those linked to clonal expansion of latently HIV-1-infected CD4+ T cells. Firstly, we 
observed an over-representation of HIV-1 integration events in the former gene subset in both MDMs and CD4+ 
T cells, but to different extents. Despite the heterogeneity of the NCBI HIV-1 Human Interaction Database29, its 
representativeness and specificity were demonstrated by the substantially lower frequency of HIV-1-interacting 
genes in random and HTLV-1 data sets. Secondly, HIV-1 integration into genes linked to clonal expansion of 
latently HIV-1-infected CD4+ T cells was over-represented in gene hotspots in CD4+ T cells but not in MDMs.
The gene cluster distribution of our CD4+ T cell data set was consistent with that derived from the study of 
Wagner et al.27, whereas such consistency was somewhat lacking between our MDM data sets with that derived 
from the study of Barr et al.18. Comparison of HIV-1 integration sites between MDMs and CD4+ T cells derived 
from the same experimental settings is important, as evident from the absolute percentages of the top 40 DAVID 
gene cluster overlaps; MDMs from the study of Barr et al.18 and CD4+ T cells from the study of Wagner et al.27 
had the same absolute values when compared to MDMs from this study. Nonetheless, the trend of gene cluster 
Figure 5. Frequency of HIV-1 integration events in genes linked to clonal expansion of latently HIV-
1-infected CD4+ T cells. (a) Each HIV-1 integration site data set was first divided into two groups: one 
comprises genes in which two or more HIV-1 integration events were identified (gene hotspots) and the other 
comprises genes in which only single HIV-1 integration events were identified. The frequency of genes linked 
to clonal expansion of latently HIV-1-infected CD4+ T cells in the two groups of genes for each data set was 
determined and the ratio was computed. (b) Ratio of frequency of genes linked to clonal expansion of latently 
HIV-1-infected CD4+ T cells in gene hotspots to in genes with single HIV-1 integration events. Autologous 
and heterologous HIV-1 data sets were combined here (closed symbols). Details of data sets derived from other 
studies (open symbols) are found in Table 2. Each random control comprised 5,000 random genes generated  
in silico instead of genes linked to clonal expansion of latently HIV-1-infected CD4+ T cells. Two random 
controls were analysed for each data set. Two-tailed Mann-Whitney U test with 95% confidence interval was 
used to test for statistical significance.
Gene Cell type
HIV-1-infected 
individual HIV-1 Intragenic region
Other 
studies
MECP2, chr. X
MDM 6 autologous Intron 1/2* (−)
14, 32, 33
MDM 6 autologous Intron 1/2* (−)
MDM 6 heterologous Intron 1/2* (−)
CD4+ T cell 6 autologous Intron 1/2* (−)
CD4+ T cell 1 autologous Intron 1/2* (−)
KANSL1, chr. 17
MDM 1 heterologous Intron 2/3* (+)
14, 31, 33
MDM 2 heterologous Intron 2/3* (+)
CD4+ T cell 1 autologous Intron 2 (+)
CD4+ T cell 1 autologous Intron 5/6* (+)
UBE2G1, chr. 17
MDM 6 autologous Intron 1 (−)
14, 31–33
MDM 1 heterologous Intron 1 (−)
CD4+ T cell 2 autologous Intron 2 (−)
CD4+ T cell 5 heterologous Intron 1 (+)
Table 3.  Gene hotspots for HIV-1 integration identified in both monocyte-derived macrophages and 
CD4+ T cells. Parentheses in the Intragenic region column indicate transcription orientation of HIV-1 
proviruses relative to the genes into which they were integrated: + indicates same whereas − indicates 
convergent. *Transcript variants.
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overlaps was consistent across all data sets that were derived from the same experimental settings, i.e. gene cluster 
overlaps were the highest between MDM data sets, followed by between MDM and CD4+ T cell data sets, and the 
lowest was observed between CD4+ T cell data sets.
We focussed on gene hotspots that were identified at least four times in both cell types, i.e. MECP2, KANSL1, 
and UBE2G1. The products of these genes are involved in transcriptional and post-translational regulations of 
genes35–37. Interestingly, downregulation of MECP2 has been reported to enhance replication of HIV-1NL4-3 in 
Jurkat cells38. Although it was unclear if these gene hotspots, as well as genes encoding HIV-1-interacting proteins 
were highly accessible prior to or upon HIV-1 infection, it is conceivable that they were transcriptionally active 
enough to allow integration14,15,18,31 and/or located in the vicinity of the nuclear pore, close to the incoming HIV-1 
DNA34. The model of Marini et al.34 describes that specific chromatin organization in the nucleus results in cer-
tain genes being closer to the nuclear pore, thus recurrently targeted by HIV-1 for integration. This model could 
be envisaged to be applicable down to the levels of genes, in which certain intragenic regions might be closer and 
more exposed to the incoming HIV-1 DNA. This would explain why HIV-1 proviruses that were found in the 
three gene hotspots preferred integration into the same introns in most cases.
The effect of T122I polymorphism on HIV-1 nucleotide selection specificity has not been reported previ-
ously. This natural and the second most abundant amino acid polymorphism at position 122 consistently altered 
the nucleotide selection specificity of HIV-1, demonstrating its role in integration site targeting. The effect of 
S119P polymorphism on HIV-1 nucleotide selection at the site of integration in cell lines has been described 
by Demeulemeester et al.23, and our observation in primary cells was consistent with theirs. Certain amino acid 
polymorphisms of the HIV-1 integrase, especially at position 119, have been associated with rapid disease pro-
gression23. However, association of natural integrase variants with disease progression could not be examined 
in our study participants because all of them have been successfully treated. Although these HIV-1 integrase 
polymorphisms altered the nucleotide selection specificity at integration sites, they did not have an effect on 
various genetic features at HIV-1 integration sites23. It is likely that the retargeting of HIV-1 was restricted by the 
repertoire of accessible genes in MDMs and CD4+ T cells.
In summary, we demonstrated in various analyses using our own data sets and of others that the repertoires of 
HIV-1-hosting genes targeted by HIV-1 in MDMs and CD4+ T cells were distinct in terms of their structural and 
functional classes and relative sizes. These cell type-dependent HIV-1 integration site patterns might account for 
the differences in the life cycle of HIV-1 in these cell populations.
Methods
HIV-1-infected study participants and HIV-1 negative donors. HIV-1-infected individuals are 
enrolled in the Zurich Primary HIV Infection (ZPHI) study, which is a non-randomized, observational, open-la-
bel, and single-centre study (www.clinicaltrials.gov; ID: NCT00537966; registered 25th September 2007)20. For the 
current sub-study, the inclusion criteria were: (i) HIV-1-infected individuals had at least 1.5 years of viral suppres-
sion of <20 HIV-1 RNA copies/mL plasma with antiretroviral therapy (ART) at the time of cell sample collection, 
and (ii) their primary HIV-1 isolates were capable of replication in monocyte-derived macrophages (MDMs).
Ethics, consent, and permission. This study was approved by the Ethics Committee of the University 
Hospital Zurich and written informed consent was obtained from all HIV-1-infected individuals and HIV-1 
negative donors. All experiments were performed in accordance with the relevant guidelines and regulations.
Generation and sequencing of primary HIV-1 isolates and clonal HIV-1 strains. The generation of 
primary HIV-1 isolates has been described elsewhere39. Briefly, CD4+ T cells from HIV-1-infected individuals in 
the acute phase of infection were co-cultured with activated donors’ peripheral blood mononuclear cells (PBMCs) 
until the HIV-1 p24 levels of the culture supernatant was >2,000 pg/mL prior to harvesting of the viral superna-
tant. HIV-1 p24 levels were measured with an enzyme-linked immunosorbent assay (ELISA)40. The 50% tissue 
culture infectious dose (TCID50) of the primary HIV-1 isolates was determined by co-culturing quadruplicates 
of 5-fold dilutions of primary HIV-1 isolates and scoring the number of p24-positive wells, and the TCID50 was 
subsequently calculated using the method of Reed and Muench41.
HIV-1JR-FL42 and HIV-1NL4-343 were generated by transfecting HEK 293T cells with pJR-FL and pNL4-
3, respectively, and the viral supernatant was harvested and cleared off of cells with a 0.22 μm filter 48 hours 
post-transfection. pJR-FL42 was obtained from Irvin SY Chen and Yoshio Koyanagi, and pNL4-343 was obtained 
from Malcolm Martin through the NIH AIDS Reagent Programme, Division of AIDS, NIAID, NIH.
We had previously developed a sensitive and robust method to amplify and sequence the full-length genomes 
of primary HIV-1 isolates with minimal artefactual in vitro recombination44. The seven selected primary HIV-1 
isolates were all confirmed to be of subtype B as determined by their pol nucleotide sequences using the REGA 
HIV-1 subtyping tool V345.
Ex vivo HIV-1 infection of monocyte-derived macrophages and CD4+ T cells. Blood samples 
of ART-treated HIV-1-infected individuals were first depleted of CD8+ T cells using RosetteSep Human CD8 
Depletion Cocktail (Stemcell Technologies). CD8− PBMCs were isolated by density gradient centrifugation 
using Lymphoprep (Stemcell Technologies). CD14+ monocytes were positively isolated by magnetic-activated 
cell sorting using CD14 microbeads (Miltenyi Biotec) whereas the remaining CD8−CD14− fraction was treated 
functionally as CD4+ T cells. The median purities of CD14+ monocytes and CD4+ T cells were 95.4% and 98.8%, 
respectively, as measured by flow cytometry. CD14+ cells were induced to differentiate into MDMs in RPMI-
1640 (10% (v/v) fetal bovine serum (FBS), 100 U/mL Penicillin, and 100 μg/mL Streptomycin) supplemented 
with 5% (v/v) human serum (Sigma) and 20 ng/mL macrophage-colony stimulating factor (M-CSF) (Peprotech) 
for eight days. CD4+ T cells were activated in RPMI-1640 (10% (v/v) FBS, 100 U/mL Penicillin, and 100 μg/mL 
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Streptomycin) supplemented with 10 U/mL IL-2 (Roche) and cultured in OKT3-coated flasks for two days. 
MDMs and activated CD4+ T cells were infected ex vivo with primary HIV-1 isolates or clonal strains (HIV-1JR-FL 
or HIV-1NL4-3) at an MOI of 0.74–1.0 for six days and 0.01 for two days, respectively.
In the screening of macrophage-tropic primary HIV-1 isolates, HIV-1 negative donors’ blood samples were 
used and treated essentially the same way to obtain MDMs and CD4+ T cells, except that the isolated CD4+ T 
cells were divided into three fractions, activated individually with 5 U/ml phytohaemagglutinin (PHA), 0.5 U/mL 
PHA, and OKT3, and pooled two days later prior to HIV-1 infection ex vivo.
Amplification and sequencing of 5′ HIV-1 integration junctions. The 5′ HIV-1 integration junc-
tions were amplified with the non-restrictive linear amplification-mediated PCR (nrLAM-PCR)21 from a total of 
0.2–1.0 μg of genomic DNA extracted from cells infected ex vivo with HIV-1 isolates. The procedure was essen-
tially the same as described elsewhere21, except: (i) the 3′ primers used for linear, first exponential, and second 
exponential amplifications were 5′ CCCTGGTGTGTAGTTCTGCC3′ , 5′ CAATCAGGGAAGTAGCCTTGTG3′ , 
and 5′ TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGN0–3 TGTGGTAGACCCACAGATCAAG3′ , 
respectively, (ii) the 5′ primer used for second exponential amplification was 5′ GTCTCGTGGGCTCGGAGATG
TGTATAAGAGACAGN0–3GATCTGAATTCAGTGGCACAG3′ , (iii) the cycling conditions for linear amplifica-
tion were 2× (95 °C for 2 min followed by 50 cycles of 95 °C for 45 s, 57 °C for 45 s, and 72 °C for 8 s) and (iv) The 
cycling conditions for first and second exponential amplifications were 95 °C for 2 min followed by 40 cycles of 
95 °C for 45 s, 57 °C for 45 s, and 72 °C for 8 s, and a final extension at 72 °C for 2 min. The HIV-1 5′ LTR-specific 
primers were designed based on the most conserved regions of the consensus sequence of HIV-1 subtype B in the 
Los Alamos HIV Sequence Database. The N0–3 random nucleotides in the primers used for the second exponen-
tial amplification were introduced to increase nucleotide diversity to enable DNA cluster generation during DNA 
sequencing with the Illumina MiSeq platform.
5′ HIV-1 integration junctions were sequenced with the Illumina MiSeq platform. Illumina sequencing adap-
tors were added to 1 ng of purified PCR products in a PCR using the following primers: 5′ AATGATACGGCGAC
CACCGAGATCTACAC(Index)TCGTCGGCAGCGTC3′ and 5′ CAAGCAGAAGACGGCATACGAGAT(Index)
GTCTCGTGGGCTCGG3′ at 0.5 μM each. The cycling conditions were 72 °C for 3 min, 95 °C for 30 s, 12 cycles 
of 95 °C for 10 s, 55 °C for 30 s, and 72 °C for 30 s, and a final extension at 72 °C for 5 min. A total of 12–14 pM of 
purified PCR products were sequenced with the MiSeq Reagent Kit v2 (300 or 500 cycles) with 8% PhiX.
Post-sequencing processing and mapping to the human genome assembly. Sequencing reads 
were filtered to remove low quality reads. True 5′ HIV-1 integration junctions were identified using an in-house 
bioinformatic pipeline, i.e. Integration Site Analysis Pipeline (InStAP), and satisfied the following criteria: 
(i) presence of both the nrLAM-PCR adaptor and 5′ HIV-1 LTR, (ii) host DNA was within 3 nucleotides from 
the end of 5′ HIV-1 LTR, and (iii) ≥ 85% of the lengths of the reads mapped to the human assembly GRCh37.
p13 with ≥ 98% identity. Contaminants were accounted for and removed from all samples in which they were 
identified except the sample that was sequenced first and/or with the highest number of read count. Manuscript 
on the details of InStAP is in preparation.
HIV-1 integration site data sets derived from this study and obtained elsewhere for comparison are shown in 
Table 2. All HIV-1 integration sites derived from this study are listed in Supplementary Table S4.
Bioinformatic databases. Annotated features of HIV-1-hosting genes were assessed using the Database 
for Annotation, Visualization and Integrated Discovery (DAVID)25,26. DAVID groups genes, which are related by 
their structural and functional annotations, into clusters and calculates an enrichment score to indicate if the gene 
clusters were significantly over-represented in a particular genomic background. Clusters of HIV-1-hosting genes 
that were significantly over-represented in the human genome are defined as having a DAVID enrichment score 
>1.3 with the stringency level in DAVID set to high. By definition, a gene cluster having a DAVID enrichment 
score >1.3 was equivalent to an overall geometric mean <0.05 for all its gene members, and a high stringency 
would consider a gene cluster as biologically significant only when the kappa coefficient, κ ≥ 0.85 for at least three 
genes with at least three related annotations between any two.
The National Centre for Biotechnology Information (NCBI) catalogues and provides access to a database of 
published interactions between HIV-1 proteins and its cellular host29. We used the November 2014 release (the 
latest at time of analysis) of the HIV-1 Human Interaction Database, which documented a total of 3,337 unique 
RefSeq protein-coding genes whose products interact physically, as well as indirectly, with HIV-1. This number 
of genes represented ~16.15% of all unique RefSeq protein-coding genes in the human genome (20,664 as of 15th 
of December 2014).
Statistical analyses. Two-tailed Fisher’s exact test, χ 2 test, and Mann-Whitney U test with a 95% confi-
dence interval were used at where indicated.
Graphical plots. Some of the graphical plots were generated using the following online platforms: Plotly 
(https://plot.ly/), WebLogo46,47, and Circos48.
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Background	
The latent reservoir is the final hurdle towards HIV eradication. HIV-1 can persist due 
to its ability to integrate its genome into that of the infected cell. Thus, investigating 
genomic features surrounding the provirus may contribute to new insights into the maintenance 
of the latent reservoir. Here, we examined the influence of the activation state of CD4+ T-cells, 
the effect of ART (on and off ART) during primary, chronic, and late HIV-1 infection on HIV-
1 integration site selection.   
Methods		
Resting and activated CD4+ T-cells were FACS sorted from longitudinally 
cryopreserved peripheral blood mononuclear cells (PBMCs) from 10 HIV-1 infected 
individuals (10 recruited at their primary HIV-1 infection stage). In addition, 
integration sites from PBMC from 2 late ART initiators during treatment were 
included in the study. HIV-1 integrations sites were amplified using nrLAM-PCR and 
mapped to the human genome. 
Results		
In total, 589 HIV-1 integration sites were identified; 357 in resting and 181 in activated 
CD4+ T-cells; 147 during primary and 391 during chronic infection; 134 on ART and 
404 off ART, in addition to 51 HIV-1 integration sites from late ART initiators’ PBMCs. 
The basic genetic landscape of integration site selection between activated and resting 
CD4 T cells was similar. Further, most gene hotspots were found shared among cell 
populations, on and off ART. 46.5% of gene hotspots during primary infection were 
observed also during chronic and late phase of infection- including BACH2. Moreover, 
43.5 % of primary integration sites in genes were observed in previous studies in 
suppressed patients and 17.1% in clonally expanded cells. We observe an enrichment 
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of integration sites in cancer associated genes in both cell populations, on and off ART 
as well as primary and chronic phase of infection.  We observed the preferential 
integration into highly expressed genes and unravel three factors that are associated 
with the integration site selection depending on the infection stage, cellular status, and 
treatment. We observe that the integration in higher expressed genes in the activated 
CD4+ T-cells disfavors its survival into the resting stage (Odds ratio (OR) 0.91, 95% 
CI 0.82-1.00). On the contrary, we found that a resting CD4+ T-cell with HIV 
integrated in a higher expressed gene is more likely to survive during treatment 1.2 
(1.1-1.3). Finally, we observe an overrepresentation of integration events in higher 
expressed genes, cancer genes, and in the opposite orientation of the host gene in the 
late ART initiators compared to the chronic and primary phase resting CD4+ T-cells 
off ART.  
Conclusion	
Our findings strongly suggest that dynamics of HIV integration site selection is not 
significantly different between activated and resting CD4 T cells, on and off treatment 
as well as infection stage. Primary gene hotspot anylysis revealed a large overlay with 
hgene hotspots during chronic phase of infection and persistant clones, suggesting 
early establishment of the reservoir. Further, integration sites, including primary IS  
were found in highly expressed genes and overrepresented in cancer genes. Further, 
we   demonstrate that the later ART is initiated the more likely it is for integration to 
occur in cancer related genes that are highly expressed. Moreover, we provide a 
potential mechanism for the frequency of cancer in patients in the later stages of HIV. 
Finally, we elucidate dynamics of integration site selection in different phases of 
infection which will help fine tune the strategies for the latent reservoir eradication.   
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BACKGROUND 
The latent reservoir of HIV is established early after infection and is the major obstacle 
for cure. The pool of latently infected cells is determined by the composition of the 
landscape of HIV integration sites. The ideal spot in the host genome for integration 
of the provirus should allow not only viral replication without interfering with the 
expression of essential genes of the host cell, but also enable the establishment of a 
latent reservoir, which permits the virus to hide for years in certain long-lived host 
cells despite suppressive antiretroviral therapy (ART) [1-5]. Given this latent reservoir 
of HIV, viral rebound is inevitable within weeks upon treatment interruption even 
after years of effective ART [6, 7].   
Numerous in vitro HIV-1 integration sites analysis studies showed a highly specific 
pattern of HIV-1 integration [8]. HIV-1 favors active genes [9, 10], mostly in introns of 
genes distributed over the whole genome, with some local hotspots [9]. The 
orientation of the viral genome relative to the direction of host gene transcription is 
believed to be globally random and has been associated with transcriptional 
interference as a mean of latency establishment and maintenance in vitro [11]. Earlier 
cross-sectional studies examining in vivo HIV-1 integration sites to reside be in active 
transcription units [15-17].  
HIV-1 infects preferentially CD4+ T-cells and macrophages, but other cell types of the 
immune system such as monocytes, dendritic cells and microglial cells have also been 
shown to be susceptible [18-20].  Different HIV-1 target cells may differentially steer 
integration events. For instance, integration events in monocyte-derived macrophages 
are less over-represented in active transcription units compared to those in CD4+ T-
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cells [21]. The repertoire of genes accessible to HIV-1 for integration is also more 
restricted in monocyte-derived macrophages [22].  
The activation state of CD4+ T-cells may also have an impact on integration and 
pathogenesis. Activated CD4+ T-cells infected with HIV-1 may revert to a resting 
memory phenotype, thus, establishing the main long-lived latent reservoir that is 
unaffected by ART. Alternatively, resting CD4+ T-cells can be infected directly, though 
this has only been shown in vitro [23, 24]. Brady et al. studied more than 2,600 
integration sites in primary resting and activated CD4+ T-cells infected with HIV-1 in 
vitro [25]. Although active transcription units were preferred in both cell populations, 
integration sites in activated CD4+ T-cells were relatively more associated with active 
gene regions compared to resting CD4+ T-cells. These results indicate that integration 
sites in resting CD4+ T-cells may occur in gene regions with surrounding chromosomal 
features that are less favorable for viral gene expression [25].  
Several recent studies investigated HIV-1 integration sites in vivo of patients during 
chronic infection [26, 27]. All groups observed multiple clonally expanded cells 
harboring integration events in the same genes, a large fraction of which is associated 
with cancer and cell cycle control, thereby suggesting that integration into these genes 
enables the maintenance of the latent HIV-1 reservoir. Examples of such genes are 
BACH2 and MKL2. Intriguingly, HIV-1 integration into these genes has been observed 
not only in the same intron, but also in the same transcription orientation as the host 
gene in longitudinal samples.  
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In the present study, we analyzed the dynamics of in vivo HIV integration site selection 
in longitudinal resting and activated CD4 T cell populations collected during primary, 
chronic and late phase of infection 
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RESULTS 
Patients’ characteristics and basic genetic features	
In vivo longitudinal patterns of HIV integration sites were studied in sorted resting 
and activated CD4+ T-cells from 10 HIV-1 infected individuals, which were diagnosed 
at their primary (<3 months post infection) or recent (3-6 months post infection) HIV-
1 infection stage. Starting from primary/recent infection and followed for 4- 6 years in 
annual intervals. Cryopreserved peripheral blood mononuclear cells (PBMC) were 
included from each individual. Furthermore, we included the analysis of HIV-1 
integration sites from two late presenters on ART.  Here we used unsorted PBMC 
based on our experience of sorted cells that the HIV-1 integration sites are almost 
exclusively found in resting CD4+ T-cells on ART, thus, these HIV-1 harboring PBMCs 
could be classified as resting CD4+ T-cells.  
HIV-1 integrations sites were amplified from genomic DNA by non-restrictive linear 
amplification PCR (nrLAM-PCR) [35] and the genomic loci were identified by an in-house 
bioinformatics pipeline InStAP ([22]).  
In total, 591 unique HIV-1 integration sites were identified in sorted cells (Table S1). 
Of those, 357 in resting and 181 in activated CD4 T-cells, 134 were on ART and 404 off 
ART, and 147 during primary and 391 during chronic stage of infection. In addition, 
51 integration sites were recovered from PBMC from late presenters during treatment.   
Basic genetic features for HIV integration- such as integration into genes, introns, 
repeats and CpG islands- did not significantly differ between the cell populations 
(activated versus resting CD4), stage of infection (chronic versus primary) and the 
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effect of ART (resting CD4 off ART versus rCD4 on ART), and were in line with 
previous studies of HIV integration sites REF. Some exceptions to that were CpG 
islands density in different window sizes and the integration in UTR5. Both showed 
significant difference between activated and resting CD4+ T-Cells, on and off ART, yet 
with the correction for multiple comparisons the association did not remain significant 
(Figure 1). 
 
FIGURE 1 HEAT MAP OF THE FEATURES SURROUNDING THE INTEGRATION SITES COPMARED 
USING LOGISTIC REGRESSIONS 
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Gene	hotspots	are	distributed	similarly	in	resting	and	activated	CD4+	T-cells,	time	
point	of	infection	and	on	and	off	ART	periods	
We found that out of 480 integration sites in genes, 98 integration sites 
(20.4%)occurred ≥2 times and were localized in 43 genes in resting and activated CD4 
T-cells. WE observed that not only does integration take place preferentially in certain 
genes, but also in the same introns (45.5%). Moreover, 75% of the integration sites in 
the same gene hotspots showed the same orientation as other integrants (Table S1).  
The proportions of each cell type among hotspots was like that of their proportion in 
the total number of integration sites, 33%, 55%, and 12% were obtained from activated 
and resting CD4+ T-cells and PBMCs, respectively (Table 1). Moreover, same hotspots 
can be found only in activated CD4+ T-cells (5 genes, Table 1), only in resting CD4+ T-
cells (14 genes, Table 2), or in both cells types (19 genes, Table 1), i.e., in the identical 
composition of pairs obtained by simulating 10^5 random samplings from a similarly 
distributed population.  
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TABLE 1 INTEGRATION EVENTS TAKING PLACE IN GENES AND THEIR FEATURES 
 
Gene hotspots
RefGene Chromosome Patient ID
Months after 
EDIa ART CD4+ T Cell Intron/Exon
Strand of 
integration
ARIH2 chr3 3* a intron 2/15 +
ARIH2 chr3 3* a intron 3/15 -
CAND1 chr12 5 a intron 1/14 -
CAND1 chr12 7 yes a intron 3/14 +
EIF4G3 chr1 6 a intron 5/34, 3/31, 8/14 -
EIF4G3 chr1 7 r intron 3/34, 1/31, 5/14 +
FOXK2 chr17 3* a intron 8/8 -
FOXK2 chr17 10 r intron 2/8 +
GNB1 chr1 2 r intron 2/11 -
GNB1 chr1 7 yes r intron 1/11 +
HN1L chr16 10 r intron 2/4 -
HN1L chr16 6 a intron 2/4 +
HN1L chr16 5 r intron 2/4 +
KANSL1 chr17 3* a intron 1/15 +
KANSL1 chr17 3* r intron 2/14, 3/15, 2/14 -
KANSL1 chr17 7 yes r intron 3/14, 4/15, 3/14 +
KPNB1 chr17 6 a intron 9/21, 8/20 -
KPNB1 chr17 5 r intron 9/21, 8/20 +
MKL2 chr16 3 37.6 r intron 6/16 +
MKL2 chr16 5 24.2 r intron 6/16 +
MKL2 chr16 5 47.5 a intron 6/16 +
MKL2 chr16 5 59.9 r intron 6/16 +
MKL2 chr16 7 49.9 yes r intron 3/16 -
ZBED4 chr22 6 a intron 1/1 -
ZBED4 chr22 10 r 5'UTR +
BACH2 chr6 1* 2.3 yes r intron 5/8, 3/6 -
BACH2 chr6 6 40.5 yes r intron 5/8, 3/6 -
BACH2 chr6 6 40.5 yes r intron 5/8, 3/6 -
BACH2 chr6 4 37.4 r intron 5/8, 3/6 -
BACH2 chr6 10 62.1 r intron 5/8, 3/6 -
BACH2 chr6 11 yes PBMC intron 4/8, 2/6 +
CD44 chr11 8 r 2/3, 5/8, 5/7, 5/9, 9/16, 5/11, 10/17 -
CD44 chr11 12 yes r 2/3, 5/8, 5/7, 5/9, 5/16, 5/11, 5/17 +
CYTH1 chr17 5 r intron 1/12 +
CYTH1 chr17 11 yes r intron 1/12 -
DNMT1 chr19 5 r 19/40,18/39 +
DNMT1 chr19 12 yes PBMC 5/40,4/39 -
LASP1 chr17 11 yes PBMC 2/5,2/6,2/7 -
LASP1 chr17 11 yes PBMC 2/5,2/6,2/7 +
SPTAN1 chr9 7 yes r overlapping gene 2/2, 38/56,37/55,36/54 +
SPTAN1 chr9 11 yes PBMC overlapping gene 2/2, 22/56,22/55,22/54 -
ZC3H3 chr8 6 yes r intron 9/11 -
ZC3H3 chr8 12 yes PBMC intron 3/11 +
ACSF3 chr16 4 yes r intron 7/10, 6/9, 5/8 -
ACSF3 chr16 6 a intron 7/10, 6/9, 5/8 -
AKAP13 chr15 5 r intron 1/36 -
AKAP13 chr15 7 yes r Exon 13/37, 5/29 -
ANKRD11 chr16 8 r intron 1/12, 1/13, 1/9 +
RD11, LOC10192 chr16 10 a intron 1/12, 1/13, 1/9, 1/2 +
CEACAM21 chr19 6 a intron 1/7 +
CEACAM21 chr19 3 a intron 1/7 +
COX10 chr17 7 yes r intron 4/6 +
COX10 chr17 11 yes PBMC intron 4/6 +
SNK1ELOC40092 chr22 6 a intron 1/14, 1/4 +
SNK1ELOC40092 chr22 5 r intron 1/14, 1/4 +
DNAJC5 chr20 6 r intron 1/4 +
DNAJC5 chr20 11 yes PBMC intron 1/4 +
ITPKB chr1 5 r intron 2/7 +
TPKB, ITPKB-IT1 chr1 3 r Intron 2/7, 1/1 +
KIAA1432 chr9 6 yes r intron 3/24, 3/25,3/21 +
KIAA1432 chr9 2 yes a intron 8/24, 8/25, 8/21 +
LPIN2LOC727896 chr18 1 yes r intron 4/19, Exon 1/1 +
LPIN2LOC727896 chr18 4 a intron 4/19, Exon 1/1 +
MKL1 chr22 3* 0.8 a intron 4/14, 4/13, 1/11 -
MKL1 chr22 6* 1.2 a intron 3/14, 3/13 -
MROH1 chr8 3* a intron 4/12, 4/43, 3/11, 3/41 -
MROH1 chr8 6* r intron 14/43, 13/41 -
PACS1 chr11 1 r intron 1/23 -
PACS1 chr11 6 yes r intron 1/23 -
PACS1 chr11 8 a intron 1/23 -
PACS1 chr11 9 yes r intron 1/23 -
PIEZO1 chr16 5 a exon 41/53 +
EZO1, LOC33905 chr16 7 yes r intron 2/50, exon 3/3 +
PPP6R2 chr22 3 a 2/22,2/23 +
PPP6R2 chr22 11 yes PBMC 2/22,2/23 +
PRMT2 chr21 4 yes r intron 3/11, 2/10,2/6, 2/8, 2/7 -
PRMT2 chr21 9 yes r intron 3/11, 2/10,2/6, 2/8, 2/7 -
PRPF6 chr20 8 r intron 4/20 -
PRPF6 chr20 6 r intron 12/20 -
PRPF6 chr20 11 yes PBMC intron 6/20 -
RASA2 chr3 7 yes r intron 19/23, 19/24 -
RASA2 chr3 8 yes r intron 4/23, 4/24 -
RBL1 chr20 3 a exon 22/22 +
RBL1 chr20 5 r intron 11/21, 11/20 +
RBM6 chr3 5 a intron 2/16, 5/20 -
RBM6 chr3 5 r intron 2/16, 5/20 -
RNF157 chr17 6 a intron 5/18 -
RNF157 chr17 11 yes PBMC intron 1/18 -
SCAPER chr15 6 r intron 7/30, 8/31 -
SCAPER chr15 5 a intron 14/30, 15/31 -
SEMA4D chr9 7 yes a intron 1/20, 1/17 +
SEMA4D chr9 8 yes r intron4/20, 4/17 +
SMG6 chr17 2 a intron 10/18, 2/10, 3/11 -
SMG6 chr17 5 a intron 13/18,5/10, 6/11 -
TRERF1 chr6 6 a intron 2/17 -
TRERF1 chr6 8 yes r intron 3/17 -
VPS29 chr12 5 a intron 3/4,2/3,2/2,4/5,3/4 +
VPS29 chr12 11 yes PBMC intron 3/4,2/3,2/2,4/5,3/4 +
XPO6 chr16 3* r intron 5/24, 4/23 -
XPO6 chr16 9* r intron 7/24, 6/23 -
* time point during primary infection
aEDI (estimated date of infection)
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Highly targeted genes with more than 3 or 4 Integration sites were BACH2, MKL2, 
PACS1, HN1L, KANSL1 and PRPF6. The most frequently HIV-1 integration site was 
found in BACH2. It was detected in resting CD4+ and in PBMCs in on and off ART in 
5 patients. Interestingly, we observed one integration event in BACH2 in intron 4 in 
the PBMC of a late ART patient (ART start CD4+ count < 50). The gene expression 
analysis of BACH2 showed a steady decline as the T-cell progressed from the activated 
to resting phase, implying lower gene expression upon infection and the reversion to 
the resting phase. (Figure 2). BACH2 has been recently recognized for its role in T-cell 
differentiation and proliferation. 
 
FIGURE 2 GENE EXPRESSION PATTERN IN DIFFERENT T-CELSS POPULATION OF TWO OF THE 
MOST HIV HIT GENES 
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MKL2 was identified in resting and in activated CD4+ T-cells in three patients. Four 
out of five integration sites were observed in intron 6, while one integration site 
resided in intron 3.  
Overall these patterns indicate that gene hotspots are neither cell type nor treatment 
specific. 
HIV	reservoir	is	seeded	early		
We analyzed integration sites from resting and activated CD4+ T-cells during primary 
infection, as early as 23 days post estimated day of infection. In total 147 integration 
sites (117 in genes) from primary/recent infection were identified, with 73 (58 in genes) 
in activated and 74 (59 in genes) in resting CD4 T-cells. 
A large number of gene hotspots for proviral integration was targeted during primary 
infection; 46.5% (20 of 43) gene hotspots were observed early during infection- 
including BACH2 (2.3 months post estimated date of infection). Four gene hotspots 
were observed exclusively during early phase of infection- ARIH2, MKL1, MROH1 and 
XPO6- of those MKL1 and ARIH2 were detected in two patients (0.8 and 1.2 months 
post estimated date of infection) only in activated CD4+ T-cells. Activated CD4 T cells 
during primary infection represent highly likely de novo infected cells und thus 
preferred loci for integration.  
The large overlap between hotspots found during primary and chronic phase (on and 
off ART) between patients suggests not only a similar pattern of integration sites 
between different phases of infection and individuals but also suggests potential early 
seeding of the HIV reservoir. To further support our hypothesis, we screened for an 
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overlay for primary integration sites with were found in previous studies in treated 
individuals. Indeed, 43.5 % of primary integration sites in genes were observed in the 
aforementioned studies and 17.1% were observed in expanded clones (Figure 3). 
Interestingly, primary integration sites in genes identified in activated CD4 T cells 
contributed more frequently to persistent clones compared to resting CD4 T cells with 
24.1% and 8.5%. Chronic integration sites in genes in activated CD4 were found with 
similar distribution in persistent clones compared t to those in resting CD4 T-cells 
(20% in activated versus 17.9 % in resting CD4). 
 
FIGURE 3 DISTRIBUTION OF INTEGRATION SITES FOUND IN GENES IN THREE DIFFERENT 
STUDIES AND THE PROPORTION FOUND IN CLONALY EXPANDED CELLS 
Primary gene hotspots were found to a large overlap also during chronic phase on and 
off ART. Further, primary integration sites were observed in other studies during long 
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term treatment in persistent clones. Our data suggest similar kinetics of integration 
site selection during early phase of infection and an early seeding of the HIV reservoir.  
Cancer	genes	are	overrepresented	in	integration	sites	during	primary,	chronic	and	
late	phase	of	infection	
We observed a significant overrepresentation between 10.1% and 30.2% of integration 
sites in genes associated with cancer (compared to 6.43% - 1650 out of 25660- of genes 
are associated with cancer in the human genome) across all populations regardless of 
the activation state of the cell or treatment status (Fisher exact test, P-value < 0.01, 
Figure 4). Moreover, preferential integration into cancer genes was already detected 
during primary infection in resting- as well as in activated CD4+ T cells. In addition, 
the proportions of cancer genes in the resting CD4+ T-cells during treatment were in 
line with that reported by previous studies in PBMC in long term ART patients Figure 
S4. However, we observed no significant difference in the proportion of cancer genes 
between the different populations (pairwise Fisher exact test P-Value > 0.05), except 
for late ART initiators. There, we observed a significant difference between late ART 
initiators integration sites and those from chronic and primary resting cells, on and off 
ART (pairwise Fisher exact test P-Value < 0.05). 
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FIGURE 4 THE COUNT AND PROPORTION OF CANCER GENES IN THE STUDIES POPULATIONS 
FROM OUR STUDY 
The preference of HIV to integrate in cancer genes remains without an explanation. 
Therefore, we examined several factors that might influence the integration and 
selection including the gene expression of cancer genes in search for a potential 
answer. We observed a sharp peek of highly expressed cancer genes in non-infected 
activated and resting CD4+ T-cells (Figure 5). This observation suggests that the 
targeting of cancer genes by HIV is mediated by their general higher expression in the 
main cellular targets of HIV, that is non-infected activated and resting CD4+ T-cells.  
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FIGURE 5 THE OVERALL GENE EXPRESSION OF CANCER GENES IN THE DIFFERENT GENE 
EXPRESSION DATASETS COVERING RESTING, ACTIVATED, CENTRAL AND EFFECTOR CD4+ 
MEMORY T-CELLS. 
Next we assessed potential factors associated with cancer genes integration events 
Table 3. We observe that treatment (viral load), time since infection, and the stage of 
infection all contribute to the incidence of being found in cancer genes.  
We detected integration sites being overrepresented in cancer genes targeted early 
during primary infection and enriched throughout the infection process. By assessing 
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factors potentially associated with integration into cancer genes (Table 3), we observe 
that treatment (viral load), time since infection, and the stage of infection all 
contribute to the incidence of being found in cancer genes. Thus, our data suggests the 
hypothesis that integration sites in cancer genes are enriched over time by positive 
selection forces. Treatment revealed overrepresentation of cancer genes over time, 
since the stable reservoir is masked by newly infected cells off treatment (10^9 cells 
are getting infected daily and die within 2 to 4 weeks after infection). 
TABLE 3 FACTORS ASSOCIATED WITH INCIDENCE OF CANCER GENE INTEGRATION EVENTS 
(EXCLUDING INTEGRATION EVENTS IN THE ACTIVATED CD4+ T-CELLS) 
Covariate Univariable OR (95% 
CI) 
Virus load (log10) 0.87 (0.77-0.98) 
Time since infection 
(years) 
1.04 (1.00-1.07) 
Infection stage  
Primary  Reference 
Chronic  0.80  (0.45-1.47) 
Late 2.65  (1.23-5.53) 
Gene expression of 
resting CD4 T-Cells 
(per 10% rank) 
1.01 (1.00-1.03) 
 
HIV-1	preferentially	integrates	in	highly	expressed	and	cancer	related	genes	
We observe a strong tendency of integration events to take place in highly expressed 
genes across all the different populations. We utilized a logistic regression model to 
evaluate the magnitude of this association with integration, with the aim to quantify 
the influence of the level of gene expression and whether a gene is known to be 
cancerous.  
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In the activated CD4 T-cells (the major HIV target cell) we observed that the 
probability of integration is enhanced 40% with each 10% increase in the gene 
expression ranking (OR 1.4 per 10% change in ranking, 95% CI 1.3-1.5). In addition, a 
gene was twice as likely to be hit were it labeled as a cancer gene (OR 2.0, 95% CI 1.5-
2.5). Interestingly, the association of cancer genes with integration appears to be partly 
mediated by the general higher level of expression they have, evident by the decrease 
in their association with integration in a multivariable model (Cancer genes 
multivariable OR 1.6, 95% 1.2-2.1). We found no evidence for interaction between the 
gene expression level and being cancerous (P-Value > 0.05 for the interaction term, 
and P-Value >0.05 for the likelihood ratio test comparing the model with the 
interaction term and without), though one cannot exclude the lack of power to assess 
this association.  
The	higher	the	expression	level	of	the	host	gene	where	integration	occurred,	the	
less	the	chances	for	the	activated	cell	to	transit	to	the	resting	state.	
We observed that the likelihood of the survival or the transition of an activated cell to 
the resting state (given integration in a gene) decreases 9% with the increase in the 
host gene expression ranking by 10% (univariable OR 0.91 per 10% change in 
expression, 95% CI 0.82-1.01). Cancer genes and the integration orientation were not 
associated with the transition from the activated to the resting state in CD4 T-cells 
(cancer genes univariable OR 1.2, 95% CI 0.58-2.70; same transcription orientation as 
the gene 1.10, 0.64-1.80). The observed association was robust to the inclusion of the 
other covariates in a multivariable model (OR 0.91, 95% CI 0.82-1.00)  
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Integration	 in	 the	 opposite	 orientation	 of	 the	 gene	 transcription	 is	
overrepresented	in	the	latent	reservoir	during	treatment	
HIV-1 provirus was found to have a slight preference for the opposite orientation with 
respect to the host gene transcription direction in all cell populations. This preference 
was more pronounced in ART+ samples compared to ART- samples (resting CD4+ on 
ART 64%, resting CD4+ off ART 54.0%; activated CD4+ on ART 63%, activated CD4+ 
off ART 53%) (Figure 6). This was further verified using a univariable logistic 
regression model, where we observed a trend towards overrepresentation of oppositely 
integrated HIV-1 provirus during ART (resting CD4+ on ART compared to resting 
CD4+ off ART OR 1.5, 95% CI 0.9-2.5, Table 4).  
 
FIGURE 6 THE ORIENTATION OF THE INTEGRANTS RELATIVE TO THE HOST GENE 
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The	 resting	CD4+	T-Cells	 in	 the	 latent	 reservoirs	during	 treatment	 tend	 to	have	
integration	 events	 in	 higher	 expressed	 genes,	 cancer	 genes,	 and	 opposite	
orientation	relative	to	the	host	gene	transcription		
We observed that CD4+ T-cells on ART (compared to off ART) show more integration 
events in higher expressed genes (OR 1.18 per 10% increase in rank, 95% CI1.05-1.33), with 
the opposite orientation, and in cancer genes having no significant association at an 
alpha of 0.05 (univariable model and multivariable model, Table 4). The association 
of higher gene expression with integrants on ART was even stronger when we 
compared integration sites from patients with delayed ART to resting CD4+ T-cells off 
ART from the chronic/primary phase (multivariable OR 1.4, 95% CI 1.2-1.7). In 
addition, cancer genes and integration opposite of the gene orientation were strongly 
overrepresented (Cancer genes multivariable 2.8, 1.2-6.4; opposite orientation 2.13, 
1.0-4.74). 
TABLE 4 LOGISTIC REGRESSION MODEL COMPARING RESTING CD4 T-CELLS OFF ART 
INTEGRATIONS SITES TO THOSE ON ART 
Covariate Univariable (OR, 95% 
CI) 
Multivariable (OR, 95% 
CI) 
Gene expression 
(per 10% rank 
change) 
1.18 (1.05-1.33) 1.17 (1.04-1.32) 
Cancer Gene 1.54 (0.77-3.04) 1.47 (0.72-2.94) 
Integration Orientation 
relative to the host gene 
  
Same Reference (1) Reference (1) 
Both 2.56 (0.10-66.12) 2.88 (0.1-79.89) 
Opposite 1.46 (0.87-2.49) 1.5 (0.88-2.57) 
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DISCUSSION 
Our study is the first to utilize longitudinal patients’ samples to examine the effects of 
the cellular activation state, treatment, and stage of infection on HIV integration site 
selection. Our findings show that basic genic features for HIV integration site selection 
generally do not differ between activated and resting CD4 T cells, on and off treatment 
as well as infection stage, as patterns for integration into genes, introns, repeat 
elements were comparable across the entire patient data set. On the same note, across 
all patients a slight preference for opposite orientation regarding the host gene was 
detected, and was even more pronounced for samples collected during treatment. It 
was shown previously that the orientation of integrated provirus results in a 10-fold 
effect on   HIV-1 gene expression. This observation may indicate transcriptional 
interference to be favorable for latently infected cells as suggested previously and 
implies a survival selection over time and ART. Similar observations were seen in other 
retroviruses, such as the human endogenous retroviruses (HERVS) representing over 
8 % of the human genome, mostly residing in intergenic regions. However, those 
HERVS which are found in genes are preferentially integrated in opposite orientation, 
which allows functioning of the host gene.  Our data suggests that during ART there is 
a significant selection towards CD4 cells with HIV integrated in the opposite 
orientation of the host gene.  
20.4% of all integration sites in genes were found in gene hotspots and distributed 
equally in all populations (independent of cell population, treatment and infection 
stage), suggesting similar dynamics for  integration. Further, we observed that not only 
does integration take place preferentially in certain genes, but also in the same introns 
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(45.5%) and strand. These findings were shared between primary and chronic infected 
patients as well as in activated and resting CD4. Primary patient samples and activated 
CD4 T cells represent samples where only a short time of survival pressure took place, 
and thus our data imply that those gene hotspots are not only preferential loci for viral 
integration, but also that the provirus may be forced to integrate in a certain loci, where 
cellular characteristics dominate or promote viral integration orientation. One of the 
cellular forces which was reported to determine viral integration is the nuclear 
architecture of the host cell. 
One of the most common integration sites we found was in the BACH2 gene –including 
the primary phase. Despite being observed several times in several patients in the 
resting CD4+ T-cells, it was not observed a single time in the activated CD4+ T-cells. 
Given BACH2 involvement in T-cell differentiation and regulation it is possible that 
any integration in BACH2 interferes with its expression forcing the cell into the resting 
state. This is further supported by the reduced expression of BACH2 (and another 
commonly found integration site MKL2) in the infected CM and TM CD4+ T-Cells 
compared to the activated and resting uninfected state. Since BACH2 integration sites 
were found only in resting CD4+ T-cells (and once in PBMCs), it may indicate that 
BACH2 is resting CD4+ T-cell specific loci. MKL2 Integration sites were observed in 
activated and resting CD4+ T-cells from on and off ART samples. This findings support 
the hypothesis that the overrepresentation of integration sites in MKL2 result not only 
due to a potential survival benefit but also may result due to preferred integration into 
MKL2 after infection, and therefore representing a true hotspot. 
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In addition, primary gene hotspot analysis revealed a large overlay with gene hotspots 
collected during chronic and late phase of infection among all patients. Indeed, of all 
primary integration sites in genes 43.5 % and 17.1 % were observed previously in 
patients with prolonged ART and persistent clones. These findings emphasize once 
more, that certain genomic loci are clearly preferred over others and some of those are 
beneficial for cell survival and persistence, and are fundamental for the establishment 
of the reservoir.  
The latent reservoir is established early and was shown first by an early study by Chun 
et al where latently infected cells were recovered as early as 10 days post symptomatic 
HIV infection. Another study in non-human primate model showed that ART 
initiation after 3 days post exposure does not prevent the establishment of the latent 
reservoir. Here, we report for the first time on primary HIV integration sites and 
hotspots in activated and resting CD4 T cells. The clustering of the integration sites 
during primary infection represent very early events after infection (23 days post 
estimated infection from Patient 4). This could imply that these genes give a survival 
advantage to the cells at which they integrate in. What this could also allude to is that 
these genes are generally preferentially targeted from the start of the infection by HIV-
1, consequently the proportion surviving harboring them is higher. Integration into 
those genes may also force the cell to express HIV early to reassure the survival of the 
virus or force the cell to survive (to secure the creation of the latent reservoir).  
Further, across the entire patient data set integration sites were found in highly 
expressed genes and overrepresented in cancer associated genes (10-30%)- including 
primary integration sites. We demonstrate that this observation was more pronounced 
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in late ART patients. We provide evidence, that the level of gene expression, treatment 
and time since infection, increase the incidence of finding an integration in a cancer 
gene. Cancer genes were shown to be highly expressed in non-infected cells and thus 
targeted cancer genes are mediated by their general higher expression in the HIV 
target genes. The findings lead to the conclusion that despite early targeting of cancer 
genes that are highly expressed, there is a survival advantage and thus higher 
representation of cancer genes in patients with late ART initiation.  
Our findings that the composition of the CD4 T cells during treatment shifts towards 
CD4 T-cells with integration in cancer genes that are highly expressed and drive cell 
survival has clear ramification for HIV pathogenesis. For example, human primates 
infected with CCR5-tropic SIV progressed to AIDS very rapidly (within the first 6 
months of infection) when the CD4+ memory T-cell collapsed early in the infection, in 
contrast the infection proceeded to the chronic stage when CD4+ memory T-cell 
regeneration was robust [Picker et al J Exp. Med 2004]. Similarly, depending on how 
delayed ART is initiated, the proportion of CD4+ memory T-cell infected with HIV 
increase, potentially compromising the overall regenerative capacity of CD4+ memory 
T-cells.  In other words, progression of S/HIV into AIDS has been found to be 
contingent on the level of damage imparted on CD4+ memory T-cells. One possible 
scenario is that as the number of circulating CD4 T-cells in untreated patients drops, 
the immune system resorts to the reactivation of memory cells for homoeostatic 
rebalance, that in return reactivates memory cells with HIV and consequently 
increases their proportion. The size of the latent reservoir corresponds to the time HIV 
was allowed to establish it, in other words the time between infection and treatment. 
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The longer this time, the more memory cell with HIV, and the more destructive these 
cycles of homeostatic expansion are.  
We show that the level of gene expression is one of the main drivers for integration site 
selection - however activated Cd4+ were found in somewhat higher expressed genes 
compared to resting CD4+ and patinets with later ART were also found in hihjer 
expressed genes compared to those after short time of infection.  
Recently it has been recognized that even if the integrated provirus is replication 
incompetent it still represents a source of continuous inflammation through the 
production of novel HIV-1 chimeric proteins that are thought to be involved in the 
continuous inflammatory response HIV patients are known for. Our finding that 
integration events in the latent reservoir (resting CD4+ Cell on ART) are 
predominantly in highly expressed genes gives further weight to the aforementioned 
finding. As even under suppression, there is probably continuous expression of the 
inflammation inducing chimeric HIV proteins owing to the 95% defective provirus 
known to populate the latent reservoir.  
The question of whether and to what extent does HIV-1 infect resting CD4 T-Cells 
remains unsettled. We observed integration sites with similar integration landscape 
across all populations, activation stage, treatment, and infection stage. We also 
observed integration events in activated CD4+ T-cells in treated patients, which could 
be re-activated resting CD4+ T-cells or freshly infected activated CD4+ T-cells. 
Another possibility is that HIV infects resting CD4 T-cells directly and favors these 
“hotspot”.  
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The integration site analysis is in line with other studies (Wagner, Mall, Cohn et al)., 
however one limitation of the present study is the inability of our amplification method 
by nrLAM-PCR to detect clonal expansion 
Our study unravels the characteristics of HIV integration sites in activated and resting 
Cd4 T cells, treatment and throughout infection. The findings from our study suggest 
that the dynamics of HIV integration sites are similar among activated and resting CD4 
T cells, on and off treatment and time since infection. In addition, profound analysis 
of gene hotspots revealed a large overlap of integration sites between primary, chronic 
and the late phase of infection. This finding lead to the conclusion that certain loci are 
clearly preferred for integration shortly after infection and are associated with long 
term survival. Further, the overlay between primary integration sites and integration 
sites from previous studies in treated patients and in persistent clones suggests an 
association between certain gene loci and their contribution to the early establishment 
of the latent reservoir. Lastly we identify the gene expression level as one of the main 
drivers for integration site selection and identified factors which increase the incidence 
of being found in an cancer gene. We also observed that CD4+ T-cells on ART or the 
latent reservoir is associated with higher expressed genes with the opposite orientation 
to the host gene, and in cancer associated genes. 
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Material and methods 
Patients	and	specimens	
10 patients examined in our study were enrolled in the Zurich Primary HIV Infection (ZPHI) 
study. The ZPHI study is an observational, open label, non-randomized, single center study 
(www.clinicaltrials.gov; ID NCT00537966) [31-33]. On average every patient contributed one 
sample per year for a period of five years. (participants characteristics are presented in Table 
S1). Furthermore, two patients participating in the Swiss HIV Cohort Study (SHCS) were 
enrolled [34]. In contrast to the ZPHI participants, they started ART very late when the CD4+ 
T-cell count was below 50 cells/µl blood (patients 11 and 12).  PBMC samples were obtained 
during the first 0 to 5 years of ART. All patients were iinfected with HIV-1 subtype B.  
The study has been approved and was conducted according to the guidelines of the Ethic 
Committee of the University Hospital Zurich, and written informed consent was obtained from 
all study participants prior to inclusion.  
We aimed to include the major HIV-1 target cell populations in the blood, therefore, we isolated 
four different populations (monocytes, resting CD4+, activated CD4+, and CD4-/low T-cells) 
from those longitudinal cryopreserved PBMC by FACS.  The proportion of sorted cells from 
PBMC was similar to that of previous studies ([36]). Monocytes were excluded from further 
analyses as viral unspliced as well as multiply spliced RNA was not detected in any patient 
sample. Integration sites derived from CD4- /low T-cells (n=8) were added up to the activated 
CD4+ T-cells population due to their low frequency in blood [36]). 
Fluorescence-activated	cell	sorting	(FACS)	of	cryopreserved	PBMC	
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Each cryopreserved PBMC sample contained a total of ten million cells. The samples were 
thawed, washed with PBS, bulk stained with ten different markers and subsequently separated 
by fluorescence activated cell sorting (FACS, FACSAriaIII BD). The separated cell 
populations are identified according to specific cell surface markers : Resting CD4+ T-cells 
(CD3+, CD4+, CD25-, CD69-, and HLA-DR-), activated CD4+ T-cells (CD3+, CD4+, and 
positive for at least one of these markers: CD25, CD69 or HLA-DR), CD4-/low T-cells (αβTCR+, 
CD3+, and CD4-/low), and monocytes (CD14+ and CD16+/-). 7-AAD staining was used to 
exclude dead cells. 
Nucleic	acid	extraction		
Genomic DNA was isolated from each cell population with the DNeasy Blood & Tissue Kit 
(Qiagen) according to the manufacturer’s recommendation. The DNA was eluted in 40 µl 
elution buffer. The flow-through from the initial step was collected and processed further with 
phenol-chloroform to extract total RNA. The extracted total RNA was re-suspended in 20 µl 
H2O. Nucleic acid was measured using Nanodrop1000 (Thermo Scientific) and stored at -80°C.  
HIV-1	integration	site	amplification	
HIV-1 integration sites were amplified with 5´ nrLAM-PCR (non-restrictive Linear 
Amplification-Mediated PCR) as described elsewhere [35]. Optimization of the protocol was 
performed to increase the sensitivity for low-input DNA and modifications were made to 
prepare the samples for Illumina MiSeq amplicon sequencing [22]. Briefly, the elongation time 
was extended to 8 sec for the linear PCR and to 9 sec for the exponential PCRs. The 1st 
exponential PCR contained 35 cycles for resting CD4+ T-cell population and 40 cycles for 
activated CD4+ and CD4-/low T-cell populations, while the 2nd exponential PCR contained 40 
cycles for all cell populations. To maximize the capturing of all the different linear 
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amplification products, two sets of adaptor-ligated ssDNA from each sample were 
subsequently amplified but pooled prior to sequencing. To minimize contaminations among 
samples, no more than six samples were amplified in parallel, only one sample per patient was 
included in each set, and different cell populations were not processed together. The genomic 
DNA of the cell line ACH-2, which harbors one HIV-1 provirus per cell, was used as a positive 
control. Illumina MiSeq library preparation was conducted as described previously [22]. 
HIV-1	integration	site	analysis	
Illumina MiSeq reads were analyzed with CLC Genomics Workbench version 6. The analysis 
included six filtering steps: 1. Selection of sequences containing the HIV-1 sequence 5’-
GGGAGTAAATTAGCCC-3’ and the adaptor sequence 5’-TCAGTGGCACAGCAGT-3’, 2. 
Removal of sequences containing the HIV-1 PPT site 5’-AAAGAAAAGGGGGGAC-3’, 3. 
Length restriction of >28 nucleotides, 4. Removal of the remaining flanking adaptor (5’-
TAGG-3’) and HIV-1 LTR sequences (5’-TTCCA-3’), 5. Removal of sequences containing 
multiple adaptors, and 6. Removal of HIV-1 2LTR circles by screening for the U5 region of 
HIV-1 LTR with the sequence 5’-GTGGAAAATCTCTAGCA-3’. Filtered reads were mapped 
to the human genome assembly using an in-house developed bioinformatics pipeline, 
Integration Site Analysis Pipeline (InStAP) (Figure S3B).  
Integration	Site	Analysis	Pipeline	(InStAP)	
Identical sequences were collapsed into one read, with the total count retained. Following that 
sequences were clustered using CDHIT v4.6.1. Out of each sequence cluster one sequence was 
chosen to be carried forward based on the following criteria: 1-The sequence with highest 
incidence frequency, 2- If identical frequency, the one with a longer read is retained, 3- If all 
equal in the two previous criteria, the cluster representative sequence is taken. The sequences 
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were then blasted using Blastn from the BLAST+ v2.3 application set against the human 
genome (hg19). Only unique hits with >= 98% sequence identity and >= 85% coverage of the 
matched sequence, and which started within 3 nucleotides from the HIV sequence were 
retained. The curated hits were then annotated using various tables from the UCSC database 
using a set of custom R scripts. Overall, the workflow was adjusted to minimize the false 
discovery rate.  As with all studies, selection bias due to the sequencing technique and 
analysis pipeline cannot be ruled out. In addition, we analyzed the integration sites 
after pooling, which ignores inter-patient variability. 
Gene	expression	analysis	
The following datasets were obtained from the GEO database (GSE60235 none HIV infected 
48h activated and resting CD4+ T-Cells, GSE9927 infected activated CD4+ T-cells, 
GSE66214 HIV-1 infected CM and TM cells (at baseline)). Gene expression data were 
normalized (quantile or RMA based normalization) and log2 transformed. If a gene had 
multiple probes, the probes expressions were averaged and the mean was assigned to the gene. 
The expression was then averaged across the biological replicates of the respective datasets. In 
order to allow for comparison across experiments the expression levels where ranked, and the 
rank was scaled to 100%. There were 16303 genes shared across the datasets. 
Cancer	genes	datasets	
We utilized an aggregated cancer genes list published by F. Bushmann lab (excluding 
mouse derived data) (http://www.bushmanlab.org/links/genelists, accessed: 
28/09/2016). 
Statistical	analysis	
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Per population only one representative of each gene was included in the analysis to 
avoid bias due to integration hotspots. Logistic regression was used to evaluate the 
determinants of integration. 
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Table S1. Overview of identified integration site in HIV-1 infected individuals. 
 
HIV-1 
infected 
individual 
months 
after EDI Viral load 
CD4 
count 
ART 
resting CD4+ activated CD4+ CD4
-/low PBMC 
  T lymphocytes 
T 
lymphocytes 
T 
lymphocytes   
1 
2003 93 648 on 6 0 n.a   
2004 <50 532 on 3 2 n.a   
2005 31500 779 off 0 1     
2006 391000 649 off 2 2     
2007 27000 719 off 3 0     
2008 27900 372 off 1 0     
2 
2004 495500 724 off 2 0     
2005 <50 712 on 0 1 n.a   
2006 13200 599 off 0 0 1   
2007 21300 580 off 0 n.a.     
2008 46100 463 off 0 1     
2010 <50 837 on 0 0     
3 
2005 10^6   off 13 48 2   
2006 <50 979 on 2 1 n.a   
2007 10400 852 off 0 n.a. 0   
2008 7050 843 off 1 0 0   
2009 44000 707 off 5 n.a. 0   
2010 22000 515 off 12 n.a. 0   
4 
2005 144000   off 6 0 0   
2006 <50   on 0 0 0   
2007 4670   off 4 1 0   
2008 5810 562 off 3 n.a. n.a   
2009 19000 492 off 0 2 n.a   
2010 <50   on 5 0 n.a   
5 
2005 75200 608 off 10 17     
2006 <50 951 on 5 0 n.a   
2007 864 870 off 9 n.a.     
2009 34000 583 off 5 3     
2010 33541 511 off 6 15     
2011 170584 484 off 49 9 4   
6 
2004 98000   off 22 4 1   
2005 46300 310 off 25 33 0   
2006 19700 237 off 10 0 0   
2007 <50 540 on 14 8 n.a   
2008 <50 517 on 13 0 n.a 2b 
2009 <50 485 on 1 3 n.a   
7 
2006 261   off 5 0 0   
2008 15700 336 off 3 1 0   
2.2009 186000 203 off 3 4 0   
12.2009 <50   on 33 1 n.a   
2010 <50   on 1 3 n.a   
  39 
2011 <50   on 5 n.a. n.a   
8 
2007 17400 848 off 2 0 0   
2008 20800 945 off 10 n.a. 0   
2009 81000 614 off 5 6 0   
2010 <50 742 on 7 n.a. n.a   
2011 79 877 on 2 n.a. n.a   
2012 <50 767 on 10 1 n.a 2b 
9 
2008 1930 723 off 2 0 0   
2009 9500 542 off 0 0 0   
2010 580000 379 off 0 0 n.a   
2011 100 456 on 1 0 n.a   
2012 <50 579 on 5 0 n.a   
10 
2009 63500 537 off 8 1     
2010 65000 537 off 1 2     
2011 181462 388 off 16 3     
2012 <50 905 on 1 0 n.a   
11 
2008 1350000 13 off n.a n.a. n.a 2c 
2009 <50 165 on n.a n.a. n.a 15c 
2013 <50 476 on n.a n.a. n.a 25c 
12 2004 121000 49 
on n.a n.a. n.a 2c 
2005 <50 231 on n.a n.a. n.a 0 
  2005 58800 15           
13 
2006 <50 113 on n.a n.a. n.a 10c 
2011 <50 352 on n.a n.a. n.a 1c 
a based on 6pg/DNA per cell       
b PBMC IS from PBMC (dry pellet)       
cPBMC IS from cryopreserved unsorted PBMC 
n.a: not applicable, EDI: Estimated day of infection      
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In an ambitious undertaking, the World health organization (WHO), the united 
nations (UN), and many of the world’s countries, declared 2030 as the year at which 
the AIDS epidemic to be ended (WHO Global AIDS Update 2016). With more than 35 
years of active research and myriad successes and disappointments, the road to HIV 
elimination remains long with occasional far dispersed lights, and two major 
milestones far in the line of sight, an effective prevention measure such as a vaccine, 
and an effective cellular eradication method. 
 
The transition of HIV from a terminal infection to a manageable chronic disease 
remains one of the greatest achievements of modern biomedical research. 
Notwithstanding the benefits of antiretroviral treatment, it comes at a considerable 
cost, manifested as numerous side effects. The extent of these collateral effects are not 
yet completely accounted for, as demonstrated in this thesis with the antibacterial 
effects of antiretroviral. Several efforts are in place to assess the potential of a 
simplified treatment with one or two drugs rather than the current standard of 3-4, 
which could minimize side effects. These attempts together with the current efforts to 
formulate some drugs into long acting formulations (3-12 months) should reduce the 
side effects, minimize the inconvenience of HIV treatment, and increase adherence, 
and thus enhance the wellbeing of the HIV infected individuals as well as reduce the 
transmission (treatment as prevention). In addition, long acting ART have the 
potential as a long-term pre-exposure prophylaxis. There are also positive collateral 
effects of ART, as we have demonstrated that dually active HIV/HBV antiretroviral 
does provide a prophylactic effect against HBV in the HIV infected. This may be of 
particular importance in patients with impaired immunity not responding yet to the 
HBV vaccine, or for HIV-infected HBV-vaccine non-responders in general. 
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Despite almost reaching the 90-90-90 standard earlier than slated, many questions 
remain unanswered regarding the HIV epidemic in Switzerland, especially the reasons 
for the unabated HIV incidence (BAG Bulleting 2000-2016). This stable incidence also 
highlights the necessity of improved prevention approaches and the optimization of 
targeting methods, given the findings in this thesis regarding the underrepresentation 
of marginalized populations.  
 
However, for this to happen, undiagnosed patients need to be targeted, screened, and 
treated. Unfortunately, globally 40% of the HIV infected remain undiagnosed, and 54% 
of those diagnosed are untreated (UNAIDS Gap Report). The question remains open 
on how many countries in addition to Switzerland will also reach the 90-90-90 goal by 
2020.  
 
In summary, despite the enormous effort that several generations put into the fight 
against HIV, it remains a formidable enemy, that is extremely resilient for eradication 
efforts. In this thesis, we tackled HIV transmission, treatment, coinfections and 
pathogenesis on the molecular, individual, and population level to help take another 
step towards a world that is HIV free. 
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